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ABSTRACT
Coronary heart disease (CHD) is the biggest single cause of death in the 
United Kingdom. The development of valid and reliable techniques of 
non-invasive assessment of coronary atherosclerosis would be invaluable in a 
number of ways and this thesis examined three techniques (titres of antibodies 
to heat shock protein 65, ultrasonographic measurement of carotid artery 
intimal-medial thickening (IMT) and levels of fibrinolytic factors). The second 
objective was to investigate the role of the immune response to hsp65 and
H.pylori and of the endogenous fibrinolytic system in the pathogenesis of CHD.
Anti-hsp65 titres correlated with the severity and extent of coronary 
atherosclerosis, but with insufficient predictive accuracy to be a useful clinical 
test. H.pylori would appear to be an important influence on IgG anti-hsp65 as 
the eradication of H.pylori lead to a significant fall in anti-hsp65 titre (from 25.64 
AU/ml to 13.75 AU/ml, p=0.033). Thus an auto-immune response to hsp65 
maybe the mechanism by which H.pylori lead to increased CHD risk.
Significant correlations between carotid IMT and the angiographic severity and 
extent of coronary atherosclerosis were demonstrated. However the 
correlations were quite modest and this casts doubt on the use of carotid IMT 
as a surrogate marker of CHD mortality and morbidity. There was no evidence 
of a correlation between plasma PAI-1 antigen or activity or t-PA antigen levels 
and coronary atherosclerosis. Novel data is presented suggesting that yGT is 
an important influence on PAI-1 antigen levels in a normotriglyceridaemic 
population.
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CHAPTER 1: INTRODUCTION
1.1 HISTORICAL BACKGROUND
1.1.1 Atherosclerosis
Atherosclerosis is the pathological condition that underlies several 
extremely important disorders including coronary artery disease, 
cerebrovascular disease, and diseases of the aorta and peripheral arterial 
circulation. Chronic coronary atherosclerosis maybe asymptomatic or cause 
stable angina; atherosclerotic plaque rupture with additional thrombosis leads 
to the clinical events of unstable angina (UA), acute myocardial infarction 
(AMI), sudden death and heart failure.
It is not a new disease as paleopathologists have shown that some Egyptian 
mummies have evidence of atherosclerosis (1). Several sixteenth century 
anatomists including Andreas Vesalius and Gabriel Falloppio, described 
aneurysms of the aorta and peripheral arteries (2) and Swiss physiologist 
Abrecht von Heller in 1755 was the first to describe progressive atherosclerotic 
changes in arteries (3).
Antonio Scarpa in 1804 published a monograph (3) on arterial 
aneurysms and suggested a link between these and atherosclerosis. He 
concluded that the most common and important antecedent to aneurysm 
formation was an ulcerated atheromatous lesion. Scarpa emphasised that an 
aneurysm was not simply a dilated portion of normal artery; it was the result of
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localised disease of the arterial wall (3). In an 1829 paper on pathological 
anatomy, French pathologist Jeanne Lobstein introduced the term "arterial 
sclerosis". In 1850 London surgeon Joseph Hodgson claimed that inflammation 
was the underlying cause of atheromatous arteries. By this time, it was 
known that arteries consisted of three distinct layers. Hodgson identified 
atheromatous material between the intima and media and proposed that 
these changes could be traced to an abnormality of the intima (3). Indeed 
during the final decades of the nineteenth century, pathologists 
abandoned the view that atherosclerosis was the result of inflammation 
and adopted the view that it was a degenerative process.
The modern era of atherosclerosis research began in 1910 when German 
chemist and Nobel prize-winner Adolf Windaus showed that cholesterol was 
present in atherosclerotic lesions in humans (3). Antischow produced the first 
animal model of atherosclerosis in 1913 by feeding cholesterol to rabbits 
(3). There was a growing interest in the clinical and scientific aspects of 
atherosclerosis during the early twentieth century. In part this is 
explained by the gradually declining morbidity and mortality from infectious 
diseases and thus by the end of the 1930's atherosclerosis had emerged 
from the position of a medical curiosity to be considered a major cause of 
death.
i
1.1.2 Coronary Atherosclerosis and Angina
Renaissance artist Leonardo Da Vinci was the first to describe and illustrate 
the coronary arteries accurately (4). English physicist and anatomist
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William Harvey in 1649 proposed that the coronary circulation nourished the 
heart (5). English physician William Heberden first described angina 
pectoris in a talk presented to members of the College of Physicians of
London in July 1768 (3). Speaking of the condition he called angina
pectoris, Heberden claimed:
There is a disorder of the breast, marked with strong and peculiar symptoms. The seat of 
it, and sense of strangling and anxiety with which it is attended, may make it not improperly be 
called angina pectoris. Those, who are afflicted with it, are seized, while they are
walking, and more particularly when they walk soon after eating, with a painful and most 
disagreeable sensation in the breast, which seems as if it would take their life away, if it 
were to increase or to continue: the moment they stand still all this uneasiness
vanishes. After it has continued some months, it will not cease so instantaneously upon 
standing still; and it will come on not only when the persons are waking, but when they are 
lying down and oblige them to rise up out of their beds (3).
Edward Jenner, best remembered for the introduction of vaccination, was 
the first to conclude that angina was caused by atherosclerosis in 1786. He 
based his conclusions on autopsy findings, explaining that they revealed "a 
kind of firm fleshy tube, formed within the coronary vessels, with a 
considerable quantity of occific matter dispersed irregularly through it" (3).
1.1.3 Coronary Atherosclerosis and Acute Myocardial Infarction 
Russian physician WP Obrastzow and ND Straschesko published the first 
description of myocardial infarction in 1910. They believed that two specific 
findings were characteristic: prolonged chest discomfort, ‘status anginosus’ 
and persistent dyspnoea ‘status dyspnoeticus’. After presenting cases
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with autopsy correlation, Obrastzow and Straschesko concluded, “the 
differential diagnosis of coronary thrombosis from angina pectoris is made by 
the presence of status anginosus with coronary thrombosis and its absence 
with isolated attacks of angina pectoris” (3,6). Two years later Chicago 
intern James Herrick published the first description in English of the clinical 
syndrome of AMI (7). He also provided an explanation of the spectrum of 
accompanying symptoms “the clinical manifestations of coronary obstruction 
will evidently vary greatly” Herrick claimed, “depending upon the size, location 
and number of vessels occluded. The symptoms and end result must also be 
influenced by blood pressure, by the condition of the myocardium not 
immediately affected by the obstruction, and by the ability of the remaining 
vessels properly to carry on their work as determined by their health or 
disease” (7).
Boston cardiologist Samuel Levine in 1929 first addressed the concept of 
what we now term cardiac risk factors and claimed that heredity, male 
sex, obesity, diabetes and hypertension predispose patients to coronary 
thrombosis (8). American cardiologist Mason Sones performed the first 
selective coronary angiography in 1958 (9).
During the middle of the twentieth century, some influential clinicians and 
pathologists began to question the role of coronary thrombosis in acute 
myocardial infarction. This controversy was finally only resolved in 1980 
after the publication of DeWoods seminal work (10). DeWood performed 
coronary angiograms in patients with AMI and found that 87% of those
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studied within 4 hrs of the onset of symptoms had occlusion of the infarct- 
related artery.
1.2 THE TOLL OF CORONARY ATHEROSCLEROSIS
1.2.1 Mortality
Coronary heart disease (CHD) is the biggest single cause of death in the 
United Kingdom (11). In 1990 there were nearly 170,000 CHD deaths in the 
United Kingdom which represents 27% of all deaths (30% for males and 23% 
for females) and of these 17% were in people under 65 years of age.
Comparison of trends in mortality rates from CHD from the twelve European 
community countries shows marked differences (see Figure 1.1). Although 
the rate for the United Kingdom is declining in 1986 (the last year for which 
data from all the E.C states is available) it was the second highest rate in the 
European community.
Figure 1.2 shows social class variations in England and Wales and the 
pattern of variation is similar for both sexes. There is a consistent gradient of 
increasing standardised mortality ratio rising from lower than the national 
average in social class I to higher than average for social class V. A similar 
social class variation has been demonstrated for Scotland.
1.2.2 Morbidity
The 1991 Health Survey for England provided data on the prevalence of 
CHD based upon individuals self report of having ever been diagnosed by a 
Doctor. 5% of men and 3% of women reported having had angina (12). The
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mean weekly incidence of acute (fatal and non-fatal) myocardial infarction in 
the U.K. is 4 per 100,000 of the population. It is estimated that in 1989/90 
CHD attracted about 4% of total NHS expenditure in the U.K. including 
Community Health Services (11).
1.3 EPIDEMIOLOGICAL RELATIONSHIP BETWEEN VASCULAR 
TERRITORIES
There is every indication that atherosclerosis is a diffuse condition involving 
the heart, brain and peripheral arterial circulation, with most risk factors 
that apply to one arterial bed, also applying to others. It is therefore, not 
surprising that having one atherosclerosis disease increases the risk of 
developing the others.
The Framingham Study provides data on the concordance of disease in the 
different arterial beds (13). The risk of other atherosclerotic events over 30 
years of follow up in persons with symptoms of peripheral vascular 
atherosclerosis (intermittent claudication) as their first manifestation of 
atherosclerosis was examined. This indicated a two to four fold excess risk of 
developing overt coronary disease, stroke, TIA or cardiac failure compared 
to people of the same age without intermittent claudication (14). Following an 
initial AMI the ten year risk of stroke was 16% in men and 24% in women (13). 
An initial atherothrombotic cerebrovascular accidents was associated with 
about a two fold excess risk of cardiac failure and CHD.
The epidemiological data from the Framingham study strongly suggests that 
development of a clinical atherosclerotic event in one arterial vascular
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territory is a hallmark of diffuse atherosclerosis. This suggests a 
common aetiology or pathogenesis underlying the disease. However, some 
significant differences in risk factors for atherosclerosis in the different 
vascular territories have been identified. For example, diabetes has a 
much greater pathogenic impact on peripheral arterial disease than on 
coronary disease or stroke (15).
1.4 PATHOGENESIS OF ATHEROSCLEROSIS
There is good evidence from post-mortem studies that the earliest stages 
of atherosclerosis develop in adolescence and that the atherosclerotic 
burden increases with age. The initiation and progression of the extent of 
atherosclerosis and the rupture of chronic plaques with additional thrombosis, 
are the primary determinants of stable angina and clinical events (UA, AMI, 
sudden death and heart failure) (16).
Normal arteries consist of intima, media and adventitia. The intima is 
lined by endothelium on the inner (luminal aspect) of the vessel and consists 
of a relatively thin layer of connective tissue containing occasional solitary 
smooth muscle cells and bounded by the internal elastic lamina on its outer 
aspect. The media is the muscular wall of the artery, bounded by the 
internal and external elastic laminae. These laminae consist of fenestrated 
sheets of elastic fibres with numerous openings large enough to permit both 
substances and cells to pass in either direction. The media of muscular 
arteries consists of spiralling layers of smooth muscle cells attached to one 
another and each cell is surrounded by a discontinuous basement membrane
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and by interspersed collagen fibrils and proteoglycan. Elastic arteries 
contain multiple lamellae of smooth muscle cells, each equivalent to a single 
media in a small muscular artery or arteriole. Each lamella is bounded by an 
elastic lamina on its inner and outer aspects. The adventitia consists of a 
dense collagenous structure containing numerous bundles of collagen fibre, 
elastic fibre and many fibroblasts, together with some smooth muscle cells.
The earliest recognisable lesion of atherosclerosis is the ‘fatty streak’, an 
aggregation of lipid-rich macrophages (foam cells) and T lymphocytes within 
the intima. Data from animal studies have shown that fatty streaks precede 
the development of ‘intermediate lesions’ which are composed of layers of 
macrophages and smooth muscle cells in the intima (17). The intermediate 
lesions in turn progress to the more advanced, complex, occlusive lesions 
called ‘fibrous plaques’. These fibrous plaques enlarge and impinge in the 
arterial lumen, thereby obstructing blood flow. They consist of a dense cap of 
connective tissue with embedded smooth muscle cells overlying a core of 
lipid and necrotic debris. The fibrous plaques contain monocyte derived 
macrophages, smooth muscle cells and T lymphocytes many of which are 
activated. Most episodes of myocardial infarction are due to complete 
arterial occlusion, secondary to fibrous plaque rupture, followed by 
superimposed thrombosis.
1.4.1 Hypotheses of Atherogenesis
The current theory of the pathogenesis of the lesions of atherosclerosis have 
developed from the earlier proposals made by Virchow (18) and Rokatanski
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(18) and Duguid (19) and combined in 1973 as the 'response to injury 
hypothesis of atherosclerosis' (20).
This theory suggests an initial endothelial insult by for example, hypertension 
or cigarette smoking. One of the most striking features of atherosclerosis is 
that it does not occur randomly, but rather at specific so-called lesion- 
prone sites and they usually occur at sites such as flow dividers, areas of 
curvature and branching sites, suggesting that it is a local haemodynamic 
environment which is important in the focal initiation of atherosclerotic lesions 
(21). In addition, it has been shown that these lesion-prone areas are 
structurally and functionally different from non-lesion prone sites, e.g. their 
endothelium has increased permeability to plasma proteins such as albumin, 
fibrinogen and Low Density Lipoprotein (LDL) cholesterol (21) and 
spontaneous monocyte recruitment and endothelial cell turnover are greater 
in these areas (21). Whether these changes are due solely to the local 
haemodynamic upset is unclear, and indeed some lesion-prone sites are not 
in areas of untoward haemodynamic circumstances. Evidence has 
accumulated to suggest that oxidised LDL is a key component in endothelial 
injury and indeed has an important role at many stages of the atherosclerotic 
process (21). LDL is oxidatively modified by free radicals generated by smooth 
muscle cells, macrophages and probably endothelial cells.
The second stage of the atherosclerotic process involves monocyte adhesion 
to injured endothelium. The adhesion is a very active event involving the 
surface expression of endothelial leucocyte adhesion molecules (ELAMs) and
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the secretion of a variety of adhesive cytokines, such as interleukin-1 ft and 
monocyte colony stimulating factor (22). The attachment is followed by 
monocyte migration across the endothelium. The monocytes are guided across 
the endothelium by a number of chemoattractants, the most important of 
which is considered to be monocyte chemotactic protein-1 (22).The 
monocytes then undergo activation - differentiation, to become macrophages 
after entering the subendothelial space of the arterial wall (23).
Lipids, in particular LDL cholesterol and Lipoprotein (a) also migrate 
transendothelially at sites of endothelial injury. Again oxidised LDL has a key 
role as it is no longer recognised by the normal LDL receptor but is 
recognised by the so-called macrophage scavenger receptor. Unlike the 
LDL receptor, the scavenger receptor does not down-regulate with cellular 
cholesterol accumulation and, thus provides a pathway for the relentless 
uptake of these chemically modified lipoproteins, with eventual 
transformation of foam cells to macrophages (20). The combination of foam 
cells, T lymphocytes which migrate at the same time as monocytes and 
smooth muscle cells form the fatty streak. The fatty streak then goes through 
the intermediate stage and, ultimately develops into a fibrous plaque through 
a combination of three fundamental biological processes as follows:
(1) proliferation of intimal smooth muscle cells together with variable 
numbers of accumulated foam cells and T lymphocytes;
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(2) secretion by the proliferated smooth muscle cells of large amounts of 
connective tissue matrix, including collagen, elastic fibres and proteoglycans;
(3) accumulation of lipid, principally in the form of cholesterol-esters 
and free cholesterol within foam cells as well as in the surrounding 
connective tissues.
It should be noted that there may be a great variability in the relative 
amounts of tissue formed by each of these processes in the lesions.
Consequently, many lesions of atherosclerosis are dense and fibrous,
whereas others may contain large amounts of lipid and necrotic debris, 
with most demonstrating combinations and variations of each of these 
characteristics (23).
An alternative hyypothesis the Monoclonal hypothesis was proposed in 1973 
and suggested that each lesion of atherosclerosis is derived from a single 
smooth muscle cell that serves as a source of all the cells within a lesion. 
Benditt and Benditt (24) examined a series of atherosclerotic plaques 
obtained at autopsy from a small number of black females who were 
heterozygous for glucose-6-phosphate dehydrogenase (G-6PD). They 
examined the isoenzyme content of the samples and deduced that each 
lesion of atherosclerosis represents a clone derived from a single smooth 
muscle cell. A later version of the monoclonal theory suggests that an 
atherosclerotic lesion is in fact a benign neoplasm, originating from the
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mutation of one cell changed by a virus or other chemical substance. On the 
whole the Monoclonal Hypothesis has little support today.
1.5 RISK FACTORS FOR CORONARY ATHEROSCLEROSIS 
The concept of risk determination by measuring variables associated with 
the occurrence of disease was formed early in the development of 
epidemiology. A risk factor is defined by common usage as any measurable 
trait or characteristic of an individual that predicts that individual's probability 
of developing clinically manifest disease.
The group that evaluated the evidence relating smoking to health in 
1964 developed the criteria to judge the causal significance of a risk 
factor association (25) and these criteria have been subsequently modified 
(26). The criteria are usually stated as follows:
1. The relative risk associated with this trait is high.
2. Dose response. The more severe the trait, the greater is the relative 
risk. Serum cholesterol, blood pressure and smoking meet this criterion.
3. Temporal sequence. The trait precedes the disease.
4. Consistency. The association appears in studies involving different 
populations, different racial groups and groups living under different 
conditions.
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5. Independence. The trait is associated with increased risk when the effects 
of other known or suspected causes or risk factors are removed.
6. Coherence. The association is consistent with the results of other sources 
of evidence: clinical investigation, animal experimentation, or in vitro research.
7. Specificity. The trait predicts the occurrence of only one disease for 
example, the effects of elevated serum cholesterol concentration are limited to 
the atherosclerotic disease.
8. Reversibility. Reduced incidence of disease when the trait is removed or 
meliorated provides the most convincing evidence of a causal relationship.
Cholesterol (27,28), hypertension (27,28), smoking (29), male sex and family 
history are well established risk factors for CHD. In 1981 Hopkins & Williams 
(30) accumulated a list of 246 risk factors for coronary atherosclerosis. This 
review used a much looser definition of risk factor than that defined by the 8 
criteria listed above. They included traits associated with established risk 
factors, characteristics associated with atherosclerosis in animal studies, and 
factors predicted from theoretical considerations. A similar review now would 
probably include another 100 or so factors fitting this looser definition. A 
few examples with varying levels of evidence in support of risk factor status 
include, triglycerides, obesity, lack of physical activity, fibrinogen, leucocyte 
count, stress and personality, water hardness, homocystinaemia and baldness.
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1.6 WHY ASSESS CORONARY ATHEROSCLEROSIS NON-INVASIVELY?
In the past the two approaches to measurement of atherosclerosis in 
epidemiological and clinical studies has been by PM evaluation and by 
angiography, and both of these have their limitations.
Coronary angiography is the investigation of choice when atherosclerosis has 
progressed to clinically significant angina or to clinical events and has a major 
role in determining those patients who would benefit from surgical treatment 
of their atherosclerosis (31).
However, angiography has a number of limitations which precludes its 
widespread use in certain patient groups and in research. The first of these is 
its invasive nature, for example coronary angiography has a reported mortality 
of between 0.1 and 0.2% and major morbidity (including Ml, stroke, ventricular 
fibrillation, vascular problems and bleeding) of between 1.7 and 2.6% (32). 
Hence, it is not ethical to perform angiography on the asymptomatic or serially 
without good indication on patients.
Also, there is evidence that angiography tends to underestimate the extent 
of disease and cannot detect early atherosclerosis. This evidence comes 
initially from the work of Glagov and colleagues (33) who examined diseased 
and non-diseased arteries at PM. They demonstrated that an artery’s 
response to eccentric accumulation of atheroma within the internal elastic 
lamina (the early development of atherosclerosis) is to undergo compensatory 
enlargement with only slow diminution of lumen diameter. Additional 
evidence showing that angiography underestimates atherosclerosis comes
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from studies using intravascular ultrasound. For example St. Goar et al have 
described the presence of extensive atherosclerosis in angiographically 
normal appearing arteries (34).
Another problem is how to quantify disease when there is a total occlusion 
of a coronary artery. Currently the occluded segment is usually scored as 
severe atherosclerosis but potentially a relatively minor stenosis has 
ruptured and superimposed thrombus has led to the complete occlusion. In 
addition, total obstruction of the lumen precludes visualisation of more distally 
located segments (35).
A fourth limitation is that because angiography is invasive in its use it is 
restricted to symptomatic populations and hence the generalisability of 
results obtained from such populations is limited (36). The final limitation is 
the difficulty with control selection in that angiography controls over­
represent related ischaemic or non-coronary cardiac conditions which have 
their own risk factor association (36).
Notwithstanding these limitations, angiography has been used to a limited 
extent in epidemiological and interventional atherosclerosis studies. There 
is little doubt that the angiographic severity of coronary atherosclerosis 
correlates with prognosis. This evidence comes from prospective studies 
published in the early 1980’s before the routine use of surgical intervention. 
Mock et al (37) reported data in 1982 from medically treated patients in the 
large coronary artery surgery study (CASS) and showed 4 year survival of 
97,92,84, and 68% for 0,1,2, and 3 vessel disease respectively. Proudfit et al
44
(38) in 1983 reported 15 year survival rates of 48,28,18 and 9% for 1,2,3 and 
left main stem disease respectively. In these two studies a vessel was scored 
as diseased if there was >1 stenosis >50%. Harris et al (39) in 1980 had 
shown that stenoses greater than 75% carried a worse prognosis than those 
measuring 50-75%. However there is a paradox here in that most myocardial 
infarctions occur as a result of the formation of thrombi on lesions that are not 
highly stenotic (40). Further, knowledge of the angiographic location of 
coronary stenosis does not allow one to predict the location of subsequent 
sites of acute occlusion (41).
Other coronary angiography studies have made an important contribution to 
our understanding of the association of coronary atherosclerosis, with various 
risk factors, especially blood levels of cholesterol, smoking, hypertension, 
alcohol and diabetes. Secondly, data from metanalysis of a number of 
angiographic studies of lipid-lowering secondary prevention has shown 
significant results (42). The metanalysis included 688 treated and 593 control 
subjects with entry and exit coronary angiograms. Analysis demonstrated that 
regression and stabilisation are 2 and 1.4 times more common in treated 
than placebo subjects and that progression is reduced by half. These results 
using the angiographic changes in atherosclerosis as a surrogate for 
cardiovascular events have been borne out by the much larger Scandinavian 
Simvastatin survival study (4S study) which used clinical endpoints (43).
It seems unlikely that non-invasive measurement of atherosclerosis will 
replace angiography for assessing the significantly symptomatic and this is
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outwith the scope of this thesis. However, the development of valid 
and reliable techniques of non-invasive assessment would be invaluable in 
a number of ways as follows:
1. As an additional diagnostic tool in those with minor or atypical symptoms 
which are insufficient to justify the risks and costs of invasive investigation.
2. To identify those with a large but still sub-clinical atherosclerotic 
load, both for intervention to halt the progression of disease and for 
intensive research. Currently an attempt to identify these high risk 
individuals is made by assessing their atherosclerotic risk factor profile. 
However, this has many limitations including inaccuracy and cost. 
Identifying these high risks individuals has become event more important 
with the recent publication of the West of Scotland Coronary Prevention 
Study (WOSCOPS)(44). This study for the first time showed definitive 
evidence that the cardiovascular benefits of lipid-lowering therapy in primary 
prevention are not offset by an increase in non-cardiovascular events. The 
study of 6,595 apparently healthy middle-aged men with mild-to-moderate 
hypercholesterolaemia (LDL cholesterol 4.5-6 mmol/L) showed a 31% peak 
(p=0.0001) reduction in the combined endpoint of fatal and non-fatal 
myocardial infarction after an average of 4.9 years of follow up.
In 1986 in the UK 66% of men aged 18-64 had a total cholesterol of greater 
than5.2 mmol/l and 28% had levels greater than 6.5 mmol/l (45). Therefore 
the cost implications of offering a significant proportion of them long­
term treatment with a relatively expensive drug (Pravastatin) at £31 per
46
month (46) is enormous. Thus, it seems likely that the use of lipid-lowering 
therapy in primary prevention will need to be rationed, and currently the 
WOSCOPS study group have recommended (47) treatment for those with an 
absolute risk of a cardiac event of greater than20% over the next 10 years 
based on their entire risk factor profile.
3. Serial measurements of atherosclerosis from an early age in 
large epidemiological studies would allow evaluation of the natural history of 
the disease. This would allow examination of which risk factor or factors, e.g. 
lipid or coagulation measure or lifestyle factor or gene are important for the 
initiation of atherosclerosis, the progression of atherosclerotic burden and 
progression of burden to clinical disease. The last point is especially 
important as the link between progression of coronary atherosclerosis and 
clinical complications remains unclear (48). For example are subjects with 
more rapid progression of atherosclerosic burden more likely to suffer 
clinical complications than those with slower progression? Intuitively the 
answer would be 'yes' but supporting data is limited. Similarly, why do certain 
lesions progress to devastating clinical events but other lesions of similar 
extent and creation remain silent. In addition, constant reassessment of 
risk factors for atherosclerosis is likely to be necessary in the future. This 
is because risk factors not previously recognised may be discovered when 
their prevalence increases or the prevalence of the other factors decrease.
4. If it can be shown that non-invasive techniques of quantification was valid 
and that the measured atherosclerotic extent correlated with the likelihood
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of clinical events, then serial measurements could be used to follow 
anti-atherosclerotic interventions, either by lifestyle adjustments 
or pharmacological interventions. Thus, similar statistical power to detect 
important effects would be achieved by much smaller patient numbers over 
shorter periods at much less cost than the current epidemiological studies 
which rely on comparatively rare clinical events as endpoints.
1.7 TECHNIQUES FOR NON-INVASIVELY ASSESSING CORONARY
ATHEROSCLEROSIS
1.7.1 Risk Factor Scores
There have been a number of attempts in the U.K. and U.S.A. over recent 
years to produce multifactorial scoring systems to assess the risk for patients 
of developing coronary heart disease. However, surveys have shown 
that these earlier multifactorial scores - for example from Framingham (49), 
Minnesota (50) and the Regional Heart Study (51) are not widely used.
These earlier scores included unmodifiable risk factors such as age, sex, 
family history, previous vascular disease and current angina and diabetes, 
along with the modifiable factors (hypertension, lipids and smoking) to 
produce a score of absolute risk. Such scores are more accurate 
predictors but very complex which may explain their poor uptake.
More recently, in 1989, the Coronary Prevention Group and the British 
Heart Foundation commissioned a new system for scoring risk with an
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emphasis on major modifiable risk factors which would be simpler to use 
and hopefully have wider acceptance.
In response to this Hugh Tunstall-Pedoe produced the Dundee Coronary Risk 
disk in 1991 (52) which measured coronary risk from smoking history, blood 
pressure and blood cholesterol. However, again the scoring system has not 
gained wide acceptance. It has been criticised because the risk factor profile 
from the Scottish population which was used in its generation differs from that 
of another area of the UK (53). They also have never been validated in 
controlled risk factor intervention studies.
1.7.2 Stress Testing
Stress testing using either exercise or pharmacological means, depends upon 
coronary atherosclerosis being sufficiently severe to produce myocardial 
ischaemia or reduced coronary blood flow and therefore they cannot detect 
early coronary atherosclerosis. There are three main techniques used, 
Exercise Electrocardiography, tress Radionuclide Scan and Stress 
Echocardiography.
The first of these is most commonly performed and electocardiograph (ECG) 
ST segment depression is used as a marker of myocardial ischaemia and 
therefore of significant coronary atherosclerosis.
However there are grave doubts about the specificity of ST segment 
depression used as the sole indicator of myocardial ischaemia since it may 
occur during ambulatory ECG monitoring in up to 20% of normal young
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subjects and in a number of other conditions (54). False positive tests are 
notoriously more common in women. In a metanalysis of 12 lead exercise 
ECG in detecting anatomically significant coronary disease, Gianrossi et al 
(55) demonstrated a sensitivity of 68% and specificity of 77%. It should be 
noted that anatomically significant coronary disease was defined as 1 or more 
stenosis > 50% at coronary angiography.
In patients without a history of chest pain, the predictive accuracy is even 
less. This is to be expected since the predictive value of any diagnostic test 
diminishes as the prevalence of the disease diminishes. Hence, for these 
reasons the exercise ECG is rarely used for screening asymptomatic 
individuals. Similar problems exist for the other stress testing modalities 
precluding their use other than in a clinical setting.
1.7.3 Ankle Arm Index
Lower limb atherosclerosis can be measured non-invasively using the ratio 
of arm blood pressure to ankle blood pressure. This is called the ankle arm 
index (AAI). The AAI was measured in 5,084 participants >65 years of age in 
the Cardiovascular Health Study (56). Participants were stratified by AAI 
(< 0.8, 0.8 to 0.9, 0.9 to 1 and greater than 1). AAI was inversely related to a 
history of clinical cardiovascular events, to cardiovascular risk factors and to 
other non-invasive measures of atherosclerosis (carotid plaques on 
ultrasound) and ECG abnormalities. AAI has been proposed as a 
surrogate marker of coronary atherosclerosis (56).
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1.7.4 Computerised Tomography
There has been a recent dramatic increase in the use of electron beam 
computerised tomography (CT) to screen for coronary calcium phosphate 
deposits largely in the USA (57). This increase in utilisation seems to be 
largely profit-driven (a test costs $400 including technical fee and professional 
interpretation). In 1993 a committee of the American Heart Association (58) 
concluded that the clinical use of ultrafast CT imaging to screen patients 
for coronary atherosclerosis is not justified at this time. Major reasons given 
were firstly, the lack of a precise correlation between the degree of 
atherosclerosis and coronary calcium and secondly, the unknown 
prognostic significance of calcification detected by this technology. Indeed 
there is some evidence that calcified plaques may be less likely to rupture 
and cause clinical events (59).
Certainly there can be little doubt that electron-beam CT scanning is a 
highly sensitive (approximating 100%) test for atherosclerosis based on data 
from autopsy studies (60) and coronary angiography in symptomatic 
patients (57). However, specificity and positive predictive values were of 
much lower magnitude (47% and 62%) respectively (57). Indeed greater 
than 60% of asymptomatic women and 80% of asymptomatic men greater 
than 60 years old have at least some detectable calcium by this method (61,62)
The current consensus is that the technology holds some promise, but much 
work remains to be done until it can be a useful test, either for clinical risk 
stratification or for epidemiological studies.
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1.7.5 Arterial Compliance
An index of arterial compliance (stiffness) can be produced by measuring 
pulse-wave velocity (PWV) at two points in the arterial system, either by use of 
magnetic resonance imaging (MRI) (63), doppler ultrasound (64) or 
applanation tonometry (65). It has been suggested that PWV measurements 
over long arterial pathways, for example the aorta, with consequent 
termination of the average compliance may give a good assessment of 
general atherosclerotic load (66).
However, there has only been limited in vivo human work in this area. Hirai et 
al (67) showed increasing abdominal and carotid artery stiffness in patients 
with increasing numbers of affected coronary arteries as assessed at 
angiography. Aortic stiffness increased in adults at increased risk of 
premature vascular disease as assessed by conventional risk factor 
profiles (64).
Although much work needs to be done, the technique is very promising as 
compliance measurements with doppler ultrasound have the necessary ease, 
safety and reproducibility to be potentially of use in long-term 
epidemiological studies (66).
1.7.6 Magnetic Resonance Imaging (MRI)
MRI is showing great potential in assessing a number of aspects of the 
cardiovascular system including left ventricular structure and function and 
myocardial ischaemia. In addition, investigators have recently shown that 
MRI can produce high resolution non-invasive coronary angiograms.
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Manning et al (68) in 1993 in 39 patients undergoing invasive 
coronary angiography showed that MRI angiography was 90% sensitive and 
92% specific in identifying individual vessels with greater than 50% stenosis 
(68). Another recent and exciting development has been the accurate 
quantification of atheroma inside carotid and popliteal arterial wall providing a 
direct measure of disease extent even when no stenosis has developed (69). 
However again this is an early preliminary finding and requires much further 
work.
MRI however is not without its limitations. It is costly and the size of the bore 
of the magnet precludes the extremely obese and claustrophobic. The 
magnetic field eliminates those with pacemakers and the technique requires 
several heartbeats to represent similar cardiac position and hence there is 
difficulty in those with cardiac dysrhythmia. In addition, the use of vascular 
clips and stents can create artefacts (70).
1.7.8 Peripheral Blood Markers
The major role to date of peripheral blood markers has been as part of overall 
risk factor scores as above. There are however examples from other diseases 
of the use of single blood markers in diagnosis and follow-up. These include 
proteins secreted from tumours (e.g prostate Specific Antigen), C-Reactive 
protein (CRP) and specific antibodies in bacterial infections and auto-immune 
antibodies in connective tissue disease (e.g Rheumatoid Factor (RF) in 
Rheumatoid Arthritis and Anti-Cardiolipin antibodies in Systemic Lupus 
Erythematosis).
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Thus in this thesis I examine the potential of two peripheral blood markers for 
the assessment of coronary atherosclerosis, antibody titres to heat shock 
protein 65 (anti-hsp65) and levels of plasma fibrinolytic factors.
1.7.9 B Mode Ultrasonography of peripheral arteries
This technique is the most widely studied and is largely regarded as providing 
the best measure of extent of whole body atherosclerosis, and as the most 
accurate surrogate marker of extent of atherosclerosis (71) and thus we 
decided to study it.
1.8 SUMMARY AND OUTLINE OF MD
This MD examines three techniques for the non-invasive measurement of 
coronary atherosclerosis: antibodies to heat shock protein 65 (reviewed in 
Chapter 2), carotid B-mode ultrasonography (reviewed in Chapter 8) and 
fibrinolytic parameters (reviewed in Chapter 10).
1.9 AIMS
1.To develop and validate an assay for antibodies to HSP65 and examine 
the population distribution of titres and factors that influence them.
2.To investigate the potential of anti-hsp65 as a marker of the 
presence, severity and diffuseness of coronary atherosclerosis.
3. Examine the relationship of anti-hsp65 antibodies with other risk factors for 
coronary atherosclerosis.
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4. Examine the relationship between anti-hsp65 and infection with Helicobacter 
pylori.
5. Investigate the potential B-mode ultrasound of carotid arteries as a marker of 
presence, severity and diffuseness of coronary atherosclerosis.
6. Compare risk factor profiles for coronary and carotid atherosclerosis.
/.Investigate the potential of endogenous fibrinolytic parameters as markers 
of presence, severity and diffuseness of coronary atherosclerosis.
8.Examine the relationship of endogenous fibrinolytic parameters with other 
cardiovascular risk factors especially elements of the Insulin Resistance 
Syndrome.
1.10 OVERALL OBJECTIVES AND POTENTIAL
1. To investigate, develop and validate methods of non-invasive 
assessment of coronary atherosclerosis. Potentially these would be of 
use in diagnosis and prognosis and epidemiological research into the 
natural history of the disease and to follow intervention.
2. To investigate whether and how the immune response to hsp65 and 
H.pylori and endogenous fibrinolytic factors might be involved in the 
pathogenesis of coronary atherosclerosis and athero-thrombosis.
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CHAPTER 2: INFECTION, IMMUNITY, HSP60/65 AND 
ATHEROSCLEROSIS
2.1 INFECTION AND ATHEROSCLEROSIS
A causative role for infection in the pathogenesis of atherosclerosis was first 
postulated by Sir William Osier in 1908 (72). Recent renewed interest has 
implicated two bacteria Helicobacter pylori and Chlamydia pneumoniae and a 
family of viruses, the Herpes viruses.
2.1.1 Helicobacter pylori
H.pylori is a chronic bacterial infection of the stomach which causes an active 
gastritis and is strongly associated with gastric cancer and peptic ulcer 
disease. 40-60% of middle aged men in the U.K are infected and the 
prevalence increases with age and lower social class (see Tables 2.1 and 2.2, 
KEL McColl, personal communication). Mendall et al (73) published the first 
data linking H. pylori infection and CHD in 1994. They compared H. pylori 
seropositivity among 111 men aged 45-65 attending a cardiology out-Patient 
clinic, compared to a group of 74 men attending a screening clinic in General 
Practice. The accrued odds ratio for CHD associated with seropositivity 
was 2.28 (95% confidence interval, 1.25-4.15). The odds ratio however, 
fell after adjustment for CHD risk factors and socio-economic status to 1.9 
(95% confidence intervals, 0.91-3.97).
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SOCIAL CLASS
1 2 3 NON- 
MANUAL
3
MANUAL
4 5
Men 26 47 63 75 77 82
Women 33 47 57 69 67 70
Both 28 47 58 74 72 74
Table 2.1 Percentage of subjects with H.pylori infection by social class 
(p<0.001).
Age Group
25-34 35-44 45-54 55-64 65-74 Total
Men 56 59 65 81 80 70
Women 50 54 61 70 69 62
Both 53 56 63 76 75 66
Table 2.2 Percentage of subjects with H.pylori infection by age group
(p<0.001).
In a second study by from the same centre in 1995 (74), Patel at al reported a 
cross-sectional study of a population based random sample of 388 white 
men. Forty-seven men had ECG evidence of myocardial ischaemia 
previous AMI. Odds ratio for abnormal ECG's was 3.82 (95% confidence 
interval, 1.6-9.1) for those seropositive for H.pylori, after adjustment for a 
range of socio-economic indicators and risk factors for CHD. Fibrinogen 
concentration and total leucocyte count in this study were independently 
positively associated with seropositivity to H.pylori and they postulated 
that H.pylori infection leads to increased CHD risk by inducing a 
hypercoaguable state. However, a study from a different centre in a 
population based random sample of over 2,000 men and women showed 
that the association between H.pylori infection and ischaemic heart 
disease (IHD) did not reach statistical significance after adjusting for all 
possible confounding influences (75). The odds ratio was 1.51 with a 95% 
confidence interval of 0.93-2.45, p=0.1 (75). In this cohort, there was a weak 
(p=0.02) negative association between H.pylori infection and Fibrinogen.
2.1.2 Chlamydia pneumoniae
Chlamydia pneumoniae is an intracellular bacteria which causes pneumonia, 
bronchitis, pharyngitis and sinusitis. However infections are usually subclinical 
and up to 60% of the population have evidence of past infection. (76). There 
have now been several studies examining the association between antibodies 
to C.pneumoniae and CHD. Saikku and colleagues (77) first reported such 
an association in 1988 when they showed that 68% of 40 males with AMI and
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50% of 36 males with chronic CHD had IgG titres > 1 2 8  and IgA > 32 to C. 
pneumoniae compared with only 17% of 40 control subjects. In an improved 
second case-control study sera from 300 subjects from the Helsinki Heart 
Study (78) were prospectively evaluated for circulating immune complexes to 
chlamydial Lipo-polysaccharide (LPS) and for antibody to C. pneumoniae and 
results were adjusted for age, smoking and hypertension. The combination of a 
high serum IgA antibody and high immune complexes to LPS held a relative 
risk for CHD of 2.6 (95 % Cl 1.3-5.2, p<0.007).
There have now been data from other groups supporting the association 
of C. pneumoniae infection and coronary (74,79,80) and carotid atherosclerosis 
(81). C. pneumoniae infection has been postulated to cause increased 
cardiovascular risk either indirectly by producing a rise in Fibrinogen (82) or 
Triglyceride (83) concentrations or more directly due to infection of 
atherosclerotic lesion cells (84).
2.1.3 Herpes Viruses
Seven members of the herpes virus family are now known to infect 
humans. Of these Herpes Simplex Virus type I (HSV-I), Herpes Simplex Virus 
type II (HSV-II) and human Cytomegalovirus (CMV) have all been associated 
with atherosclerosis. More than half of children demonstrate antibodies to 
HSV-I by 10 years of age, and the prevalence of HSV-I I infection is variously 
cited as 0.3-22%. Antibodies to CMV are even more widespread in the 
population, with cited previous infection rates of greater than 50% of adults
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(77). Evidence for involvement of herpes virus with atherosclerosis is 
accumulating rapidly.
In vivo studies in an animal model of atherosclerosis induced by a herpes 
virus has been developed by Fabricant et al (85). Pathogen free normo- 
cholesterolaemic chickens were infected with Marek disease virus and 30 
weeks after infection the chickens demonstrated gross atherosclerotic lesions 
in the large coronary arteries, the aorta and the major aortic branches (85).
In vivo studies of human atherosclerosis by electron microscopic and molecular 
biological techniques gives further support for a link with Herpes virus infection 
(86,87). Positive sero-epidemiological studies have been reported linking CMV 
antibodies with coronary (88) and carotid atherosclerosis (89).
2.2 INFLAMMATION, IMMUNITY AND ATHEROSCLEROSIS 
There has been increasing evidence over the last 10 years for the 
involvement of the immune response in atherosclerosis. Initially this area of 
research was largely neglected because the immune response was 
considered to be of a largely secondary nature, but recent evidence 
suggests that it may have a more prominent pathogenic role both in 
atherosclerosis and athero-thrombosis.
2.2.1 CRP Is A Risk Factor For AMI
C reactive protein (CRP) is an acute phase reactant and measurement of 
serum CRP levels reflects whole body inflammation. Using new more 
sensitive assay techniques, it has recently been shown in stable (90) and
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unstable angina (UA) (91) that higher levels of CRP is a risk factor for 
progression of atherosclerosis to myocardial infarction. In both these 
studies this association was independent of the angiographic 
severity of atherosclerosis.
2.2.2 Macrophages And Activated T Cells In Atherosclerotic Plaques. 
Immuno-histochemical analysis which has shown macrophages in all stages of 
atherosclerotic plaques and the lipid-rich region of advanced 
atherosclerotic plaques are dominated by macrophages (92). T cells are 
also present in all stages of atherosclerotic plaques (92) and many of these 
are in an activated state (93). Recent molecular genetic studies have 
shown that these activated T cells are heterogeneous in terms of their 
immunological specificity (94). In the early lesions cytotoxic T cells (CD8 
positive) dominate over helper T cells (CD4 positive) with a ratio of 
approximately 2:1. This situation is reversed in the advanced plaque (95) 
suggesting there may be a switch from a response driven by HLA class I 
restricted antigen to HLA class II restricted antigen during the evolution of the 
fatty streak into a fibro-fatty plaque. Also, mechanical testing of aortic fibrous 
caps indicates that increased macrophage infiltration weakens caps locally, 
reducing their tensile strength (96). This has been corroborated by 
immunohistochemical studies showing that there are more macrophages at 
regions of plaque rupture than at unruptured segments (97).
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2.2.3 Immunoglobulin And Complement Component In Plaques 
Immunoglobulins are present in high concentrations in the atherosclerotic 
plaque (98) B-lymphocytes are infrequent in the plaque and immunoglobulins 
are synthesised elsewhere and accumulate extracellularly and also in the 
cytoplasm of injured endothelial cells. Their role and antigen specificity 
remains unclear.
Several complement components have also been detected in the 
atherosclerotic intima, notably C1 and C3 (99) and C5b-9 (100). The finding of 
the latter is particularly important since it indicates activation of the 
complement cascade, however it’s role in atherosclerosis is unclear. Muscari 
et al (101) have shown an association of serum C3 levels with the risk 
of myocardial infarction. They studied 444 men and 416 women, all 
asymptomatic, and followed them up for 4 years. Elevated serum C3 was 
found to be independently associated with ischaemic atherosclerotic events.
2.2.4 Cytokines Are Present In Atherosclerotic Plaques 
Pro-inflammatory cytokines including interleukin-1, tumour necrosis factor, 
interleukin-6 and gamma-interferon are secreted in the plaque (102), probably 
by T lymphocytes, macrophages, endothelial cells and smooth muscle cells. 
Pathogenic consequences of such paracrine, cytokine secretion could include 
activation of macrophages and endothelial cells, stimulation of the 
immune responses, modulation of cholesterol uptake, and regulation of 
vascular haemostatic properties(102).
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2.2.5 Circulating Antibodies To Plaque Antigens
(i) Antibodies to Oxidised LDL
Oxidised LDL have been proposed to have a central role in the 
pathogenesis of atherosclerosis (see Chapter 1). Antibodies to oxidised LDL 
but not native LDL, occur naturally in man. They are not found in young 
adults, but are detectable in a high proportion of patients with advanced 
atherosclerosis (103). Salonen et al (104) in a case-control study showed 
that an elevated titre of antibodies to oxidatively modified LDL was 
associated with progression of carotid atherosclerosis. In 30 cases with rapid 
progression of atherosclerosis over two years the mean titre of oxidised-LDL 
was 2.67 compared to 2.06 in the controls (p=0.003). Even after adjusting for 
potential confounders (smoking, cholesterol and serum copper) and baseline 
severity of atherosclerosis the difference in antibody titre remained significant 
(p=0.031). Puurunen et al (105) have studied titres in 135 cases and 
controls from the Helsinki Heart Study. After adjustment for age, 
smoking, blood pressure and high density lipoprotein cholesterol level, there 
was a 2.5 fold increased risk (95% confidence interval, 1.3-4.9) of a cardiac 
endpoint in the highest tertile of antibody level versus the lowest tertile 
(p=0.005 for trend) (105).
(ii) Antibodies To Cytoskeletal Proteins
Nikkari et al (106) found statistically significantly elevated titres of 
autoantibodies to various cytoskeletal proteins in 10-25% of patients with 
coronary atherosclerosis compared to normal controls.
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(iii) Anti-Cardiolipin Antibodies
The data concerning the relationship between antibodies binding to 
anionic phospholipids such as cardiolipin and myocardial infarction in 
subjects without evidence of overt autoimmune disease are conflicting. All 
published studies have been performed on survivors of myocardial infarction 
or in patients with established coronary heart disease. Vaarala et al 
(107) examined a prospective cohort of 133 patients with cardiac endpoints 
and 133 controls, again from the Helsinki Heart Study. The subjects with 
antibody levels in the highest quartile of the distribution had an independent 
relative risk for myocardial infarction of 2.0(95%  confidence interval, 1.1- 
3.5). Further, there was a correlation between the levels of anti-cardiolipin 
antibodies and antibodies to oxidised LDL (r=0.40, p<0.001), and their joint 
effect was additive for risk. Two other studies have supported this result but 
three others have not (107).
2.3 HSP60/65 AND ATHEROSCLEROSIS
An offshoot of the research effort into thermal therapy for cancer has been an 
understanding of the mechanisms of cellular response to heat stress. 
Exposure of cells to heat stress, leads to the intracellular accumulation 
of so-called heat shock protein (hsp) (108), it has now been shown that 
increased hsp expression can also be induced by other cellular stresses 
such as infection, high temperature, free radicals, mechanical stress and 
hypoxia. However, many hsps including hsp 60/65 and 70 are constitutively 
expressed and necessary for normal cell function.
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There are 24 heat shock protein ‘families’ currently known. Members of a given 
family are defined by their molecular weight and share many features other 
than size, in particular members of a given family are highly conserved in 
phylogeny from bacteria to man. They appear to play a crucial cellular 
homeostatic role. Their cellular function is the intracellular handling of 
polypeptides, permitting them to reach their appropriate cellular destination, or 
to transport them across cell membranes, or, simply to prevent incorrect 
folding. As a result of these roles, the hsp's are often referred to as molecular 
chaperones (108).
2.3.1 Heat Shock Protein 60/65
Heat shock proteins of the hsp60/65 family (the abbreviation hsp60/65 refers to 
the whole family) include the GroEL protein of E.Coli, mycobacterial hsp65 
(hsp65), hsp62 of Helicobacter pylori, Human hsp60 (hsp60) and many others 
(109). Like all hsp families hsp60/65 is highly conserved between species, for 
example hsp65 is 75% homologous with hsp60 and hamster and rat 
hsp60 differ from human hsp60 by only 2 aminoacids (110). Hsp60/65 
appears to be present within mitochondria of all cells, although 
synthesis is cytoplasmic. There may also be cytosolic expression (111) and 
Xu et al have shown cell membrane expression on endothelial cell, 
macrophages and smooth muscle cells (112).
Hsp60/65 binds unfolded polypeptides which upon binding are converted to 
an ahelical structure (113). Hsp 60/65 is also considered to be essential for 
the correct assembly of unfolded polypeptides. (113)
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2.3.2 Hsp60/65, Autoimmunity and Atherosclerosis
Many hsp families have been implicated in various autoimmune diseases 
(reviewed in 108) including hsp70 in Graves' disease and Hashimoto's 
thyroiditis. There has also been data suggesting that hsp70 might be 
involved in atherosclerosis. Berberin et al (114) showed increased 
expression of hsp70 in the central portion of more thickened atheroma, 
around the site of necrosis and lipid accumulation. However most of the 
work relating hsp to auto-immunity generally and atherosclerosis specifically 
has been with regard to the hsp60/65 family.
Hsp65 of micro-organisms has been shown to be an immunodominant antigen. 
Up to 40% of the T cell response to mycobacteria is against hsp65 (115) and 
a variety of T cell types isolated from apparently healthy individuals have been 
found to recognise hsp60/65 (108). Over 90% of infants have detectable titres 
of antibodies to hsp60 (116). Further, Jones et al compared the amino acid 
sequence of hsp60 with a database of all sequenced human peptides and 
proteins (117). They showed that huhsp 60 shared sequence homology with 86 
peptides, of which 19 were known autoantigens including thyroglobulin in 
myasthenia gravis, cytokeratin in rheumatoid arthritis and 21 Hydroxylase in 
Addison’s disease. A similar analysis of albumin produced 136 peptides with 
sequence homology but only 4 of these were autoantigens (p<0.0003). In 
addition the sequences of hsp60 with similarity to autoantigens occurred at 
sites with high antigenic potential (117).
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There is increasing evidence to support a role for the hsp60/65 role in various 
auto-immune diseases including Rheumatoid Arthritis, Diabetes Mellitus, 
Kawasaki disease, psoriasis and atherosclerosis. The majority of the work has 
centred on experimental models and clinical studies of Rheumatoid arthritis.
A group of rheumatoid arthritis patients have been shown to have higher 
mean levels of IgG anti-hsp65 antibodies than controls (118). Bahr et al 
found a similar result (119) and in addition demonstrated no HLA linkage. Two 
other papers found no difference between case and controls (120,121). There 
is also some evidence for cellular immunity as T cells specific to hsp60 are 
detectable in synovial fluid of rheumatoid patients (122).
In Diabetes Mellitus Elias et al (123) suggested that a p cell target antigen in 
non-obese diabetic mice is a molecule cross-reactive with hsp65. The 
development of diabetes was associated with antibodies to hsp65 and T cell 
clones reactive to hsp65 were able to induce insulitis and hyperglycaemia in 
young pre-diabetic mice. However, the relationship between diabetes and 
hsp 60/65 remains controversial (108). Yokota et al (124) showed 
antibodies to hsp60 and hsp65 in convalescent, but not acute sera of 
young patients with Kawasaki’s disease. Increased antibody to hsp65 has 
been demonstrated in psoriasis, which may be related to disease severity 
(125).
There is accumulating evidence for involvement of hsp60/65 in atherosclerosis 
and this is largely the work of Qingbo Xu and colleagues. They initially 
injected a panel of antigens into normo-cholesterolaemic New Zealand white
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rabbits (126). The antigens included human and rabbit atherosclerotic 
lesion proteins, ovalbumin, various adjuvants and recombinant hsp65. The 
animals were sacrificed after 16 weeks and atherosclerotic lesions were found 
to have developed only in those animals immunised with antigenic 
preparations containing hsp65, either in the form of whole mycobacteria or 
purified recombinant hsp65.
Immunohistochemistry and immunofluorescence on serial frozen tissue 
sections from human atherosclerotic lesions as well as saphenous veins and 
vena cavae (112), detected hsp60 on endothelium, smooth muscle cells and 
macrophages in atherosclerotic plaque, whereas vessels of smaller diameter 
with normal intima showed no detectable expression of the stress protein. 
The intensity of hsp60 expression correlated positively with the 
atherosclerotic severity. In addition, a population of T cells in the 
atherosclerotic lesion were hsp60 antigen specific.
They then selected 15 human serum samples, with either high or low titres 
to hsp65 and investigated the reactivity of human atherosclerosis 
lesion components by immunoblotting and immunofluorescence techniques 
(127). The showed that all 5 high titres reacted with a 60 kD band 
of atherosclerotic lesion protein and human recombinant hsp60 on 
western blots. Pooled sera with low antibody titres to hsp65 did not show 
reactivity with any atherosclerotic lesion and media proteins.
In vitro studies with cultured rat endothelial cells showed that anti-hsp65 
antibodies induced complement mediated antibody lysis of the cells (128).
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Further culturing the endothelial cells under stressful conditions, including 
various cytokines produced increased cytoplasmic and surface expression of 
hsp60 (128). Similarly Heng and Heng working in the USA (129) have 
demonstrated in vitro that increased hsp60 expression in ischaemic human 
arterial walls occurs within 30 minutes of external ligation (129).
Finally Xu et al measured titres of antibody against hsp65 in 867 normal 
inhabitants of South Tyrol (age 40-79) and a significant correlation was 
found between anti-hsp65 antibody titres and the extent of carotid 
atherosclerotic plaque (r=0.23, p=0.001) (130). If other factors including age 
and sex were taken into account by multiple linear regression, the correlation 
of antibody titre with lesion size was of only borderline significance 
(p=0.083). However, elevated anti-hsp65 titre was significantly associated 
with the presence of carotid atherosclerosis after correcting for age, sex and 
10 other CHD risk factors in multifactorial logistic regression (p=0.002).
In an accompanying Lancet editorial Hansson stated that antibody to hsp65 
may prove to be the diagnostic marker of atherosclerosis that clinical 
medicine has been awaiting for many years (131). I explore this hypothesis in 
this thesis and examine factors influencing anti-hsp65 titres (chapters 3-7).
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CHAPTER 3: DEVELOPMENT OF ELISA FOR MEASUREMENT 
OF ANTI-HEAT SHOCK PROTEIN 65 ANTIBODIES
3.1 INTRODUCTION
ELISA (enzyme linked immunosorbent assays) has been developed in 
many configurations and for many applications. A direct ELISA was developed 
in this study to measure IgG and IgA anti-hsp65 levels. Initially the antigen 
(hsp65) is adsorbed on to a solid support, the wells of a polypropylene 96 
well microtitre plate. The plates are washed between all stages of the ELISA. 
Unbound sites are then blocked by using an unrelated protein (BSA) which 
binds to any free sites on the plate. The serum samples are then added to the 
plates for 1 hour to allow conjugation between specific antibody and the 
bound antigen. The serum samples are then washed off leaving complexed 
antibody and antigen. A purified anti-human antibody conjugated with a 
Horse-radish Peroxidase enzyme is then added. After this the developing 
solution is added and a colour reaction occurs, which is proportional to the 
amount of specific bound antibody. The colour is then assayed by 
spectrophotometry
3.2 MATERIALS
CHEMICALS (Sigma Chemical Co. Limited, Poole, Dorset).
Bovine serum albumin (BSA), Tween 20, O-Phenylenediamine (OPD)
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ANTI-SERA (Dakopatts, Glostrup, Denmark)
Horseradish peroxidase conjugated rabbit anti-human IgG
ANTIGEN (National Institute of Public Health and Environmental Protection, 
Bilthoven, The Netherlands)
Recombinant hsp65 was produced, purified, aliquoted, and lyophilised with 
support from the UNDPA/Vorld Bank/WHO special programme for research 
and training in tropical diseases. The protein was obtained from heat- 
induced E. coli K12 strain M1164, which carries plasmid pRIB1300. Cells were 
lysed by lysozyme treatment and sonication. After centrifugation, the protein 
was precipitated from the supernatant with ammonium sulphate (20-55% 
cut). The precipitate was dialysed and further purified by DEAE anion 
exchange chromatography, dialysed against 10 mM ammonium bicarbonate, 
aliquoted and lyophilised. There was a total of 0.7mg in each vial provided. 
On arrival in Glasgow, the protein was dissolved in 1 ml of 
phosphate-buffered saline (PBS) and stored at -20°C in 50 pL aliquots.
BUFFERS
All buffers were prepared with Analar reagents (British Drug Houses, Poole, 
Dorset) and deionised water.
(i) Phosphate buffered saline (x 20)
NaCI 320g
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K2HP04 48.4g 
KH2P 04 13.6g
These chemicals were dissolved in deionised water and the solution was 
made up to 2 litres.
(ii) Coating buffer 
Na2C 03 0.79g 
NaHC03 1.46g
These chemicals were dissolved in deionised water and the final solution 
made up to 500 mis. The final pH was checked to ensure that it was 9.6.
(iii) O-phenyldiamine (OPD) developing solution
Concentrated KOH was added drop-wise to 25 mis of 0.2 M citric acid until the 
pH was adjusted to pH5. This was then made up to 50 mis total volume with 
deionised water and 0.025 mg of OPD was added. Immediately prior to 
use, 25 pL of 30% w/v hydrogen peroxide was added.
3.3 METHODS
3.3.1 Caprylic Acid Purification of IgG
IgG was purified from a serum sample with a high IgG anti-hsp65 concentration 
according to published methods (132). Briefly 0.1 M Acetic Acid was added to 
the sample to reduce the pH to 4.5 to 5 and the final sample volume 
measured. Caprylic acid was then added to give a 5% suspension, which was 
then mixed vigorously and spun for 7 minutes at 10,000g. The supernatant
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was then removed, a 50% saturated ammonium sulphate cut was performed 
and the solution was mixed at room temperature for 2 hours. It was then spun 
at 10,000g for 7 minutes and the pellet was re-suspended in PBS and then 
dialysed overnight into PBS. The subsequent concentration of purified IgG 
was then calculated by spectrophotometry.
3.3.2 IgG anti-hsp65 ELISA conditions
This was developed and modified from the method described by Xu et al (130). 
They did not use a standard curve with their test samples and merely 
expressed their concentrations of anti-hsp65 as OD units. We incorporated a 
standard curve into the assay to give more accurate and reproducible results. 
For this we used purified IgG as described in section 2.1 above.
Microtitre plates were coated with 1 pg/ml of recombinant hsp65 in 100pL of 
PBS per well at 4°C overnight. The plates were then washed with 0.01% 
Tween in PBS and blocked with 200 pL 0.1% BSA in PBS (PBS-BSA) at room 
temperature for 1 hr. The plates were washed again and then incubated with 
100 pL of serum samples diluted 1:400 with PBS-BSA. After a further wash 
in PBS-Tween the plates were incubated with HRP-conjugated rabbit anti­
human IgG diluted 1:3000 in PBS-BSA. This was left at room temperature 
for 1 hr and the plates were washed again with PBS-Tween again. Colour 
was developed using OPD and the reaction stopped with 4N H2S 04. The 
mean absorbence was calculated for each test sample and compared with 
the serial dilution’s of the standard. The unknown values for each test sample 
were interpolated from the standard curve, and the values expressed as
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Arbitrary Units per ml (AU/ml). A representative standard curve is shown in 
Figure 3.1.
Two coating antigen concentrations (1 pg/ml, 2 pg/ml), 6 serum dilutions 
(1/25, 1/50, 1/100, 1/200, 1/400,1/800) and 2 HRP conjugated rabbit anti­
human IgG concentrations (1:1000 and 1:3000) were tried in various 
combinations to optimise assay conditions. The combination of antigen at 
1mg/ml, serum dilution of 1/400 and anti-IgG antibody 1:3000 was finally 
chosen so that most test samples fell within the middle of the standard curve. 
Optical densities interpolated from nearer the middle of the standard curve give 
a more precise outcome than optical densities near the boundaries (133). If 
sample readings were very high, they were repeated at a greater dilution so 
that their optical density fell within the middle range of the standard curve.
Samples were run in triplicate and if any of the three readings varied by 
greater than 10% from the mean, the sample was repeated.
3.3.3 IgA anti-hsp65 ELISA condition
The ELISA conditions were exactly as for IgG anti-hsp65 above with three 
exceptions; the serum samples were diluted 1:100; HRP conjugated rabbit 
anti-human IgA 1:3000 was used; a serum sample with a high titre of IgA anti- 
hsp65 was serially diluted from 1/25 to generate the standard curve. Again pre 
and post samples from a given patient were assayed on the same plate.
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3.3.4 Effect Of Storage Conditions On Anti-hsp65 Measurement
The effect of repeated freeze/thaw cycles on anti-hsp65 titres were investigated 
by running two control samples with all 13 plates used in chapter 4. The 
control samples were thawed and refrozen on each occassion and it was 
noted that there was a significant decrease in control titres with time. Thus, it 
was concluded that the anti-hsp65 antibody seemed to be particularly 
susceptible to repeated freeze thaw cycles and in all subsequent 
experiments the following precautions were taken.
1. Serum samples were thawed for the absolute minimum time possible.
2. Control samples were multiply aliquoted so that each aliquot had been 
frozen and thawed the same number of times.
3. It was checked that all test serum samples in a given experiment had 
been frozen and thawed the same number of times prior to assay and that this 
was not greater than 3.
3.4 REPRODUCIBILITY
3.4.1 Inter-assay variation
Inter-assay variation was established by running aliquots of 2 samples on 10 
consecutive plates. The following results for the two samples were obtained:
Sample
No.
Mean S.D C.V (%)
1 57.9 5.38 9.29
2 40.1 5.62 14.00
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3.4.2 Intra-assay variation
Intra-assay variation was established by running 2 samples 8 times each on the 
same plate (different samples than used in calculation of inter-assay variation).
Sample
No.
Mean S.D C.V (%)
1 48.00 2.62 5.40
2 92.29 3.10 3.40
3.4.3 Standardisation between chapters
Different control sera were used in chapters 4, 5 and 6. The same controls 
were used in chapters 6 and 7. Thus, absolute figures for anti-hsp65 titres can 
only be compared between chapters 6 and 7.
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CHAPTER 4: THE DISTRIBUTION OF ANTI-HSP65 IN A 
POPULATION OF NORMAL TWINS
4.1 INTRODUCTION AND OBJECTIVES
The main objective of this chapter was to establish the population distribution of 
anti-hsp65 antibody titres. We studied 123 pairs of normal twins for this 
purpose, this population could also be used to examine the effects of age, 
sex, genetic and environment on antibody titres.
A secondary objective was to examine the relationship of anti-hsp65 with 
rheumatoid factor (RF) titres and the rationale for this is as follows.
The part played by RF, (anti-IgG) in the pathogenesis of rheumatoid arthritis 
(RA) remains unclear. RA is an inflammatory disease of the articular synovium 
resulting in erosion and deformity of the involved joints. Rheumatoid arthritis 
is now considered to be an autoimmune disease because of the local 
infiltration of T and B lymphocytes, its HLA associations, particularly with 
DR4, and the presence of B lymphocytes in plasma cells synthesising RF 
within the synovium (134).
Environmental and genetic factors have been implicated as causal factors 
in the development of RA. Many now accept that experimental RA can be 
induced by bacterial and viral triggers, and several have been 
implicated as playing an important role in the induction of RA. In recent 
years much interest has focused on the antigens derived from
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myocobacteria. Studies have shown that normal subjects have B cells 
capable of producing RF when they have help from appropriate helper 
T cells (TH) (135) and in this situation bacterial superantigens have been 
shown to activate the necessary TH cells. Mycobacterial heat shock 
protein (hsp65) is such an antigen and there is some evidence for involvement 
of this antigen in rheumatoid arthritis (see chapter 2). In addition, patients with 
rheumatoid arthritis have an mortality from IHD by an unknown mechanism 
(136). For these reasons we felt it was important to examine the relationship 
between these two antibodies in this population.
4.2 MATERIALS AND METHODS
4.2.1 Subjects
Following appeals on local radio and in the National and local press, 123 
pairs of twins were recruited into the study. The study was approved by the 
hospital ethical committee and all patents gave written informed consent. Each 
set of twins were reared together until adulthood was reached. The age 
range was 14-79 with a mean of 37.3. Their were 8 monozygotic male pairs, 
53 monozygotic female, 6 dizygotic male, 35 dizygotic female and 21 
dizygotic male-female twin pairs. Zygosity and sex were confirmed by blood 
group testing (137). A full medical history and examination was performed and 
twin pairs excluded from further analysis if either twin had any infection or 
chronic inflammatory disorder at the time of interview. 40 ml of venous blood 
was taken from each individual and allowed to clot at room temperature for 1 
hr and then placed in ice for 30 minutes to allow clot retraction. After 
centrifugation (2,000g at 2°C for 15 minutes] the serum was removed and
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stored in aliquots at -70°C. The serum samples were arranged in a strictly 
random order for each assay and were analysed blindly for the three RF 
isotypes and for anti-hsp65.
4.2.2 Anti-hsp65 Assay
Antibody titres were measured as described in chapter 3. The standard was 
given an IgG anti-hsp65 titre of 2.8 AU/ml based on the estimated IgG 
concentration purified from the standard sera.
4.2.3 RF Assay
Rheumatoid factor isotypes were measured by ELISA using a modification of 
the method described by Faith et al (138). Briefly, microtitre plates were 
coated with human IgG (5pg/ml) for IgM-RF and IgA-RF assays and rabbit 
IgG (5pg/ml) for IgG-RF assay. Between all stages plates were washed 
extensively in phosphate buffered saline (PBS) containing 0.05% Tween-20 
(Sigma). The remaining active binding sites were blocked with 0.1% gelatin 
(BDH). After incubation with serial dilutions of a standard or with test 
samples, horseradish peroxidase (HRP) conjugated F(ab/)2 anti-IgM or 
anti-lgA or anti-IgG (Dakopatts) was added to detect bound antibodies.
The colour reaction was developed using OPD (Sigma) and the reaction 
stopped with 4N H2S 04. Absorption was read at 490 nm on an automatic 
ELISA reader and the mean absorbance was calculated for each test 
sample and serial dilutions of the standard. The standards were given an RF 
value of 5,000 Arbitrary Units/ml (AU/ml) 400 AU/ml and 1,000 AU/ml for the 
IgM, IgA and IgG assays respectively. The AU/ml value of each test sample
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was read from the appropriate standard curves and corrected for dilution 
factors.
4.2.4 Statistical Analysis
There were significant differences between different assay plates, and this 
was corrected as far as possible by subtracting the corresponding plate 
mean and adding the grand mean. This left the mean log anti-hsp65 
unchanged; i.e. left the geometric mean of anti-hsp65 unchanged. The 
relationship with age and the familial resemblance between twins was then 
measured by Spearman's rank correlation coefficient. The effect of sex was 
examined by Student’s T-test.
Correlations between RF and anti-hsp65 titres were examined by 
rank correlation analysis after separating the data set into two. The first set 
comprising the first twin of each pair and the second comprising the second 
twin pair, so as to ensure that the items of data within any one data set were 
mutually independent.
4.3 RESULTS
4.3.1 Anti-hsp65
The anti-hsp65 titres showed a strong positive skew, and so for 
descriptive purposes logarithmic data were used. The lower limit of detection 
was about 0.3 AU/ml, so observations off the bottom of the scale were 
arbitrarily set at half this value before taking logs. Anti-hsp65 antibodies were 
detectable in 90.5% of subjects with a geometric mean (SD) of 1.50 (2.57) and 
range of 0.15-19.7 AU/ml (The distribution is illustrated in Figure 4.1). There
79
were 3 unrelated twins with very elevated levels of anti-hsp65 at 12.1, 15.0 
and 19.7 AU/ml respectively. We calculated the normal range by defining 
limits so that 214% of the total number of subjects (i.e. 6) were below the 
lower limit and 6 subjects were above the upper limit of normal. This gave a 
normal range of 0.19-8.0 AU/ml. There was no statistically significant 
correlation of the titres of anti-hsp65 antibodies with age (Figure 4.2). There 
was a trend for females to have a higher mean titre (2.29 compared to 2.19 
AU/ml, see Figure 4.3) but this did not reach statistical significance.
Complete data was available on 57 pairs of monozygotic twins and 57 
pairs of dizygotic twins. When anti-hsp65 levels were compared between 
individuals of a twin pair, the correlation coefficient was 0.015 for the 
monozygotic twins and 0.025 for dizygotic twins (see Figure 4.4).
4.3.2 RF and Anti-hsp65
There was no significant correlation between anti-hsp65 titres and any of 
the RF isotypes (see Table 4.1) None of the twins with very elevated anti- 
hsp65 titres had elevated RF titres or vice-versa.
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IgM RF IgA RF IgG RF
First twin 
anti-hsp65 -0.15 0.086 -0.056
Second twin 
anti-hsp65 -0.050 -0.023 0.026
Table 4.1 Correlations between anti-hsp65 and RF isotypes (p=ns for all).
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4.4 DISCUSSION
Anti-hsp65 was detectable in 90.5% of this population (normal range 0.15 -
8.0 AU/ml) who had none of the chronic inflammatory diseases 
commonly associated with these antibodies. This is very similar to the work of 
Giudice and co-workers (139) who showed that 88.9% of infants produced 
rising titres of anti-hsp65 after pertussis vaccination. These results together 
suggest that about 10% of the normal population are non-responders to hsp65 
or alternatively may respond initially (IgM or IgA) but do not develop lasting IgG 
titres.
There was no evidence of an effect of age (Figure 4.2) or sex (Figure 4.3) on 
anti-hsp65 titre. Pilkington et al (140) also showed no influence of age on anti- 
hsp65 or anti-hsp60 titre in a population of 173 children aged 6 months to 10 
years. Tsoufla et al (118) studied a population consisting of 91 RA cases, 90 
Tuberculosis cases and 130 controls with an overall mean age about 35 and 
could demonstrate no age effect. On the contrary Xu et al (130) did find a 
significant independent association (r=0.21, p=0.002) between age and anti- 
hsp65 titre in a population based random sample of 847 middle aged and older 
Austrians (mean age about 60). This population was older than ours (mean
37.3 years ) and the other two quoted. Thus it may be that in later life age is 
associated with anti-hsp65 titre. Certainly most auto-antibodies have a least 
some evidence of a positive relationship with age for example Xu et al (130) 
showed that RF increased with age.
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We demonstrate that females had slightly higher anti-hsp65 titres (2.29 
compared to 2.19 AU/ml) but this did not reach statistical significance. Xu et al 
(130) showed a clear trend in the older age range for females to have higher 
titres but Worthington et al (120) showed no sex difference. Most auto­
antibodies have higher titres in females, for example Xu and colleagues 
demonstrated a significant positive association between female sex and four 
auto-antibodies (130).
The correlations of anti-hsp65 antibodies between twin pairs was 
poor, suggesting that at most there are only minor familial influences on 
anti-hsp65 titres. In addition, we found the correlation to be greater between 
dizygotic twins, and hence there is no evidence of a genetic effect on titres.
Similar findings have been shown by Bahr et al (119) who examined the 
relationship between HLA tissue type in 84 normal individuals with anti- 
hsp65 titres and found none to exist. Importantly, Thompson et al (141) 
showed that specific pathogen-free mice (SPF) maintained in an isolator, 
have negligible levels of anti-hsp65 antibodies, but when exposed to normal 
animal house conditions, the mice became antibody positive. Thus the
evidence strongly indicates anti-hsp65 antibody levels are predominantly a 
result of environmental conditions. However, Worthington and co-workers 
(120) suggested that there may be a minor genetic influence in titres.
They examined anti-hsp65 antibody titres in a population of twins
discordant for RA and showed that the estimate of heredibility was greater in 
monozygotic twins (r=0.296) compared to dizygotic twins (r=0.201),
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suggesting that to a very small extent there may be a genetic role in anti- 
hsp65 responses. However they did not state whether these estimates were 
statistically significant. Possible explanations for these contradictory results 
include because the populations were different as in Worthington’s study their 
twins were discordant for RA, a potentially important confounder. Also they do 
not state in their methodology whether samples were analysed blindly and in 
random order. If members of twin pairs were assayed on the same batch or 
even on the same day then spurious intra-pair correlations may be created due 
to inter-batch variation.
We found no evidence of a correlation between anti-hsp65 and any of 
the RF isotypes. This argues against the hypothesis of hsp65 working as 
bacterial superantigen to provide TH for RF production. Worthington et al 
(120) is the only other study to examine the relationship between rheumatoid 
factor and anti-hsp65 titres. They also showed, albeit in a rather indirect 
fashion, no evidence of correlation between RF and anti-hsp65 titres; 64% of 
their subjects with RA were RF positive against 7% of disease free subjects 
and there was no difference between the groups in anti-hsp65 titre.
In summary, anti-hsp65 titres were detectable in 90.5% of subjects, 
similar to previous work. There was no evidence of significant familial, age 
or sex influences on anti-hsp65 titres. In addition, there was no evidence to 
support the hypothesis that hsp65 functions as a bacterial superantigen to 
provide helper T cell support for RF production.
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CHAPTER 5: ANTI-HSP65 TITRES IN ACUTE CORONARY 
SYNDROMES
5.1 INTRODUCTION
Acute myocardial infarction is defined as necrosis of cardiac tissue due to 
occlusion of the infarct artery (10). Unstable angina is defined as angina 
of increasing frequency and severity, not only induced by effort, but also 
occurring at rest (142).
The occlusion of a coronary artery leading to AMI appears to be the final 
common pathway, resulting from a complex and dynamic interaction between 
chronic atherosclerosis, vasospasm, plaque rupture and platelet activation, 
ultimately leading to thrombosis and occlusion. Evidence from PM histology 
(143) and acute angiography (144) suggests that atherosclerotic plaque 
rupture is a central event with subsequent superimposed occlusive 
thrombus. Pathological studies of patients with UA are rare, but suggestive 
of interaction of coronary vasospasm and plaque rupture with non-occlusive 
thrombus (142). Thus, plaque disruption is the central event in 
transforming chronic atherosclerosis to acute coronary syndrome. Whether 
AMI or UA develops depends upon whether the subsequent superimposed 
thrombotic occlusion is complete for greater than 30-40 minutes.
84
The risk of plaque disruption is related to extrinsic factors acting on plaques 
(‘rupture triggers’) and to intrinsic properties of the individual plaques (‘their 
vulnerability’)(97).
Coronary plaques are constantly stressed by a variety of extrinsic 
biomechanical and haemodynamic forces that may precipitate disruption of 
plaques.. From Laplace’s Law the tension created in fibrous caps of mildly or 
moderately stenotic plaques is greater than that created in caps of severely 
stenotic plaque (smaller lumen) with the same cap thickness and exposed 
to the same blood pressure. This may partly explain the observed findings 
that less severe stenotic plaques are more prone to rupture (97).
There is some in vivo evidence that haemodynamic rupture triggers may be 
important as a proportion of acute coronary events do appear to be 
precipitated by external factors or conditions including emotional stress 
and vigorous exercise. However the majority of plaque ruptures are not clearly 
related to an episode of haemodynamic stress and in these cases the plaques 
intrinsic vulnerability may be more important (although there is likely to be an 
interaction with triggering factors). Pathological examination of intact and 
disrupted plaques and mechanical testing of isolated fibrous caps indicate 
that a plaque's intrinsic vulnerability to rupture depends on three main 
factors (97).
Firstly, the size and consistency of atheromatous core varies greatly from 
plaque to plaque and appears critical to the stability of individual lesions based 
on the work of Gertz & Roberts (145). They reported the composition of
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plaques in 5 i^m segments from 17 infarct-related arteries examined PM and 
found much larger atheromatous cores in the 39 segments with plaque 
disruption than the 229 segments with intact surface (32% and 5-12% of 
plaque area respectively) (145).
Secondly it has been demonstrated in vitro that fibrous cap thinning and 
reduced collagen content increase a plaque's vulnerability to rupture (146).
Thirdly, mechanical testing of aortic fibrous caps indicates that increased 
foam cell infiltration weakens caps locally, reducing their tensile strength (96). 
This has been corroborated by immunohistochemical studies showing there are 
more macrophages at regions of plaque rupture than at unruptured segments 
(97). These findings suggest that the inflammatory status of plaques may be an 
important influence on plaque stability and the chapter examines this hyothesis.
5.2 OBJECTIVES
1. To examine whether AMI leads to a change in anti-hsp65 titres. This could 
either be secondary to increased hsp65 expression consequent to 
myocardial ischaemia with oxygen radical generation. Alternatively, the 
autoimmune response between hsp65 on atherosclerosis cells and host- 
specific T cells and immunoglobulins might contribute to plaque disruption.
2.To investigate whether patients with acute coronary syndromes have 
elevated anti-hsp65 titres compared with those with chronic stable 
atherosclerosis. Elevated titres in unstable syndromes might reflect 
heightened immunological/inflammatory response in the atherosclerotic
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lesions. Potentially anti-hsp65 titres could be useful to risk stratify patients 
with stable chronic atherosclerosis who are more likely to go on to plaque 
disruption and acute coronary syndromes.
5.3 MATERIALS AND METHODS
5.3.1 Subjects
The study was approved by the hospital ethical committee and all patents gave 
written informed consent.
Subjects were excluded if they had a history or clinical evidence of any other 
disease associated with elevated anti-hsp65 titres (including diabetes, 
rheumatoid arthritis, on-going inflammation, infection or neoplasm). Only males 
were recruited in three cohorts a follows:
(i) Chronic atherosclerosis
We recruited 136 consecutive eligible male subjects admitted for elective 
cardiac catheterisation. Subjects were excluded if they had any other 
disease associated with elevated anti-hsp65 titre, including diabetes 
mellitus (fasting glucose of greater than 7.8 mmol/l), rheumatoid arthritis, 
SLE or had other evidence of active infection, inflammation or 
malignancy or other significant disease (including more than mild renal or 
hepatic dysfunction), history of AMI or UA in the previous three months or 
had had previous coronary angioplasty or coronary artery bypass surgery. 
A further 18 of the 136 subjects were also excluded as they did not have a 
history typical of stable angina as assessed by the Rose questionnaire (147). 
In the majority of cases, the angiography was indicated for the
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assessment of chest pain and a smaller group of patients were being 
investigated for valvular abnormalities. The subjects were recruited over a 
seven month period and the population demographics are listed in Table 
5.1. The study was approved by the hospital Ethical Committee and all 
patients gave informed consent. Patients were examined including weight and 
height and excluded if any of the exclusion criteria were revealed. Patients 
filled in a short health questionnaire, including questions on past and 
concomitant health problems, history of hypertension, and smoking record. 
Smoking was treated as a categorical variable (smoker, non-smoker, ex­
smoker).
(ii) Unstable Angina
Inclusion criteria-both of the following had to be present
1.History compatible with unstable angina, i.e. recent onset or increase in 
typical angina, with symptoms occurring on minimal exertion or at rest, but 
lasting less than 30 minutes.
2.ECG evidence of myocardial ischaemia consisting of at least T wave 
inversion (greater than 1 mm) in two contiguous limb leads and/or ST 
depression (greater than 1 mm) in two contiguous leads.
Exclusion criteria-if one was present the patient was excluded
1. Cardiac enzyme rise, Creatinine Kinase (CK) greater than 2 times upper 
limit of normal) or sequential ECG changes diagnostic of acute Ml.
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2. AMI within the previous 3 months.
3. Pulmonary oedema or haemodynamic compromise.
4. Other significant on-going hepatic, renal or cardiac disease.
A total of 12 men who met these criteria were recruited over a 4 month 
period (see Table 5.1).
(iii) Acute Myocardial Infarction
Inclusion criteria- all three of the following had to be met
1. History of significant on-going chest pain lasting greater than 30 minutes.
2. ECG evidence of acute transmural myocardial infarction, i.e. ST elevation 
of greater than 1 mm in two contiguous limb leads or greater than 2 mm in 
two contiguous chest leads.
3. A rise in CK to greater than twice the upper limit of normal, confirming the 
diagnosis of acute Ml.
Exclusion criteria-if one was present the patient was excluded.
1. History of episode of unstable angina or myocardial infarction within 
3 months of admission.
2. Cardiac enzyme rise (CK greater than 2 times upper limit of normal) but no 
ECG changes diagnostic of acute transmural Ml.
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3. AMI within the previous 3 months.
4. Pulmonary oedema or haemodynamic compromise.
5. Other significant on-going hepatic, renal or cardiac disease.
A total of 12 men who met these criteria were recruited over a 4 month 
period (see Table 5.1).
5.3.2 Blood sampling
In the chronic atherosclerosis group this was performed on the 
morning of angiography as detailed in Chapter 6. In the unstable angina 
group, this was performed within 12 hours of admission. In the AMI group 
three blood samples were drawn from each patient. The first of these was 
taken as soon as possible after admission and before thrombolytic therapy 
was administered to the patient. The second was drawn about 72 hours 
after admission and the third after 120 hours. Serum samples were 
immediately put on ice and centrifuged within 1 hr and stored at -20°C for 
subsequent analysis.
5.3.3 Antihsp65 Assays
The assays were performed as in chapter 3. The samples from the three 
patient groups were analysed together in random order and blinded to the 
underlying diagnosis.
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5.3.4 Statistical Analysis
The anti-hsp65 titres showed a strong positive skew, and so for 
statistical purposes logarithmic data were used. There were significant 
differences between assay batches and each log titre was corrected as far as 
possible by subtracting the mean log titre of the corresponding plate and 
adding the grand mean log titre. This left the mean log IgG anti-hsp65 
level unchanged, i.e. left the geometric mean IgG anti-hsp65 titre 
unchanged.
One-way Analysis of Variance was used to examined for differences in age and 
anti-hsp65 titre between the three groups. This technique was also used to 
examine the serial anti-hsp65 titres following acute Ml. Finally, Student’s t- 
test was used to investigate differences in mean titre between stable 
and unstable coronary syndromes.
5.4 RESULTS
There was no difference in demographics between the three different 
coronary syndrome groups (Table 5.1). There was a trend for anti-hsp65 titres 
to fall with time in the acute Ml cohort, although this did not reach statistical 
significance (Figure 5.1). Figure 5.2 illustrates individual patient data. Titres 
fell in 9/12 patients, stayed the same in two and rose slightly in one. There was 
no difference in anti-hsp65 titres between the three cohorts (Figure 5.3). In 
addition, there was no statistical difference between the chronic 
atherosclerotic group and the combined acute coronary syndrome group 
(Figure 5.4).
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Ml (n=12) UA (n=12) SA (n=118)
Age (years) 58.0 58.5 56.4
BMI (kg/m2 ) 24.18 26.32 26.47
Hypertension (%) 18.2 27.3 29.3
Smoking - Current data
unavailable
41.6 20.7
-E x 58.3 63.0
- Never 0 16.3
Table 5.1 Description of cohorts (p=ns for all comparisons)
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5.5 DISCUSSION
There was no evidence of a rise in anti-hsp65 titres following AMI. Indeed there 
was a trend for the titres to fall in the first five days post-infarct (Figures 5.1 and 
5.2). This data argues against the autoimmune response with hsp65 on 
atherosclerosis cells contributing to plaque disruption.
Heng and Heng (129) have recently shown in vitro, increased hsp65 
expression on human medial cells within 30 minutes of external arterial ligation. 
They studied 35 branches of the gastro-duodenal, superior and inferior 
mesenteric arteries and all 22 ligated arterial specimens reacted 
positively to monoclonal antibodies against mycobacterial hsp65, 
whereas all 13 non-ligated arteries were negative. Further, hsp65 was 
closely associated with activated T cells at sites of arterial injury. Thus it seems 
probable that there is increased local hsp65 expression at the time of 
arterial occlusion and injury during AMI, but this is not reflected by a rise in 
anti-hsp65. This is perhaps because none of the additional hsp65 is released 
systemically to induce a further immune response. However the trend for the 
titres to fall suggests the alternative explanation that the additional hsp65 is 
cleared by the pre-existing antibodies, and there is insufficient new antigen 
load to stimulate a rise in anti-hsp65 titres.
One potential criticism of our methodology is that we sampled only up to 5 
days. However, all patients had detectable antibody titres at base-line, 
suggesting that any additional antibody rise would be a secondary immune
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response and would be obvious within the 5 days. Thus, it appears that 
acute myocardial infarction does not lead to a serial rise in anti-hsp65 titres.
The second conclusion is that there was no significant difference in titre 
between acute coronary syndromes and stable chronic atherosclerosis. 
Indeed, there was a trend for patients with stable symptoms seem to have 
higher titres than those with acute coronary syndromes. However it is also 
possible that because of the small numbers in two of the cohorts, that the study 
had insufficient power to detect a difference in titres.
Nevertheless the data certainly argues against the possibility of anti-hsp65 
titres having a discriminant role in risk stratifying patients with stable angina 
to determine those more likely to go on to plaque rupture and clinical events. 
These results are disappointing in view of the recent emerging data regarding 
C-reactive protein as a risk factor for progression of atherosclerosis to 
myocardial infarction irrespective of the underlying severity of atherosclerosis 
(90)(see chapter2). It is unclear whether the increased CRP reflects the 
inflammatory activity in the coronary arteries or parallels the effects of recurrent 
ischaemia on the myocardium. If the former is true then the inflammatory 
activity of coronary lesions appears to effect clinical outcome (148). This is in 
keeping with the in vitro studies of plaque stability detailed above. Prospective 
studies of anti-hsp65 titres in stable and unstable coronary syndromes are 
required to fully assess whether anti-hsp65 is a risk factor for progression of 
progression of a stable coronary atherosclerosis to plaque rupture and 
unstable coronary syndromes.
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CHAPTER 6: RELATIONSHIP BETWEEN ANTI-HSP65 TITRES,
CORONARY ATHEROSCLEROSIS AND CHD RISK FACTORS
6.1 INTRODUCTION
Xu et al showed a significant independent relationship between anti-hsp65 titre 
and the presence of carotid atherosclerosis (130) (reviewed in Chapter 2). 
This was heralded as potentially the diagnostic marker of atherosclerosis that 
clinical medicine has been awaiting (131). My study examined titres in 
coronary atherosclerosis for the first time and had three main objectives.
6.2 OBJECTIVES
1.To examine the correlations between anti-hsp65 titres and severity and 
extent of coronary atherosclerosis as assessed at coronary angiography.
2. To assess whether anti-hsp65 titre is a useful, clinical diagnostic marker of 
the presence and significance of coronary atherosclerosis.
3. To compare the relationship of anti-hsp65 titre with CHD risk factors.
6.3 MATERIALS AND METHODS
6.3.1 Subjects
136 consecutive eligible male subjects as detailed in chapter 5, population 
demographics listed in Table 6.1. Family history was also recorded and 
regarded as positive if >1 first degree relative had an AMI or developed angina
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before the age of 60. Smoking was treated as a categorical variable (smoker, 
non-smoker, ex-smoker) and a continuous variable (estimated lifetime number 
of packets consumed).
6.3.2 Sample Preparation
The patients fasted overnight and 40 ml of blood was removed the following 
morning prior to coronary angiography. Samples were centrifuged within 2 
hours of collection and the serum and plasma stored at -20°C for subsequent 
assay.
6.3.3 Assays
The IgG anti-hsp65 titres were measured as outlined in Chapter 3.
In addition, subjects had the following assayed: Total cholesterol was 
measured using an adaptation of the Abell-Kendall reference method. 
After ultracentrifugation HDL-Cholesterol was measured by the 
Heparin/MnCI2 precipitation method and Ldl-cholesterol calculated (149). 
Triglycerides were assayed by enzymatic hydrolysis with subsequent 
determination of the liberated glycerol by colorimetry. CRP was measured 
using specific antiserum to form a precipitate which was measured 
turbidimetrically and compared with known standards. Lipoprotein (a) and 
fibrinogen were also quantified by immunoprecipitin analysis.
6.3.4 Coronary Angiography
This was performed using standard techniques and recorded in multiple 
projections for left and right coronary arteries. Scoring of the angiograms
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was performed by a single independent observer. A random 10% were 
analysed a second time by the same observer blind to the first results to 
enable calculation of intra-observer variability. The clinical severity of 
coronary artery disease was assessed on the basis of a modified score of 
Negri et al (150). Coronary circulation was divided into 8 segments (see 
Figure 6.1): left main coronary artery; proximal middle and distal 
segments of left anterior descending (LAD); proximal and distal right 
coronary (RCA) and proximal and distal circumflex (CFX). Each segment was 
scored depending upon the severity of stenosis as follows: normal segment 
scoring 0, < 50% stenosis - 1, 50-90% stenosis - 12.5, 91-99% stenosis - 20, 
100% stenosis - 25 and the overall score was the sum of the 8 individual 
segments. The intra-observer correlation was 0.94.
The extent of atherosclerosis was assessed in three ways. Firstly, by a 
'vessel score' from 0 to 3 representing the number of arteries with any 
evidence of luminal diameter reduction or luminal irregularity. The number of 
vessels involved was calculated as follows: RCA or Posterior Descending 
Branch = 1, LAD or either of the first two diagonals = 1, CFX or obtuse 
marginal or Posterior Lateral Branch or Posterior Descending Branches = 
I.The intra-observer and inter-observer correlations were 0.94 and 
Secondly a 'clinical vessel score on a scale of 0-3 based on the system 
ofOberman et al (151) was the number of vessels with a luminal diameter 
reduction of greater than 50%. The number of vessels involved was calculated 
as follows: RCA = 1, CFX = 1 and LAD, first diagonal or both= 1. The intra­
observer correlation was 0.82. These vessel scores enable calculation of
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sensitivity and specificity of anti-hsp65 as a diagnostic indicator of 
atherosclerosis and clinically significant atherosclerosis (>1 stenosis >50%) 
Thirdly, a more detailed 'diffuseness score', as previous work has 
demonstrated greater correlations between risk factors and these scores 
than with the simpler vessel scores (152).This score was based on a 
modification of the method of Negri et al (150)(see Figure 6.1).The 
coronary circulation is divided into 15 segments and eight of these are first 
order segments: proximal and middle RCA, left main coronary artery, proximal 
middle and distal LAD and proximal and distal CFX. In addition, there were 7 
second order segments: distal RCA, posterior descending branch (whether 
arising from circumflex or right coronary artery), obtuse marginal branch, 
posterolateral branch of CFX and the first two diagonal branches of the LAD. 
The first order segments received a score of 1 if there was any evidence of 
atherosclerosis, and the second order segments scored 0.5. The overall 
diffuseness score was the sum of the individual segment scores and the 
maximum score attainable was 11.5. The intra-observer correlation was 
0.80.
6.3.5 Statistical Analysis
The anti-hsp65 titres showed a distribution with a strong positive skew and 
so logarithmic data were used for all parametric methods. There were 
significant differences between assay batches and each log titre was 
corrected as far as possible by subtracting the mean log titre of the 
corresponding ELISA plate and adding the grand mean log titre. This left the 
mean log IgG anti-hsp65 level unchanged, i.e. left the geometric mean
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IgG anti-hsp65 titre unchanged. Three of the other variables measured, 
Lipoprotein (a), triglycerides and CRP were approximately log-normally 
distributed and thus were expressed logarithmically before calculating 
confidence intervals. Correlations between continuous variables were 
examined using Spearman's rank correlation analysis. Relationships 
between continuous variables and categorical variables were assessed by 
Mann-Whitney and Kruskal-Wallis tests. Receiver operator characteristic 
(ROC) curves were used to assess anti-hsp65 as a diagnostic indicator of 
coronary atherosclerosis. ROC analysis is regarded by many as the best 
assessment of whether a surrogate test can be used in routine clinical practise 
(153). The ROC curve represents the overall performance of a diagnostic test 
in terms of sensitivity and specificity as the ratio of true positives to false 
positives. The area under this curve quantifies the usefulness of the test. An 
ideal diagnostic test would inscribe an rectangular line passing from the origin 
to the top right hand point by way of the top left hand corner (see Figure 6.2); 
the area beneath such a curve would be nearly 100% of the total area (154) A 
completely non-discriminatory test would result in a diagonal line from bottom 
left to top right of the graph (see Figure 6.3), all points on the line representing 
a ratio of true to false positives of 1:1, the area beneath the curve would be 
half the total area(154). Multiple linear regression analysis was used to 
test for residual relationships among interval variables while correcting 
for possible confounding influences.
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6.4 RESULTS
The distribution of the anti-hsp65 titres and other measured serum and plasma 
variables are listed in Table 6.2. The ‘vessel score’ counted an artery as 
affected if there was any evidence of luminal irregularity, and by this score 
there were 19, 7, 35 and 75 patients with 0, 1, 2 and 3 affected coronary 
arteries respectively. Using the ‘clinical vessel’ score which scores an artery as 
affected if there is > 1 stenosis > 50% there were 19, 7, 35 and 75 patients 
with 0, 1, 2 and 3 affected coronary arteries respectively. The atherosclerosis 
severity and diffuseness scores had mean values (SD) of 39.7 (31.4) and 4.1 
(2.7) respectively. As expected there were very strong correlations between the 
four coronary atherosclerosis scores (Table 6.3).
The four coronary atherosclerosis scores correlated significantly although quite 
weakly (r=0.18-0.21, p<0.05) with the titres of IgG anti-hsp65 and this is 
demonstrated in Table 6.3. Table 6.4 lists the sensitivity and specificity of anti- 
hsp65 levels as a diagnostic indicator of the presence of coronary 
atherosclerosis (i.e any evidence of luminal irregularity, calculated from the 
‘vessel score’) and of clinically significant coronary atherosclerosis (> I stenosis 
> 50% in > 1 artery, calculated from the ‘clinical vessel score’). These are 
presented graphically in the form of receiver-operator curves (ROCs) in Figures
6.4 and 6.5.
Anti-hsp65 titres correlated with age (r=0.24, p=0.005) and lifetime cigarette 
consumption (r=0.18 p=0.049) but not with any other continuous CHD risk 
factors (shown in Table 6.5).
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Categorical risk factors are compared with continuous risk factors in Tables 
6.6-6.8. Again there is evidence that smoking appears to have an influence on 
anti-hsp65 (Table 6.6) with a trend for an increasing titre through categories of 
non-smoker, ex-smoker and current smoker. The pattern remained after 
adjusting for baseline severity and diffuseness of coronary atherosclerosis. A 
similar pattern is observed for total WBC (p=0.038). A history of hypertension 
does not affect anti-hsp65 (Table 6.7). However as expected hypertensives 
were significantly heavier and had trends to higher glucose and triglycerides.
A family history of premature CHD is associated with a higher titre of anti-hsp65 
(33.80 AU/ml compared to 23.99 AU/ml, p=0.052, Table 6.8). Subjects with a 
positive family history had less severe coronary atherosclerosis than those with 
no family history but after age adjustment the family history group had slightly 
more severe atherosclerosis (41.6 versus 40.3, p=0.81).
Anti-hsp65 titres were adjusted for the potential confounding influences of age, 
smoking (packets) and family history and the significance of the association 
with the coronary atherosclerosis scores was lost (see Table 6.9). However the 
group with any evidence of coronary atherosclerosis (from the vessel score) 
had significantly higher adjusted anti-hsp65 than those with no coronary 
atherosclerosis (27.86 AU/ml compared to 17.10 AU/ml, p=0.012).
Lastly, correlations between other continuous CHD risk factors and the 
angiographic severity and extent of coronary atherosclerosis are shown in 
Table 6.10 and 6.11. There were moderately strong correlations between age 
and all the coronary angiography scores (r=0.26-0.42, p<0.01-<0.001, Table
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6.10). There was a weak but significant correlation between LDL-Cholesterol 
and severity and extent of disease (r=0.17-0.23, p<0.05). There was a clear 
trend for current smokers to have more severe and diffuse disease than non- 
smokers with ex-smokers having an intermediate level (Table 6.11). There was 
no consistent relationship with hypertension, while a positive family history 
initially appearing to confer a protective benefit. However this relationship was 
lost after adjustment for the confounding influence of age.
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Age mean (SD) 55.3 (10.4)
Body Mass Index (kg/m'1) 26.7 (3.7)
History of hypertension 30.9%
Family history of coronary atherosclerosis 47.5%
Never smoked 18.5%
Ex-smoker 61.4%
Current smoker 20.1%
Indication for angiography
Chest pain 95.6%
Valvular abnormality 4.4%
Table 6.1 Description of cohort of 136 male subjects
Variable Number Mean S.D
Total Cholesterol (mmol/I) 133 5.62 1.01
LDL Cholesterol (mmol/I) 119 3.66 0.76
HDL Cholesterol (mmol/l) 127 0.90 0.22
Total/HDL ratio 127 6.63 1.93
Triglycerides (mmol/l)* 133 1.66 1.70
Lipoprotein (a) (mg/dl)* 121 21.87 2.57
Fibrinogen (mg/dl) 123 330.4 76.7
Glucose (mmol/l) 133 5.76 0.66
White Cell Count (x103/l) 120 7.07 1.56
Platelets (x10 12/l) 121 226.2 56.2
CRP (mg/l) 123 9.69 8.76
Anti-hsp65* (AU/ml) 136 26.30 2.29
Table 6.2 Distribution of serum and plasma factors (* variables which 
were log-transformed before analysis; geometric mean and approximate 
SD are expressed)
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Correlation with anti-hsp65 titre
Factor Correlation P value
Age 0.24 0.005
BMI -0.05 0.53
Social class -0.09 0.28
Packets of cigarettes 0.18 0.049
Lipoprotein (a) -0.08 0.41
Triglycerides -0.02 0.17
Total Cholesterol -0.05 0.55
Total/HDL cholesterol -0.22 0.81
Fibrinogen -0.10 0.25
Table 6.5 Spearman’s rank correlations between anti-hsp65 titres.
Never Smoked 
(n=24)
Ex-smoker (n=84 ) Current smoker 
(n=28)
Age (years) 55.4 56.2 52.9
BMI (kg/m") 27.69 26.73 25.59
Cigarette* 
consumption (pkts)
0 11515 13714
Anti-hsp65*** 22.89 28.84 33.88
WBC (x10a/l)** 6.41 7.06 7.62
Neutrophils (x10a/l) 3.93 4.30 4.55
Lymphocytes
(x107l)
1.92 2.10 2.29
Platelets (xIO1"/!) 208.40 231.7 224.7
CRP (mg/l) 6.76 7.94 7.41
Glucose (mmol/l) 5.76 5.82 5.53
Total Cholesterol 
(mmol/l)
5.31 5.50 5.75
Ratio LDL/HDL 6.28 6.89 6.20
Triglycerides
(mmol/l)
1.58 1.45 1.90
Lipoprotein (a) 26.91 13.49 17.38
Fibrinogen (g/dl) 331.20 329.14 374.08
Table 6.6 Comparison of mean values of cardiovascular risk factors 
between groups of non smokers, ex-smokers and current smokers (Anti- 
hsp65, Triglycerides and Fibrinogen age adjusted data, *p<0.0001, 
**p=0.038, otherwise p=ns including *** p=0.29).
No hypertension (n= 95) Hypertension (n=41) P value
Age (years) 55.3 55.5 0.92
BMI (kg/m") 25.77 28.67 <0.00001
Cigarette
consumption (pkts)
9972 8646 0.51
Anti-hsp65 26.91 25.12 0.57
WBC (x10a/l) 7.17 6.84 0.20
Neutrophils (x10a/l) 4.27 4.35 0.70
Lymphocytes 
(x10 /I)
2.19 1.93 0.044
Platelets (xIO1"/!) 230.2 216.8 0.21
CRP (mg/l) 7.76 7.41 0.69
Glucose (mmol/l) 5.71 5.87 0.19
Total Cholesterol 
(mmol/l)
5.60 5.66 0.74
Ratio LDL/HDL 6.64 6.64 1.0
Triglycerides
(mmol/l)
1.58 1.74 0.37
Lipoprotein (a) 20.89 24.54 0.44
Fibrinogen (g/dl) 330.3 330.7 0.98
Table 6.7 Comparison of mean values of cardiovascular risk factors 
between groups of with and without a history of hypertension.
No Family History 
(n=67)
Family History 
(n=56)
P value
Age (years) 58.25 51.33 0.0001
BMI (kg/m") 26.64 27.35 0.27
Cigarette
consumption (pkts)
9021 9884 0.64
Anti-hsp65 23.99 33.80 0.052
WBC (x10a/l) 7.18 6.91 0.94
Neutrophils (x10y/l) 4.39 4.22 0.44
Lymphocytes 
(x10 /I)
2.11 2.10 0.92
Platelets (x101"/!) 225.5 229.2 0.73
CRP (mg/l) 8.53 6.76 0.042
Glucose (mmol/l) 5.79 7.78 0.93
Total Cholesterol 
(mmol/l)
5.55 5.76 0.27
Ratio LDL/HDL 6.64 6.62 0.97
Triglycerides
(mmol/l)
1.62 2.00 0.067
Lipoprotein (a) 21.42 22.23 0.83
Fibrinogen (g/dl) 332.8 345.7 0.067
Table 6.8 Comparison of mean values of cardiovascular risk factors 
between groups with and without a family history of premature coronary 
heart disease, defined as a first degree relative having symptoms < 60 
years of age. (data adjusted for age)
Correlation before 
adjustment
Correlation after 
adjustment
Severity score 0.21* 0.09
Vessel score 0.18* 0.09
Clinical vessel score 0.21* 0.11
Diffuseness score 0.21* 0.07
Table 6.9 Correlation of anti-hsp65 titres with angiographic extent and 
severity coronary atherosclerosis before and after correction for 
confounding influences (age, smoking consumption and family history) 
*p<0.05.
Severity score Vessel score Clinical Vessel 
score
Diffuseness
score
Age (years) 0.30*** 0.38*** 0.26** 0.42***
BMI 0.00 -0.11 -0.08 -0.04
Cigarette
consumption
0.02 0.19 0.08 0.04
Glucose 0.12 0.06 0.06 0.19
Lipoprotein (a) 0.02 0.06 0.04 -0.02
Triglycerides 0.05 0.03 0.01 0.02
Cholesterol 0.16 0.14 0.13 0.09
LDL cholesterol 0.17 0.23* 0.17 0.17
HDL
cholesterol
0.04 -0.01 0.01 0.11
Ratio 0.08 0.16 0.13 0.01
Fibrinogen 0.06 0.13 0.09 0.09
CRP -0.19 -0.15 -0.15 -0.18
WBC -0.12 -0.07 -0.09 -0.05
Platelets -0.13 -0.01 -0.09 -0.031
Table 6.10 Correlations between other continuous CVS risk factors and 
the severity and extent of coronary atherosclerosis (p<0.05, **p<0.01,
***p<0.001).
Severity
score
vessel score Clinical 
vessel score
diffuseness
score
Non- smoker 33.96 1.83 1.42 3.71
Ex smoker 38.53 2.25 1.66 4.01
smoker 48.70 2.43 2.07 4.70
No
hypertension
38.4 2.24 1.67 4.17
Hypertension 43.0 2.17 1.78 4.00
No family 
history
42.8 2.34 1.78 4.36
Family
History
38.3 2.04 1.61 3.84
Table 6.11 Relationship between categorical CHD risk factors and the 
severity and extent of coronary atherosclerosis (p=ns for all)
A  •r« a
Fig 6.1 The Coronary Circulation. Segments 1-3, 5-8, 1 and 13 were used to 
calculate the atherosclerosis severity score. Al segments were used in the 
calculation of difuseness, vessel and clinical vessel scores. Right Coronary 
Artery (RCA), Left Anterior Descending (LAD), Circumflex (CFX).
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6.5 DISCUSSION
We show clear evidence that anti-hsp65 antibodies are associated with 
angiographically detected coronary atherosclerosis with statistically significant 
correlations between titres and severity or extent of disease (r=0.18-0.21, 
p<0.05 Table 6.3). However these correlations although statistically significant 
are quite weak and obviously anti-hsp65 titre will have insufficient predictive 
accuracy to be a useful clinical test This is shown in Table 6.4 which lists the 
sensitivity and specificity of anti-hsp65 levels as a diagnostic indicator of the 
presence of coronary atherosclerosis and of clinically significant coronary 
atherosclerosis (> I stenosis > 50% in > 1 artery, calculated from the ‘clinical 
vessel score’). At best using a discriminant titre of 15 AU/ml the test has only 
77.8% sensitivity and 57.8% specificity for the presence of disease. These are 
presented graphically in the form of receiver-operator curves (ROCs) in Figures
6.3 and 6.4.
Anti-hsp65 titre also correlated with age (r=0.24, p=0.005) and with smoking as 
a continuous variable (r=0.18, p=0.049) but not with other continuous CHD risk 
factors (Tables 6.5). Further evidence that smoking has an influence on anti- 
hsp65 titre is shown in Table 6.6. There was a clear trend for smokers to have 
higher mean anti-hsp65 titre than lifelong non-smokers with ex-smokers having 
an intermediate titre (33.88, 22.89 and 28.84 AU/ml respectively). The pattern 
remained after adjusting for the other possible confounding influence of 
severity of angiographic coronary atherosclerosis. Xu et al (130) is the only 
other study to examine the effect of smoking on anti-hsp65 titre and they also
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showed a significant positive relationship considering it as a continuous 
variable.
A similar and statistically significant relationship is observed for total WBC 
(p=0.038) as has been previously observed (155). This is shown to be due to 
variations in both neutrophils and lymphocytes (Table 6.6). I also confirm the 
well established influence of smoking on fibrinogen level. Smokers in our 
cohort had a mean fibrinogen of 374.0 mg/dl compared to 329.5 mg/dl for non- 
smokers (p=0.08). Elevating fibrinogen is considered to be one of the major 
pathogenic processes by which smoking leads to increased CHD risk (156). 
However there are many other putative mechanisms and our data suggests that 
anti-hsp65 should potentially be added to the list.
The other CHD risk factor which appeared to influence anti-hsp65 titre is a 
family history of premature coronary atherosclerosis (Table 6.8). Subjects with 
a positive family history had a mean titre after age adjustment of 33.80 AU/ml 
compared to 23.99 (p=0.052). There were no obvious confounders, most 
importantly those with a positive family history had less severe coronary 
atherosclerosis than those with no family history. This initially seems 
paradoxical but can be explained by the different ages of the two groups. After 
age adjustment the family history group had slightly more severe 
atherosclerosis (41.6 versus 40.3, p=0.81).
These data suggest that there is a hereditary component to anti-hsp65 titres 
similar to another study (120) but contrary to that reported in chapter 4. The 
populations in my two studies are quite different; in chapter 4 we studied a
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predominantly female cohort with a mean age of 37.3 while in this chapter our 
cohort was exclusively male with a mean age of 55.3 years.
The statistical significance of the relationship between titre and severity and 
extent of disease was lost after adjustment for the possible confounding 
influences of age, smoking and family history (see Table 6.9). However the 
group with any evidence of coronary atherosclerosis (from the vessel score) 
had significantly higher adjusted anti-hsp65 than those with no coronary 
atherosclerosis (27.86 AU/ml compared to 17.10 AU/ml, p=0.012).
These results are similar to the findings of Xu et al (130) who in a study of 
carotid atherosclerosis showed that titres of anti-hsp65 correlated with the 
extent of atherosclerosis and with age and smoking but not other CHD risk 
factors. However, again similarly to our results, their correlation between titre 
and extent of disease lost significance after correction for confounders 
(p=0.083). They concluded that this showed anti-hsp65 was an independent 
risk factor for the presence of carotid plaque.
Coronary angiography may miss early atheromatous change as discussed in 
Chapter 1. Thus, in our group with angiographically normal coronary arteries, 
there may be some with minor atheroma and thus the difference in anti-hsp65 
titres between truly atheroma-negative subjects and atheroma-positive subjects 
may be larger than that indicated.
Two other points of note arose from this study. First it has been shown in 
stable (90) and unstable angina(91) patients that higher levels of CRP is a risk
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factor for progression of atherosclerosis to myocardial infarction. However, 
there was no evidence of a correlation of CRP with clinical severity or extent of 
atherosclerosis in our cohort (Table 6.10), suggesting that elevating CRP 
reflects an additional inflammatory factor in the disease process. The 
additional factor may at least partly be the anti-hsp60/65 immune response.
Secondly, it has recently been suggested that lipoprotein (a) may exert its 
adverse affects via an autoimmune mechanism triggered by infection (157). 
However, we could find no evidence to support this as there was no correlation 
of lipoprotein (a) with anti-hsp65 titres (Table 6.5).
In summary therefore we have demonstrated that anti-hsp65 titres correlate 
with the severity and extent of coronary atherosclerosis, but with insufficient 
predictive accuracy to be a useful clinical test. Three CHD risk factors age, 
smoking and family history influenced anti-hsp65 titre. After correction for 
these confounding factors, the elevated anti-hsp65 titre remains statistically 
significantly associated with the presence of coronary atherosclerosis (27.86 
AU/ml compared to 17.10 AU/ml, p=0.012).
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CHAPTER 7: HELICOBACTER PYLORI, ANTI-HSP65 AND
ATHEROSCLEROSIS
7.1 INTRODUCTION
There have been three papers to date AMI examining the relationship 
between Helicobacter Pylori infection and clinically manifest ischaemic 
heart disease (reviewed in Chapter 2). Two (73,74) support an association 
which is independent of age, sex, social class and CHD risk factors but the 
third (75) did not.
Clearly there are difficulties in investigating a residual relationship 
between H. pylori infection and CHD when each individually is strongly 
related to social class (see Figure 1.2 and Table 2.2) and age. After correcting 
for age and social class the loss of significance does not exclude a causal 
relationship between H.pylori and CHD, as H.pylori infection could be a 
mechanism by which these factors increase the risk of CHD. Thus, it is 
important to test the hypothesis of a causal relationship in other ways and one 
of these is by investigating possible pathogenic processes.
An early postulate suggested that the pathogenic link between H. pylori 
infection and IHD was due to the systemic effects of H. pylori on fibrinogen 
concentration and total white blood cell count (74). Patel et al (74) showed 
that men seropositive for Helicobacter pylori had significantly higher 
fibrinogen (by 0.175 g/l, 95% confidence interval, 0.039-0.311) and log
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white cell count (by 0.123, 95% confidence interval, 0.041-0.205) after 
correction for age, smoking history, body mass index and social class, 
than seronegative subjects. However, Murray et al (75) in a larger study a 
weak negative association between Helicobacter pylori infection and fibrinogen 
(mean(SE) difference in fibrinogen between infected and uninfected -0.09 
(0.04) g/l, p= 0.02.)
Thus, it is important to look for alternative mechanisms and in this 
chapter I investigate the possibility of an auto-immune process provoked by 
H.pylori infection. The immune cells in H.pylori gastritis include neutrophils, 
macrophage/monocytes, plasma cells and predominantly Tcells (mostly TH 
cells)(158). There is marked heterogeneity in the T cell responses to purified
H.pylori antigens (159). In general the seronegative subjects responses were 
more marked than the seronegative suggesting antigen specific suppression of 
T cell activation occurs in infected individuals (159). Western blotting of 
mucosal derived antibodies show that different patients have different response 
patterns of antibodies to the various antigens of H.pylori (160) reflecting 
differences between the strains of H.pylori and also host immune response 
differences too. The majority of the humoral response is to the surface 
expressed urease enzyme and the 62 Kd heat shock protein (hsp62) a member 
of the hsp60/65 family (159,161). H.pylori specific serum antibodies of both IgA 
and IgG isotypes are detectable (162,163) but the relative importance of these 
isotypes is unclear. Potentially the IgA antibodies are more important as they
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have a central role in the mucosal associated lymphoid system (MALT) and can 
be secreted onto the mucosal surface (164).
7.2 OBJECTIVES
1. To examine whether H.pylori infection and titres of antibodies to H.pylori are 
independent risk factors for coronary atherosclerosis.
2. To examine the relationship between anti-H.pylori antibodies, infection 
and CHD risk factors
3. To examine the influence of H.pylori infection on anti-hsp65 titre (IgG and 
IgA isotype, before and after adjustment for confounding influences).
Two studies have been performed, the first uses the same cohort as described 
in Chapter 6; the second examines the effects of H.pylori eradication on anti- 
hsp65 titre.
7.3 MATERIALS AND METHODS
7.3.1 Subjects
In the first study we used the same cohort as in chapter 6. Briefly, we 
recruited 136 consecutive eligible men admitted for routine cardiac 
catheterisation for the investigation of chest pain (95.6%) or valvular 
abnormalities (4.4%). Social class was assessed using deprivation 
categories derived from Carstairs scores of postcode sectors. These 
deprivation categories (DEPCATS 1-7) provide a measure of deprivation or 
affluence on the basis of a combination of selected 1991 Census variables 
standardised to their mean (165). The variables used to create the scores were
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car ownership, male unemployment, head of household occupation and 
overcrowding.
In the second study we recruited 100 subjects (age mean 43.1 years, range 
17-67, 30 males) all with active H.pylori infection confirmed by Urea breath 
test. The subjects were recruited over a three month period and the study was 
approved by the Hospital Ethical Committee and all patients gave informed 
consent. The subjects were double blindly randomised to active treatment 
(n=48) or placebo (n=52). Active treatment consisted of Omeprazole 20 mg 
bd, Metronidazole 400mg tid and amoxycillin 500mg tid for 14 days.The 
placebo group received two weeks of Omeprazole 20mg bd plus placebo 
antibiotics. The subjects returned one year after commencing therapy and 
had a further breath test. Subjects were excluded if the follow-up breath test 
result did not confirm successful eradication in the active treatment group 
or continuing infection in the placebo group. This left 33 in the treatment 
group and 41 in the placebo group (see Table 7.1).
7.3.2 Sample Preparation
The patients fasted overnight and 40 ml of blood was removed the following 
morning prior to coronary angiography or breath testing. Samples were 
centrifuged within 2 hours of collection and the serum and plasma stored at - 
20°C for subsequent assay.
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7.3.3 Assays
IgG and IgA anti-hsp65 were measured by ELISA as described in chapter 3. 
Pre and post samples from a given patient were assayed on the same 
plate.
IgG antibodies specific to H.pylori were quantified by using the BIO-Rad 
(California, USA) G.A.P. IgG test kit. This is an ELISA system using plates 
coated with H.pylori antigens. IgG specific H.pylori antibodies are 
quantified in units/ml (U/ml) and a cut-off titre of 12 U/ml has been shown 
to be 94.9% sensitive and 91.3% specific for culture proven H.pylori gastric 
infection (166).
The samples were all assayed without prior knowledge of the coronary 
angiography findings.
7.3.4 Coronary Angiography 
As chapter 6.
7.3.5 Statistical Analysis
In the first study, anti-H. pylori titre was approximately log-normally 
distributed and thus were expressed logarithmically before calculating 
confidence intervals. Correlations between continuous variables were 
examined using Spearman's rank correlation analysis. Relationships 
between continuous variables and categorical variables were assessed by 
Mann-Whitney and Kruskal-Wallis tests. Multiple linear regression 
analysis was used to test for residual relationships among interval
110
variables while correcting for possible confounding influences. The Chi- 
square test was used to assess whether the presence of H. pylori infection was 
significantly associated with the presence of atherosclerosis. T-tests were 
used to compare the means of biochemical risk factors in H. pylori 
seropositive and seronegative subjects, before and after correcting for 
possible confounding influences.
In the second study, there were no significant differences between IgG 
anti-hsp65 assay batches but there was differences between IgA assay 
batches. Thus each IgA anti-hsp65 titre was corrected as far as possible by 
dividing by the mean titre of the corresponding ELISA plate and multiplying 
by the grand mean titre. This left the mean IgA anti-hsp65 level unchanged, 
i.e. left the geometric mean IgG anti-hsp65 titre unchanged. Depending on 
a variable’s distribution either the Mann-Whitney Test or Student’s T Test was 
used to examine for differences between the active and placebo groups. 
Correlations between IgG and IgA anti-hsp65 titres (pre, post and ratios) were 
examined by Spearman’s rank correlation coefficients.
7.4 RESULTS
In the first study, there were significant correlations between all the 
atherosclerosis scores and anti-hsp65 titres and between three scores ( 
severity, vessel score and diffuseness score) and antibodies to H.pylori (Table 
7.2). Generally the correlations with atherosclerosis were stronger for anti- 
hsp65 than for anti-H.pylori. There was a strong and highly statistically
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significant correlation between anti-hsp65 titre and antibody titre to H.pylori 
(r=0.39, p<10'5, see Figure 7.1).
There was a significant correlation between anti-H.pylori titres and smoking 
as a continuous variable (r=0.28, p=0.002) and between anti-H.pylori titre and 
fibrinogen (r=0.20, p=0.031) (see Table 7.3). There was no relationship 
between anti-H.pylori titres and categorical variables of hypertension and 
family history, but there was a positive relationship with smoking (data not 
shown). Current smokers had a significantly higher mean titre of anti-H.pylori 
than lifelong non-smokers with ex-smokers having an intermediate level (28.71, 
12.88 and 25.80 U/ml respectively, p=0.004).
An anW-H.pylori titre of >12 U/ml has been shown to be 94.9% sensitive 
and 91.3% specific for culture proven H.pylori gastric infection (9). Using 
this discriminant titre in the group with no coronary atherosclerosis, 
58% were seropositive for H. pylori compared with 71% of subjects with 
coronary atherosclerosis (difference not statistically significant). However 
H.pylori positive subjects had significantly more severe and diffuse coronary 
atherosclerosis than seronegative (Table 7.4). However the statistical 
significance was lost after adjusting for confounders (Table 7.4)
Comparing mean levels of continuous (Table 7.5) and categorical CHD risk 
factors (Table 7.6) between groups seropositive and seronegative for H.pylori 
infection indicated that H.pylori infection was not associated with raised 
concentrations of fibrinogen, cholesterol, triglycerides or glucose. However 
the former group had statistically higher mean titres of two potential CHD risk
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factors (WBC and anti-hsp65 titre) and borderline significant relationships with 
social class and smoking consumption. The relationship between social class 
and H.pylori seropositivity is shown in Figure 7.2. Their is also a borderline 
significant association between seropositivity and smoking as a categorical 
variable (50, 72 and 79 % of non smokers, ex-smokers and current smokers 
are seropositive respectively, p=0.06).
Thus based on the above data and those of others (see Tables 2.1 and 2.2) 
age, social class and smoking appear to be the three most important 
confounding influences on a possible relationship between IHD and H.pylori 
infection. Thus anti-H.pylori titre was adjusted for these possible confounding 
influences and re-examined and the statistical significance of the relationship 
between titre and atherosclerosis was lost (see Table 7.2). Similarly although 
the trends remained there was no statistically significant difference in the 
severity or diffuseness of coronary atherosclerosis between seropositive and 
seronegative groups after adjustment for these factors (Table 7.4).
The correlations between the anti-hsp65 titres and antibody titres to H.pylori 
were also re-examined after adjusting for their possible common 
relationships with age, smoking and social class and the correlation 
remained significant (r=0.38, p<10'4). In addition, in the sub-group with 
likely active H.pylori infection (IgG anti-/-/.pylori titre > 1 2  U/ml) the correlation 
between antihsp65 and anti-H.pylori remained (r=0.28, p=0.006). There was no 
elevation of WBC or anti-hsp65 titre after adjustment (Table 7.6)
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In the second study, there was no difference in titres between the sexes. In 
the placebo group (n=41) 27 titres fell, 2 did not change and 12 rose. In 
comparison in the treatment group (n=34), 27 titres fell, 3 stayed the same and 
4 rose. (p=0.066 for comparison of proportion of patients whose titres fell or 
remained static 29/41 (70.1%) and 30/34 (88.2%) in the placebo and treatment 
groups, respectively).
Pre-therapy anti-hsp65 titres did not differ significantly between the placebo 
and treatment groups (Table 7.8). With successful eradication of H.pylori IgG 
anti-hsp65 titre fell from 25.6 to13.8 AU/ml (p=0.033). In comparison with 
placebo the titre remained essentially static (25.7 Au/ml initially and 22.4 Au/ml 
at one year, p=0.45).The IgG anti-hsp65 titres pre and post therapy in the 
placebo group is illustrated in Figure 7.3 and in the treatment group in Figure 
7.4.
There was no difference in pre or post treatment IgA anti-hsp65 titres between 
the two groups (see Table 7.9 and Figure 7.5 and 7.6). The correlations 
between IgA and IgG anti-hsp65 titres are shown in Table 7.10. Figure 7.7 
illustrates pre-treatment IgG anti-hsp65 with pre-treatment IgA anti-hsp65 
(r=0.26, p=0.029)
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Placebo Treatment Significance
Number 41 33
Sex 16M 25F 14M 19F ns
Age Mean 
(range)
41.7(17-65) 43.4 (21-62) 0.55
Mean (SD) Pre­
treatment Breath 
Test
184.6 (90.9) 179.8(97.5) 0.83
Mean (SD) Post­
treatment Breath 
Test
177.6 (92.4) 5.9 (4.4) <0.0001
Table 7.1 Description of groups in H.pylori eradication study
Atherosclerosis
score
Correlation 
with anti- 
H. pylori
Correlation with 
IgG anti-hsp65 
(before 
adjustment)
Correlation with 
IgG anti-hsp65 
(after
adjustment)
severity score 0.18 (p=0.040) 0.21 (p=0.018) 0.17 (p=0.08)
Vessel score 0.17 (p=0.036) 0.18 (p=0.036) 0.07 (p=ns)
Clinical vessel 
score
0.12 (p=0.150) 0.21 (p=0.012) 0.11 (p=ns)
diffuseness
score
0.22 (p=0.011) 0.21 (p=0.016) 0.17 (p=0.08)
Anti-H.pylori 0.39 (p<10'5) 0.38 (p<10-5)
Table 7.2 Spearman’s rank correlations between severity and extent of 
coronary atherosclerosis and titres of antibodies to hsp65 and to H.pylori 
(before and after adjusting for confounders: age, social class and smoking 
consumption).
Correlation with anti-H.pylori titre
Factor Correlation P value
Age 0.139 0.107
BMI -0.190 0.83
Social class 0.15 0.076
Packets of cigarettes 0.284 0.002*
Lipoprotein (a) -0.038 0.68
Triglycerides -0.038 0.68
Total Cholesterol -0.055 0.53
Total/HDL cholesterol -0.064 -0.47
Glucose (mmol/l) 0.075 0.932
CRP 0.12 0.199
Fibrinogen 0.196 0.031*
Table 7.3 Spearman’s rank correlations between anti-H.pylori titres and 
CVS risk factors (* p<0.05).
Before adjustment After adjustment
H.pylori 
seroneg 
ative
H. pylori
seroposi
tive
P value H. pylori 
seroneg 
ative
H.pylori
seroposi
tive
P value
severity
score
32.3 43.3 0.049 39.1 39.7 0.79
diffusen
ess
score
3.18 4.54 0.002 3.8 4.39 0.79
Table 7.4 Relationship between H. pylori seropositivity and coronary 
atherosclerosis scores, before and after adjustment for confounding 
influences (age, social class and smoking consumption).
H.pylori seronegative H.pylori seropositive
Age (years) 53.6 56.2
BMI (kg/m2) 26.3 26.8
Cigarette consumption 
(pkts)*
7172 10534
Social Class 
(DEPCAT)*
3.55 4.11
Table 7.5 Relationship between H.pylori seropositivity and demographic 
data (*p=0.06).
Before adjustment After adjustment
H.pylori
seronegative
H.pylori
seropositive
H.pylori
seronegative
H.pylori
seropositive
Glucose (mmol/l) 5.75 5.76 5.71 5.77
Lipoprotein (a) 
(mg/dl)
22.39 21.87 22.91 21.88
Triglycerides
(mmol/l)
1.58 1.68 1.62 1.66
Cholesterol
(mmol/l)
5.75 5.55 5.64 5.63
LDL cholesterol 
(mmol/l)
3.82 3.58 3.66 3.68
HDL cholesterol 
(mmol/l)
0.87 0.91 0.91 0.89
Ratio 6.95 6.50
Fibrinogen (mg/dl) 3.30 3.30 3.28 3.31
CRP (mg/l) 7.4 7.7 7.6 7.8
WBC (x10y/l)* 6.52 7.35 7.08 7.14
Anti-hsp65
(AU/ml)**
18.75 30.27 25.12 26.30
Table 7.6 Relationship between H.pylori seropositivity and continuous 
CVS risk factors before and after adjustment for confounders (age, 
smoking and social class) (* p=0.007, ** p=0.0008).
H.pylori
seronegative
H.pylori
seropositive
%
seropositive
P value
Non- smoker 12 12 50.0
Ex smoker 23 59 72.0
smoker 6 22 78.6 p=0.06
No
hypertension
30 62 67.4
Hypertension 11 30 73.2 p=ns
No family 
history
19 45 70.3
Family
History
16 38 70.3 p=ns
Table 7.7 Relationship between H.pylori seropositivity and categorical 
CVS risk factors.
Pre-hsp65
Mean
(SEM)
Post-hsp65
Mean
(SEM)
Difference
between
means
P value 
difference 
between 
means
pre/post 
therapy 
titre ratio
Placebo
(n=41)
25.70
(4.09)
22.47
(3.89)
3.23 0.450 0.874
Treatmen 
t (n=33)
25.64
(5.09)
13.75
(2.47)
11.89 0.033 0.536
Table 7.8 IgG anti-hsp65 titres pre and post therapy (p= 0.38 for 
comparison of pre-therapy titres, p= 0.030 for comparison of post therapy 
titres and p= 0.026 for comparison of post/pre titre ratios)
Pre IgA anti- 
hsp65 (AU/ml) 
Mean(SEM)
Post IgA anti- 
hsp65 (AU/ml) 
Mean(SEM)
P value
Placebo (n=38) 10.47(1.3) 9.05 (0.9) 0.38
Treatment
(n=32)
7.84 (0.78) 7.19(0.59) 0.51
Table 7.9 IgA anti-hsp65 titres pre and post therapy.
IgG Pre IgA Pre IgG Ratio IgA Ratio
IgG Pre 0.26* -0.34** 0.017
IgA Pre 0.26* 0.13 -0.32***
IgG Ratio -0.34** -0.13 0.08
IgA Ratio 0.017 -0.32*** 0.08
Table 7.10 Spearmen’s Rank Correlation coefficients for IgG and IgA 
anti-hsp65 titres pre therapy and ratio of post/pre therapy. (* p=0.029, 
**p=0.004, *** p=0.008, all other correlations are not significant).
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7.5 DISCUSSION
Titres of antibodies to H.pylori were shown to correlate positively with the 
severity and extent of coronary atherosclerosis (r=0.17-0.22, p<0.05, Table 
7.2). Similarly H.pylori seropositive subjects (IgG anti -H.pylori titre > 12 U/ml) 
had more diffuse and severe coronary atherosclerosis than seronegative 
(diffuseness score 4.54 versus 3.18 and severity score 43.3 versus 32.3, Table 
7.4) This supports other recent studies linking H.pylori infection with 
clinically manifest coronary artery disease (73,74). In the present study 
and one previous study (75) the trends were still apparent but they were no 
longer statistically significant after correction for their common relationships 
with age, smoking and social class (see Tables 7.2 and 7.4).
Previously it has been postulated that the association between H.pylori 
infection and ischaemic heart disease is due to systemic effects of H.pylori 
infection on fibrinogen concentrations and total white blood cell count (74) but 
this has been challenged by a larger study (75). Our own data showed no 
difference in fibrinogen levels between the seropositive and seronegative 
groups (Table 7.6). However, the seropositive group clearly had elevated 
anti-hsp65 titres and white cell count compared with the seronegative group 
(prior to correction for age, smoking and social class) supporting the 
possibility of an autoimmune process.
Titres of antibodies to hsp65 and to H.pylori correlated highly significantly 
(r=0.39, p<1 O'5, Figure 7.1). This relationship remained strong and highly 
significant even after adjustment for possible confounding influences
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(r=0.38, p<10'5). This suggests that H.pylori infection might be an 
influence on anti-hsp65 titres and this was further investigated in the second 
study.
There is clear evidence that eradication of H.pylori infection is associated with 
a significant fall in anti-hsp65 titres. Mean anti-hsp65 titre fell from 25.64 AU/ml 
to 13.75 AU/ml (Figure 7.4) with successful eradication of H. pylori infection 
(p=0.033). There was a small fall in mean titre from 25.70 AU/ml to 22.47 AU/ml 
(Figure 7.3) in the placebo control group but this was not significant.
These results are in keeping with other data. H. pylori 62 kD heat shock 
protein (hsp62)(5) is surface expressed and a member of the hsp60/65 family 
(75% homologous to hsp65 and human hsp60(167)). Sharma et al (159) 
demonstrated that this hsp62 antigen provokes an antibody response after 
H.pylori infection. Engstrand et al (161) showed that IgG ar\W-H.pylori 
hsp62 titres were elevated in 10 of 10 H.pylori culture positive individuals. 
After conventional H.pylori eradication treatment, recolonisation was shown by 
biopsy to have occurred in 8 of 10 people. In these 8, anti -H.pylori hsp62 
titres stayed the same, whilst in the other two titres fell. This suggests that 
although hsp62 of H.pylori cross-reacts with hsp60/65 of other gut 
commensals, that it possesses some unique epitopes and is possibly an 
important influence on anti-hsp65 titres.
Interestingly the post/pre therapy IgG anti-hsp65 titre ratio in the treatment 
group (13.75/25.64 = 0.536 Table 7.6) is similar to the ratio of sero-negative to 
sero-positive IgG anti-hsp65 titres in the first study (18.75/30.27 = 0.62, Table
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7.6). Indeed perhaps the post/pre ratio should be adjusted for the minor attrition 
in titre over the year of the study observed in the placebo group. Such an 
adjustment (treatment group post therapy titre/treatment group pre-therapy 
titre-difference between pre and post therapy titres in the placebo group) give a 
ratio of 0.614, even closer to the sero-negative/sero-positive ratio. Taken 
together these results suggest that about 40% of the anti-hsp65 titre in H.pylori 
infected individuals is due to the H.pylori infection.
This inter-individual anti-hsp65 response to H.pylori infection maybe due to 
either host or organism factors. Factors such as the infecting load of H.pylori 
either as a single initial infection or the number of repeated exposures, and the 
known variations in the immune response to H.pylori (159,160) will undoubtedly 
alter the final antigenic load. Organism factors might be inter-strain variation in 
either levels of hsp62 expression or variation in expression of epitopes that 
cross-react with hsp65. Therefore it may be only some strains of H.pylori that 
generate an antibody titre to hsp65. Presumably exposure to other micro­
organisms with cross-reacting hsp60/65 will also contribute to the titres. 
Certainly some of our data suggest this including most importantly from the 
second study where 7/34 (20.6%) subjects who had successful eradication of 
H.pylori, anti-hsp65 titres stayed the same or rose. There is also supporting 
data from the first study including the fact that the correlation between 
antibodies to H.pylori and anti-hsp65 was no greater than 0.39 and in addition 
some subjects who were seronegative for H. pylori infection had significant 
titres of anti-hsp65.
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Chlamydia pneumoniae infection has also been implicated in the pathogenesis 
of atherosclerosis by an unexplained mechanism (74,77-80,82-84). The 
relationship remained after adjustment for CHD risk factors including social 
class (74). C pneumoniae also expresses an hsp57 which shows close 
sequence homology with human hsp60 (76). Indeed another interpretation of 
our data is that the antibiotics given to eradicate H.pylori may have eradicated 
or decreased the load of other chronic bacterial infections and the reduction of 
these infections may be responsible to a greater or lesser extent for the fall in 
anti-hsp65 titre. In support of this is our data in from the group who received 
antibiotics but subsequent breath tests indicated persistent H. pylori infection. 
In this cohort (n=15) there was a trend for anti-hsp65 titre to fall (from 10.3 
AU/ml to 9.31 Au/ml). It can at least be concluded that giving antibiotics leads 
to a fall in anti-hsp65 titre thus indicating that bacterial infections are an 
important influence on anti-hsp65 titre.
Thus, an alternative hypothesis to explain the association between 
H.pylori and ischaemic heart disease based on the results of this current 
study, data of Xu et al and the known immunology of H.pylori can be 
summarised as follows: endogenous hsp60 expression is induced on 
normal arterial intima by stresses such as smoking. Exposure to H.pylori 
and other micro-organisms induces an immune response to bacterial 
hsp60/62/65 and the antibodies produced cross-react with the human 
hsp60. This could either initiate or contribute to the local inflammatory and 
autoimmune process in the arterial intima, leading to initiation or worsening of
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atherosclerotic lesions. Thus, it may be the relatively infecting load and 
extent of the immune response to infection that is important, rather than just 
infection per se and this may partly explain the contradictory results from 
studies (73-75) looking at seropositivity for H.pylori alone as a risk factor for 
ischaemic heart disease. Interestingly in this regard Kreuning et al 
(162) have recently shown a relationship between IgG and IgA antibody 
titres against H.pylori in serum and the severity of gastritis and density of 
H.pylori colonisation in asymptomatic subjects.
There was no significant change in IgA titres with eradication of anti-hsp65 
titres (Table 7.6, Figures 7.5 and 7.6). There is no obvious explanation for this 
finding however two recent papers suggest that systemic IgA H.pylori 
antibodies are less accurate than systemic IgG at diagnosing and quantifying 
H.pylori infection and this may partly be due to the compartmentalisation of IgA 
into the mucosal associated lymphoid system and thus IgA inconsistently 
reaches the systemic circulation. In the first study systemic IgA was highly 
specific (94.4%) but less sensitive for detecting H.pylori infection (76.6%) (163). 
In comparison IgG had specificity and sensitivity of 98.6% and 97.1% 
respectively. Secondly in Kreuning’s study above (162) serum IgG but not IgA 
H.pylori antibody titres correlated with the density of H.pylori colonisation of the 
gastric antrum. In our study there was a minor correlation between IgA and IgG 
anti-hsp65 titres before treatment (r=0.26, p=0.029 Figure 7.7). However there 
was no relationship between the isotypes in change in in titres with treatment 
(IgG post/pre ratio compared to IgA post/pre ratio, r=0.08, p=ns).
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Thus it seems likely that H.pylori eradication does not influence systemic IgA 
anti-hsp65 titre because the infection inconsistently provokes circulating 
antibodies of this isotype either because it does not stimulate any IgA anti- 
hsp65 or these antibodies do not become systemic.
In summary therefore, titres of antibodies to H.pylori were shown to correlate 
positively with the severity and extent of coronary atherosclerosis (r=0.17-
0.22, p<0.05, Table 7.2). Similarily H.pylori seropositive subjects (IgG anti-
H.pylori titre > 12 U/ml) had more diffuse and severe coronary atherosclerosis 
than seronegative (diffuseness score 4.54 versus 3.18 and severity score 43.3 
versus 32.3, Table 7.4).
Secondly titres of H.pylori antibodies correlated with cigarette consumption and 
subjects seropositive for H.pylori were older, smoked more cigarettes and were 
of lower social class confirming these three as the important confounders of a 
possible relationship with IHD. Trends for H.pylori infected subjects to have 
more severe coronary atherosclerosis were still apparent after correction for 
these factors but they were no longer statistically significant.
Thirdly H.pylori would appear to be an important influence on IgG anti-hsp65 as 
the antibody titres correlated (r=0.38,p<10'5 ) and most importantly eradication 
of H.pylori lead to a significant fall in anti-hap65 titre (from 25.64 AU/ml to 
13.75 AU/ml).
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CHAPTER 8: CAROTID B-MODE ULTRASONOGRAPHY IN THE 
ASSESSMENT OF CORONARY ATHEROSCLEROSIS
8.1 HISTORICAL BACKGROUND
During the 1970's non-invasive ultrasonic methods evolved to provide 2D 
images of arterial walls and lumen. This permitted a more detailed study 
of early non-stenotic atherosclerotic changes in arterial walls before that 
which could be assessed with angiography (168). Experimental studies on 
non-human primates (169) and on human subjects (33,170,171), indicate that 
atherosclerotic lesions may progress without a reduction in the luminal size 
because of dilatation of the arterial wall. Therefore it was suggested that 
the correct estimation of the size of atherosclerotic lesions requires 
simultaneous measurements of arterial wall thickness and residual luminal 
size (172).
In 1981, a multicentre validation study was initiated to compare B-Mode 
ultrasound images with angiographic pictures of the carotid system and to 
compare both methods with pathology. Subsequently Ricotta et al (173) in 
1988 reported from this study the first validation that carotid artery lesion 
width could be measured by B-Mode scanning. They showed that the 
ultrasound assessment of plaque lesion width correlated better with 
pathologic measurement of end arterectomy specimens than with the 
angiographic assessment. They suggested that B Mode ultrasonography
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held considerable promise for population based studies of atherosclerosis 
(177).
Pignoli et al (174) in 1984 performed the first in vitro validation study of B- 
Mode ultrasonography for the direct measurement of arterial wall thickness. 
They initially studied a limited number of normal or moderately diseased 
arterial segments. A significant correlation between results of gross 
pathological evaluations and measurement by B-Mode imaging of arterial wall 
thickness was found.
In a more detailed second study in 1986 (172) (which has subsequently proven 
to be a landmark paper) they had three main objectives. Firstly they aimed to 
determine the anatomic structures involved in ultrasound energy reflection 
in the arterial wall. They examined 10 aortic specimens in dissection 
experiments. The specimens were then interrogated by ultrasound and 
evaluated by microscopy. The findings on beamed scan images were 
compared with the structural changes on microscopy induced by various 
dissections in the arterial wall. They found in almost all specimens, a similar 
"double line pattern" separated by an hypo-echoic or anechoic space The 
luminal line was more regular and smooth and thinner than the outer one. A 
similar pattern was found in carotid artery specimens (Figure 8.1).
To delineate the origin of the luminal line on the B-Mode scan, a small 
incision was made in the luminal surface of the artery. Histology showed that 
the incision penetrated intima but not the media. B-Mode scanning revealed 
that there was loss of the luminal line at the site of the incision, indicating
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Figure 8.1 B-mode ultrasonographic interfaces of the Common Carotid artery.
1. Periadventitial - adventitia near wall interface
2. Adventitial - media near wall interface 
3 Intimal - lumen near wall interface
4. Lumen - intima far wall interface 
5 Medial - adventitial far wall interface
Ithat the inner line is generated by the intimal-luminal interface (lines 3 and 4 
Figure 8.1). Adventitia was then removed from the media (confirmed by 
histology) and B-Mode images of these specimens showed disappearance of 
the outer line in the region without adventitia, indicating that this line was 
generated by the media-adventitia interface (lines 2 and 5 Figure 8.1).
They then showed B-Mode measures of presumed combined Intimal- 
Medial Thickness (IMT) correlated with IMT values obtained by histology 
and gross-pathology. The same B-Mode measures correlated less well with 
the values for the other components of the vessel wall alone or in combination.
Their second objective was to assess the accuracy of IMT measured on B- 
Mode images against gross pathology and histology. Quantitative ultrasound 
was performed in 95 aortic specimens. The specimens were placed in a glass 
tank filled with water and then scanned. The absolute differences between B- 
Mode and gross pathological findings was 0.19+0.23 mm and the 
percentage difference was 11.5+10.4%. Similarly, they scanned segments 
of carotid artery and showed no significant difference with findings in 
histology and pathology, but rather surprisingly did not show their data or 
quote statistics.
Thirdly, they showed the typical B-Mode double line image observed on in 
vitro specimens was also present in both common carotid arteries of 10 live 
subjects. In addition, they showed that the mean IMT in these subjects did not 
differ from that assessed in vitro by B-mode scan or histology or pathology.
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More recently data from intravascular ultrasound experience has challenged 
the accuracy of quantitative transcutaneous vascular sonography (175-176). 
In response to this, Wong et al performed a further ultrasonic pathological 
validation study in 1993 (177). Segments from common carotid and 
femoral arteries were obtained during the autopsies of 36 male subjects. The 
segments were suspended on a frame and placed in an imaging tank filled 
with glycerin and water solution and images obtained using a 7 mHz linear 
array probe. The ultrasound readings were then compared with histological 
measurement and they showed that tissue processing caused only 2.5% 
shrinkage. Ultrasonography consistently overestimated the thickness of 
the intima and adventitia and underestimated the thickness of the media. 
However, for combined IMT of the far wall, the differences between 
histology and imaging was insignificant, averaging 4% for carotid artery 
specimens and 9% for femoral artery specimens. In the near wall 
projection, however, sonographic IMT was consistently about 20% 
less than that determined histologically. They concluded that 
ultrasonography is limited mainly by axial resolution in quantifying the 
dimensions of individual arterial tunica, but is capable of accurately measuring 
far wall IMT (177).
8.2 METHODOLOGY
One of the problems in comparing results from various studies using B-Mode 
ultrasound are the different methodologies adopted, including different 
equipment, different scanning techniques and different reading protocols.
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There is now a general move to try and standardise all these factors (72) but 
there remain a number of areas of contention.
8.2.1 Which Artery Or Arteries To Image And Measure.
Most studies to date have been based on carotid artery measurements, partly 
because femoral arteries are more difficult to image. In addition, in Wong et 
al’s (177) histological validation study there was a larger variation between 
histology and sonographic IMT measurement in femoral specimens (9%) 
than carotid specimens (4%). However, a few studies have used both arteries 
(178-179). The present study (chapter 9) examined the carotid artery and thus 
the following discussion does not include femoral arteries.
8.2.2 The Near Wall/Far Wall Controversy.
The near wall/far wall controversy has been debated at length over the last 2- 
3 years (72). The question is whether it is possible to perform accurate near 
wall IMT measurements. Theoretically it is not because the anatomical 
location of a biological structure is always defined by a leading edge of an 
echo and the thickness of a structure is the difference between the leading 
edge of two different echoes. This is possible in the far wall, but not in the 
near wall. This consideration seems borne out by the findings of Wong et al 
(177) who showed sonographic near wall IMT could not be accurately 
measured in comparison with the histological measurement of the same IMT. 
The current consensus is that near and far wall measurements should be 
presented separately in scientific papers to allow the reader to make his/her
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own interpretation, and that further research is required to resolve this issue 
(72).
Regardless of whether both are to be measured, it has been recommended 
that frames to be analysed should show both far wall and near wall IMT 
simultaneously, thus indicating that the ultrasound beam is positioned well into 
the longitudinal axis of the vessel (180).
8.2.3 Which Arterial Segments To Image And Measure.
There has also been considerable debate about how many points along the 
carotid artery the IMT should be measured, and whether both arteries should 
be assessed. The internal carotid artery (ICA) is most prone to plaque 
formation, with the carotid bifurcation (BIF) next while the common carotid 
artery (CCA) rarely has plaque involvement until late in life (181). 
Unfortunately the ease and reproducibility of imaging these segments is 
inversely proportional to their propensity to plaque formation. For example, 
in the large ongoing Atherosclerosis Risk In Community (ARIC) study (182) 
ICA-IMT could only be measured in about 40% of women and 58% of men. 
Thus, some workers suggested that ICA-IMT should not be routinely measured 
(72) but others continue to do so.
The three segments, however, all display varying IMT and this brings into 
question exactly what process we are assessing in measuring IMT. In normal 
arteries, the media is much thicker than the intima, but the atherosclerotic 
process usually involves just the intima. It is possible therefore that in 
assessing increased IMT in the absence of discrete plaque we are measuring
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a diffuse thickening of the media (183). Therefore it is unclear whether wall 
thickening represents an early phase of atherosclerosis or a fundamentally 
different pathological process from atherosclerosis (36). However, in defence 
of the technique researchers have found that even in the lower end of the 
spectrum of IMT, e.g. CCA-IMT 0.6 mm to 0.9 mm, IMT correlated with CHD 
risk factors (180).
Most investigators now measure IMT at 12 points from each patient (reviewed 
in 36), consisting of near and far wall measurements at 3 sites in each of the 
carotid arteries. The boundaries are as defined in the large ARIC study (168) 
(see Figure 8.2). The extracranial carotid arteries are divided into three 
segments: the distal 1 cm straight portion of the common carotid artery, the 
carotid BIF (bulb) and the proximal 1 cm of the ICA. The distal 1 cm length of 
the CCA is defined by the BIF origin. The second reference, which defines 
the superior extent of the BIF and the proximal boundary of the ICA, is the tip 
of the flow divider.
The current evidence would seem to support measurements at multiple sites 
rather than just at a single site. For example, although IMT between the 
same site on different sides and between sites on the same side correlate, 
the correlation is not strong, and there are frequent discrepancies between 
sites showing the focal nature of atherosclerosis (184). In support of this 
Crose et al (185) showed that the mean aggregate IMT was the only 
independent variable associated with the status of CHD in a group of 270
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Figure 8.2 Divisions of the Carotid Artery (NW = Near Wall, FW = Far Wall).
patients (185). Their data also supported the use of mean common plus 
BIF IMT scores.
The ARIC investigators have also argued in support of using data from 
multiple sites because of the focal nature of the disease and predilection of 
disease for more distal segments, and in addition because of the greater 
clinical significance of more distal disease (184). They also raise the 
possibility that there may be interactive effects of risk factors at 
different anatomical sites in the carotid circulation (184).
Another approach is to use computerised edge detection to accurately 
measure IMT in only one arterial segment. For example, Adams et al (186) 
used an edge detection programme which measures IMT at 150-200 
points along a 10 mm segment of left common carotid far wall to produce 
a mean IMT score for that segment.
Thus, it can be concluded that single maximum or mean maximum IMT 
from multiple segments or even a single mean from a single segment, may 
be informative in cross-sectional studies. In longitudinal studies, however, 
the greater stability associated with mean aggregate measurements is likely 
to improve analytic power (185). It should also be noted that there has never 
been any systematic difference in IMT between left and right carotid artery 
(180).
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8.2.4 Which IMT Scoring System To Use.
A large number of different scoring systems have now been developed and 
what appears to be evolving is the use of different types of score for different 
situations. Even in studies using measurements from 12 segments there is 
discrepancy as exactly what is measured in each segment and how the 
overall score is calculated and basically there are two different approaches.
The first approach measure the IMT at a single point in each individual 
segment at the point of maximal IMT (185).The overall score is then either the 
mean of the 12 maximum IMT's (Mean aggregate) or the greatest of the 12 
maximum IMT's (Maximum aggregate)(185). Similarily mean or maximum 
scores can be calculated for various combinations of arterial segments e.g ' 
Maximum BIF' or 'Mean far wall' etc.
The second approach measures the IMT in a given segment at 5-10 equally 
spaced points in the segment to produce a segment specific mean IMT 
(168).These means from any combination of up to 12 segments can then be 
used to produce mean and maximum scores. There clearly is a lot of potential 
for confusion between the two approaches. For example, a mean common 
carotid score by the first system is the mean of the four maximal IMTs (far and 
near, left and right). Whilst by the second system it means the mean of the 
four mean IMTs.
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Crouse et al (187) have advocated two main scores, a severity measure which 
is the single largest IMT throughout the carotid bed and an extent score which 
is the mean of the 12 maximum IMTs but again this issue is largely unresolved.
8.2.5 Miscellaneous Measurement Issues.
The participants of a symposium to discuss IMT measurement issues have 
recently drawn a number of further conclusions (72). Firstly, that if plaque is 
localised where IMT measurements should be performed, the plaque thickness 
should be included in the IMT value. Secondly, that the available data do not 
allow for a valid decision as to whether adjustment for body size should be 
undertaken. The issue is a complex one as there are theoretical grounds to 
suggest that obesity has a causal relationship with atherosclerosis (72).
8.2.6 Methodological Conclusions
More work is required to resolve the above methodological issues. Until they 
are resolved it is imperative that investigators clearly state exactly what was 
measured and how and by whom and how the IMT score was calculated. In 
addition the differing methodologies should at all times be taken into account 
when comparing results between studies.
8.3 THE POTENTIAL OF CAROTID B-MODE ULTRASONOGRAPHY IN 
ASSESSING CORONARY ATHEROSCLEROSIS
The potential of carotid ultrasound measurements relies on certain 
assumptions, some of which are being tested in studies and others that are 
speculative. One assumption is that the test is sufficiently precise and 
reproducible. A second assumption is that the images provide a valid
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assessment of coronary atherosclerosis. Finally, increased IMT should 
correlate with CHD morbidity and mortality to make it a useful surrogate 
endpoint.
8.3.1 Reproducibility
The reproducibility has been assessed in a number of large studies measuring 
different segments and combination of segments using differing methodologies 
and figures are quoted for intra and inter-sonographer variability and intra 
and inter-reader variability whether they are the same or different people 
performing the scans and reading them.
It is difficult in large studies to have the same person read all the images, 
however, having several readers introduces problems of reader variability. The 
difference in mean IMTs between readers can be significant. For example in a 
combined report (188) from the three atherosclerosis intervention studies, the 
maximum differences between readers in a pool of 12 was 0.11 mm, four 
times the annual progression rate (188). The problem can theoretically be 
overcome by adjustment for reader in the analysis. Another and more 
attractive solution is to have the same reader perform all measurements in 
each patient (188).
Figures for intra and inter-reader and intra and inter-sonographer 
reproducibility in four other studies are listed in Table 8.1. Correlations 
between repeat measures in all categories ranged from 0.73 to 0.93. In 
addition, in a single centre population base study using far wall common 
carotid artery measurements only, Salonen and Salonen (191) showed a
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correlation of 0.91 between scans performed 1 week apart by the same 
sonographer and read by a different reader. It should also be noted that 
Riley et al in the ACAPS study (189) showed the variability was three to four 
times for single maximum IMT than a mean maximum of 12 segments, 
again arguing for a score based on a number of segments.
8.3.2 Validity
The evidence that B-Mode carotid ultrasonography is a valid tool for 
assessing coronary atherosclerosis is four fold.
(i) Autopsy Evidence
Autopsy evidence demonstrated that the extent of atherosclerosis in carotid 
vessels correlated with the extent in other beds in monkeys (192) and in 
humans (193-195). The correlation between carotid and coronary circulations 
is strongest (Pearson's correlation coefficient r=0.4 to 0.6) (193-195).
(ii) IMT Population Distribution
The population distribution of IMT corresponds with the known 
population distribution of clinical manifestations of atherosclerosis (182).
(iii) Correlations Between CHD Risk Factors And Carotid IMT
Established CHD risk factors such as age, systolic blood pressure, total 
cholesterol, HDL cholesterol (inverse), body mass index and smoking are 
consistently and positively associated with increasing IMT of the carotid 
artery(196-201) For example in the ARIC study for each 30% increase in LDL 
cholesterol there was a mean increase in IMT, independent of age, of 0.026
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mm for males and 0.029 mm for females (200). Moreover, recent findings from 
population-based studies have indicated that candidate risk factors including 
lipoprotein (a) (202), haemostatic factors (including fibrinogen, beta- 
thromboglobulin, and factor vii) (203-206), fibrinolytic factors (207), 
antioxidants (beta-carotene, vitamin A) (208), dietary components of 
supposed atherogenicity (209-210), cardiovascular fitness (211) and 
angiotensin converting enzyme D/D genotype (212) are all associated with 
carotid IMT.
Even without the presence of discrete plaque, lower degrees of CCA-IMT may 
indicate the presence of atherosclerosis in other arteries in which 
atherosclerosis develops earlier in life. In support of this CCA-IMT ranging 
from 0.6 to 0.9 mm shows graded association with CHD risk factors and with 
ankle arm index (a measure of femoral atherosclerosis extent) and with 
prevalent CHD (180). Age is the most powerful determinant of IMT which 
increases by about 0.01 to 0.02 mm a year (191).
Finally, studies which reduced risk factors for CHD can influence the 
progression rates of carotid atherosclerosis as measured by B-Mode or 
doppler ultrasound (191,212,213).
(iv) Correlation Between Carotid IMT And Coronary Atherosclerosis 
The presence of carotid artery plaque has been shown to be associated 
with coronary atherosclerosis as assessed non-invasively either by the 
surrogate of a positive exercise test (214) or by ultrafast CT scanning to 
detect coronary artery calcification (215). However, most of the evidence
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showing correlations between extent of coronary and carotid atherosclerosis 
in vivo have used invasive measures, i.e. coronary angiography to assess 
coronary atherosclerosis and to date there has been 7 of these studies.
Three of these studies have come from the same group at the Bowman 
Gray Medical School in America. Firstly, in 1990 Craven et al (216) compared 
a B-Mode score (sum of 12 carotid artery segments) between 343 
angiographically proven coronary atherosclerosis positive patients with 167 
disease-free controls. In univariate analysis they showed a strong 
association between coronary status and extent of carotid atherosclerosis. 
Logistic models including CHD risk factors showed that the extent of 
carotid atherosclerosis was a strong statistically significant independent 
variable for the presence of coronary atherosclerosis in people aged greater 
than 50. The B-Mode score was at least as useful as known CHD risk 
factors for identifying patients with coronary atherosclerosis.
The second Bowman Gray paper was published in 1995 by Wofford et al 
(217). They measured extent of carotid atherosclerosis at 9 sites on 
both sides and summed the results to produce a score. They then divided 
their cohort of 434 patients into 4 quartiles based on the B-Mode score and 
showed a significant relationship between quartile and coronary 
atherosclerosis extent, as assessed by the number of diseased coronary 
arteries on a scale of 0-4.
The third Bowman Gray paper was published by Crouse et al (185) also in 
1995. They tested various B-Mode scores derived from 12 carotid artery
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segments for their ability to discriminate between the presence and absence 
of coronary atherosclerosis in 270 patients. They showed that scores based 
on mean BIF, mean common plus BIF and meaned aggregate were most 
strongly related to case control status; however, the predictive power of the 
mean CCA was also strong.
The fourth paper was produced by a group from London, UK and published 
in 1994 by Geurolakos et al (218) who measured far wall CCA-IMT on both 
sides and produced a mean score in 75 male patients undergoing 
coronary angiography. They showed a significant linear trend between mean 
IMT and number of diseased coronary vessels (r=0.44, p<0.0001).
Fifthly, in a sub-group of 57 patients from the CLAS Study at baseline (219) 
distal common carotid artery far wall IMT correlated with coronary artery 
average percentage stenosis (r=0.27, p<0.05) and a similar correlation 
(r=0.29) was also demonstrated after 2 years of intervention.
The sixth, and latest paper comparing extent of coronary atherosclerosis 
angiography against carotid IMT was published in October 1995 by Adams et 
al (186) from Sydney in Australia. They measured mean left CCA far wall IMT 
and compared this with three different coronary angiographic scores in 
350 consecutive eligible patients. They used a summary score based on a 
number of vessels with luminal stenosis >50%; a modified Gensini score 
which gave a measure of both severity and extent of coronary 
atherosclerosis and lastly an extent score based on the percentage of 
affected coronary circulation, as identified by any luminal irregularity.
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They showed that the left CCA far wall IMT was weakly, but significantly 
(p<0.0001) correlated with all three scores (r=0.26, r=0.29 and r=0.23)
respectively. On the basis of these relatively weak correlations they 
sounded a cautionary note to all of the epidemiological and 
interventional studies that are using IMT measurements as a non-invasive 
marker of coronary atherosclerosis extent. They also demonstrated that CCA- 
IMT has insufficient predictive accuracy to be a useful clinical test for the 
exclusion of significant coronary atherosclerosis. They showed that no value of 
CCA-IMT had both a sensitivity and specificity of greater than 80%. However, 
it must be noted that they used only a single segment of CCA on only 1 side 
for their comparisons.
The correlations between a B-Mode score based on a number of segments 
and a detailed coronary atherosclerosis extent score has not been examined 
to date.
8.3.3 Carotid IMT As A Risk Factor For CHD Events
The third assumption underlying the use of IMT as a surrogate for coronary 
atherosclerosis, and in particular, as a surrogate for CHD morbidity and 
mortality, is that increased IMT should be shown to correlate with CHD 
morbidity and mortality. To date there has only been one prospective 
study of the prognostic significance of variation in IMT. Salonen & Salonen 
(220) reported findings in 1,257 Finnish men who had 36 AMIs over 2 years. 
They showed that any atherosclerotic lesion in the common carotid artery 
increased the risk of Ml three fold (95% confidence intervals, 1.4-6.5).
136
Thus, in conclusion, although others are more sceptical (186), the recent 
consensus symposium (72) concluded that on the basis of the direct 
validation of the ultrasound measurements against autopsy and indirect 
validation versus known risk factors, ultrasound IMT is a valid estimate of the 
degree of early atherosclerosis in humans.
8.4 USE OF CARO ID IMT AS A SURROGATE MARKER
The attraction of using IMT as a surrogate endpoint is clear. Power 
calculations have shown that assuming an IMT progression rate of 0.05 mm 
per year you would require only 672 patients in a two arm trial followed up for 2 
years or 430 patients for 3 years to be 90% sure of detecting a significant 
difference between the treatments (65). Indeed, the Colestipol-Niacin 
therapy study (219) has shown statistically significant results with much 
smaller numbers. These sample sizes are in comparison for example with the 
recent placebo controlled multicentre 4S study (44) assessing the effects 
of simvastatin on CHD morbidity and mortality which enrolled 4,444 
patients and followed them up over 5 years. To date greater than 40,000 
patients have been or are involved in greater than 20 clinical trials and 
observational studies with carotid IMT as an endpoint (186).
8.5 CONCLUSIONS
B-Mode measurement of Carotid IMT has been shown to be valid and 
reproducible. Based on evidence from autopsy studies, correlations between 
B-Mode IMT and CHD risk factors and between B-Mode IMT and extent of 
coronary atherosclerosis, B-Mode IMT is widely regarded as the most accurate
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surrogate estimate of the extent of general and coronary atherosclerosis (65). 
The use of a continuous variable (IMT) in epidemiological studies affords many 
practical advantages. Most importantly research can be performed with much 
smaller numbers of patients over shorter periods of time and consequently less 
expensively.
However a recent paper (186) has sounded a cautionary note in this regard 
and better validation of carotid B-Mode IMT against the extent of 
atherosclerosis in the coronary circulation and in other vascular beds are 
urgently required. Most importantly the validity of IMT as a surrogate marker of 
CHD mortality and morbidity requires more prospective studies.
Other goals for the future to strengthen the rationale for using B-Mode 
ultrasound in the assessment of the natural history of atherosclerosis include; 
resolution of the remaining technical issues; development of methods including 
complementary use of both angiographic measurements of lumen diameter and 
ultrasound assessment of arterial wall; evaluation of new methodology that may 
allow assessment of the anatomy of lesions and/or their potential for rupture. In 
this last regard, an exciting recent development has been the use of 3-D 
ultrasound imaging to measure plaque volume. Delcker et al (221) in a 
small pilot study of 54 patients showed that diastolic blood pressure and 
diabetes significantly affected the progression of plaque volume over 1 
year.
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CHAPTER 9: ASSESSMENT OF CAROTID ARTERY INTIMA - 
MEDIAL THICKNESS AS A SURROGATE MARKER OF THE 
SEVERITY AND EXTENT OF CORONARY ATHEROSCLEROSIS
9.1 INTRODUCTION
As discussed in Chapter 8, a large number of epidemiological and 
interventional studies are using serial carotid artery intimal-medial 
thickness (IMT) measurements as a surrogate marker for CHD morbidity 
and mortality. However, a number of questions about this approach 
remain to be answered, most importantly are serial carotid IMTs a valid 
surrogate? Other questions include which carotid artery IMT score should be 
used; Should the IMT score be adjusted for body size? The question of 
whether the size of a person influences IMT is a complex one and the 
associations of IMT with height, weight, BMI and BSA should be analysed(72); 
Also should the IMT score be adjusted for carotid artery lumen diameter as 
experimental evidence suggests that arteries dilate in response to early 
atherosclerosis (169-171)?
This present study aimed to produce data towards answering these questions 
and had four main objectives.
9.2 OBJECTIVES
Firstly, to examine the correlation between the extent and severity of 
coronary atherosclerosis and the extent and severity of carotid
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atherosclerosis. Previous studies have compared a detailed analysis of the 
extent of carotid atherosclerosis with a very simple quantification of 
coronary atherosclerosis (185, 216-219) or vice versa (186). Nobody has 
examined the correlation between detailed analyses of the extent of 
atherosclerosis in both systems.
Secondly, to investigate which carotid artery IMT score is the best 
correlation of detailed coronary atherosclerosis severity and extent.
Thirdly, to investigate whether correction for body size or carotid artery 
diameter improved these correlations.
Fourthly, to compare risk factor profiles for carotid and coronary 
atherosclerosis.
9.3 MATERIALS AND METHODS
9.3.1 Subjects
Seventy consecutive, eligible white men (age mean 57.7 range 35.0-75.2) 
admitted for routine cardiac catheterisation for the assessment of chest pain. 
Exclusion criteria included previous history of coronary artery bypass 
surgery or PTCA and also history of Diabetes Mellitus (either previously 
diagnosed or a screening fasting glucose >7.8 mmol/L. We decided to recruit 
only men and to exclude diabetes as Adams et al (186) have recently shown 
that these are two out of the three (Age being the other) most important 
factors predicting more severe coronary atherosclerosis than average for 
a given level of carotid IMT.
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In the majority of cases (65/70, 92.9%) cardiac catheterisation was indicated 
for the assessment of chest pain and the remainder were being investigated 
for valvular abnormalities. The subjects were recruited over an 8 
month period and the population demographics are listed in Table 9.1. 
The study was approved by the Hospital Ethical Committee and all 
patients signed written informed consent forms. Patients completed a 
short health questionnaire regarding their personal medical history, family 
history and social history of smoking and alcohol consumption. Patients 
also underwent a physical examination. BSA was calculated from a validated 
nomogram (222). There was a minor overlap of this cohort (about 25 patients) 
with Chapter 6.
9.3.2 Sample Preparation 
See Chapter 6.
9.3.3 Assays
Total cholesterol, beta quantification, fibrinogen, lipoprotein (a) and CRP were 
all assayed as in Chapter 6.
9.3.4 Coronary Angiography
This was performed and analysed as in Chapter 6, with the exception 
that an additional coronary atherosclerosis score was used, called the 
modified GENSINI Score. This was adopted to reproduce the methodology 
of Adams et al (186) and has previously been described and validated (223). 
This score gives an indication of both the severity and extent of 
atherosclerosis. The most severe stenosis in each of eight coronary segments
141
(the same segments used in the calculation of the diffuseness score see Figure 
6.1) was graded from 1 to 4. 1, 1 to 49% lumen reduction, 2.5 50-90% stenosis, 
3, 90-99% stenosis and 4, 100% occlusion to give a total score of between 0 
and 32) The angiograms were again all analysed by a single observer blinded 
to all other results for the subjects. The distribution of the Severity, 
diffuseness and Gensini scores are shown in Table 10.2. Using the ‘vessel 
score’ there was 7, 2, 18 and 43 subjects with 0, 1, 2 and 3 diseased coronary 
arteries respectively. The same Figures for the ‘clinical vessel score’ are 11, 8, 
25 and 26.
9.3.5 Carotid Ultrasonography Methodology
These were all performed by a single experienced ultrasonographer 
using a Biosound 2000 II (Biosound Inc., Indianapolis, USA) with an 8 MHZ 
transducer. Scans were recorded on super-VHS video tape for 
subsequent analysis.
The carotid artery is divided into three sections for scanning and analysis, the 
ICA (ICA), the BIF (BIF) and the CCA (CCA) as previously defined in the ARIC 
Study (see Chapter 8 and Figure 8.2 for details). The ultrasonographer places 
the cursor at the level of the delineating landmarks for the guidance of the 
reader. The scanning protocol was rigid and re-defined and similar to that 
used in the ARIC Study (168) and took about 20 minutes per patient.
The examination begins on the right side by placing the transducer on the skin 
in a manner that allows a longitudinal image of the mid portion of the right 
common carotid artery to be seen on the monitor. The transducer is then
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moved cranially, keeping the common carotid artery in focus until the crest 
at the origin of the carotid bulb is demonstrated. The transducer is 
then rotated anteriorly and posteriorly until the sonographer has
demonstrated and marked with the cursor the position of the crest of the BIF. 
Usually, this position is either lateral or posterior-lateral. The sonographer 
then focuses attention demonstrating as clearly as possible, the six interfaces 
required for measurement of arterial wall thicknesses within the right distal 
CCA (CCA). The sonographer then searches carefully for the thickest 2-3 
and 4-5 sites (See Figure 9.1) present within this region by rotating the 
transducer anteriorly and then posteriorly. After the transducer has been 
moved as far posteriorly as possible, it is then rotated anteriorly until the 
crest at the origin of the bulb is most clearly demonstrated.
The BIF is then positioned within the central region of the monitor. The 
transducer is then rotated with the aim of demonstrating as clearly as 
possible the superior V shaped arc of the flow divider. Once this is 
accomplished the interfaces associated with the near and far arterial walls 
are optimally imaged. After locating that angle which best demonstrates 
the flow divider, the transducer is carefully and slowly moved anteriorly 
while keeping the BIF in focus. When the most anterior angle is reached 
the transducer is rotated, slowly and carefully as far posterior as possible, 
then back to that angle which best demonstrates the flow divider.
After the right BIF has been examined, the ICA is examined. The transducer 
is rotated anteriorly as far possible, keeping the ICA interfaces focused. The
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transducer is then rotated posteriorly as far as possible. After this is 
accomplished the transducer is rotated back to the optimal position which 
shows the flow divider. After these images have been acquired and recorded 
on the right side, a similar examination is done on the left side of the neck.
9.3.6 Carotid B-mode Scan Analysis
The carotid artery scans were all read by a single observer blinded to the 
subject's other results. The reading protocol consisted of an initial viewing of 
the entire video recording for a given patient. As many as possible of the 
arterial segments were identified using the cursors and predefined 
landmarks, as above. However, it became clear that ICA’s were not 
visualised in about 50% of subjects and similarly the near walls of most 
segments were not reproducibly seen. Thus, these segments were not 
measured. After the initial viewing, each segment was reviewed again and 
the end diastolic frame which best showed the maximal IMT in that segment 
was frozen and digitised by a Digital Time-Base corrector (FA-310 P,FOR- 
A Company Limited, Tokyo, Japan). The images were then analysed 
using a quantitative computerised analysis system (Cardiotrace Version 
3.03, Cinegraphic Inc, Grand Prairie, Texas, U.S.A.). This system gives an 
axial resolution of 0.001 mm.
The frames were calibrated against a recorded reference marker of known 
size. The region containing maximum IMT was enlarged ten times and 
markers placed at leading edges of echoes from interfaces 4 and 5 (see 
Figure 9.1 - represents near wall IMT) and at the leading edges of interfaces
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2 and 5 (represents carotid artery diameter). This process was repeated 
twice for each segment and the maximum IMT for that segment was the mean 
of the two. The process was then repeated for each segment in turn, 
(although the arterial diameter was only assessed at the level of the CCA on 
both sides).
9.3.7 IMT Scores
A maximum of four segments were measured for each patient (left and right far 
wall CCA and BIF and a number of IMT scores were computed. A mean 
score was the average of the maximum scores at the indicated sites, a 
maximum score was the greatest of all the maximum IMTs at the indicated 
sites. For example CCAMAx is the greater of the two CCA measurements and 
TOTmean is the average of the four (2 CCA and 2 BIF) measurements etc. The 
distribution of the IMT scores are shown in Table 9.2. If a measurement which 
should have contributed to the calculation of a given IMT score was missing 
then that IMT score was not calculated.
9.3.8 Statistical analysis
All of the continuous variables were approximately normally distributed with the 
exception of lipopoprotein(a) which had to be log-transformed. Correlations 
between continuous variables (coronary atherosclerosis scores, carotid artery 
measurements, carotid atherosclerosis scores and CHD risk factors), were 
examined using Pearson’s Correlation analysis. Comparison between 
continuous and categorical variables was performed using student’s T-Test (2 
categories) and one-way analysis of variance (>2 categories). Multiple linear
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regression analysis was used to test for residual relationships among 
interval variables while correcting for possible confounding influences.
9.4 RESULTS
Table 9.3 shows the correlations between the carotid artery IMT scores and 
the coronary artery scores. Generally the highest correlations were with 
CCAmean scores (r=0.29 for severity illustrated in Figure 9.1 and r=0.26 for 
Gensini and r=0.20 for diffuseness). CCAmean and BIFmean IMT scores 
increased with successively more diseased coronary arteries (Figure 9.2 and 
9.3) however as illustrated there was significant overlap between the groups. 
Figures 9.4 and 9.5 illustrate this overlap in two patients.
Table 9.4 demonstrates the lack of any correlation between the IMT scores 
and measures of body size (BMI and BSA). The same Tables show that 
there was a correlation between arterial size and IMT.
Tables 9.5, 9.6 and 9.7 indicate the correlations between carotid artery 
IMT scores adjusted for BMI, BSA and carotid artery diameter 
respectively and coronary angiography scores. Only the adjustment 
for BMI improved the correlation and at best the correlation between 
CCAmax adjusted for BMI and severity of coronary atherosclerosis was 0.32.
Table 9.8 lists the distribution of the continuous CHD risk factors. Tables 9.9 
and 9.10 demonstrate univariate correlations between these continuous 
variables and carotid IMT scores and coronary angiography scores 
respectively. Table 9.11 repeats a selection of the data from Tables 9.9 and
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9.10 to compare univariate correlations between risk factors and carotid IMT 
with correlations between risk factors and coronary angiography score (Gensini 
Score). There was no significant relationship between categorical risk factors 
(family history of IHD, reported history of hypertension and smoking habit) and 
either carotid IMT or any of the coronary angiography scores (data not shown). 
The only result which was nearly significant was smoking habit against Carotid 
IMT. For example the mean TOTmax score for the never smoked group was 
1.41mm (0.36) in comparison to 1.80mm (0.72) for the current and ex-smoker 
group (p=0.066). Tables 9.12 and 9.13 are multiple linear regression analysis 
of risk factors for carotid and coronary atherosclerosis.
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Number Mean S.D
Age (years) 70 57.70 9.11
Weight (kg) 68 78.93 12.34
Height (cm) 68 173.90 5.82
BMI (kg/m2) 68 26.08 3.76
BSA (m2) 68 2.13 1.20
Table 9.1 Demographics of cohort (n=70).
Number Mean S.D
CCAmean (mm) 70 0.74 0.18
BIFmean (mm) 58 1.48 0.58
TOTmean (mm) 47 1.11 0.35
CCAMAx(mm) 70 0.83 0.22
BIFMAx(mm) 57 1.71 0.67
TOTMAx(mm) 57 1.71 0.67
CAD severity 67 45.16 31.1
CAD diffuseness 67 4.81 2.73
CAD Gensini 67 9.59 5.93
Table 9.2 Distribution of Carotid Artery and 3 coronary angiography 
scores (for the vessel and clinical vessel score’s distributions see text).
CAD
Severity
Vessel
Score
Clinical
Vessel
CAD
Diffuseness
CAD
Gensini
CCAmean 0.29* 0.21 0.28** 0.20 0 26***
BIFmean 0.12 0.17 0.06 0.17 0.11
TO Tmean 0.11 0.18 0.17 0.15 0.13
CCAmax 0.27**** 0.19 0.26**** 0.18 0.25*****
BIFmax 0.12 0.15 0.10 0.12 0.07
TOTmax 0.12 0.15 0.10 0.12 0.07
Table 9.3 Pearson’s Correlations between Carotid IMT scores and
coronary angiography scores (*p=0.016, **p=0.019, ***p=0.037,
****p=0.029, *****p=0.045 all other correlations are not significant).
C C A mean B IF mean T O T mean BMI BSA
BMI -0.14 -0.103 -0.16
BSA -0.15 0.19 0.01 0.61*
C C A diam 0.47* 0.32** 0.43*** 0.18 0.23
Table 9.4 Pearson’s Correlations between Carotid IMT scores and Carotid 
diameter, BSA and BSA (*p<0.001, **p=0.002, ***p=0.014, all other
correlations are not significant).
CAD
Severity
Vessel
Score
Clinical
Vessel
CAD
Diffuseness
CAD
Gensini
CCAmean 0.29* 0.22 0.24* 0.21 0.25*
BIFmean 0.13 0.21 0.05 0.22 0.14
TOTmean 0.15 0.24 0.15 0.25 0.20
CCAmax 0.26* 0.19 0.22 0.19 0.24
BIFmax 0.13 0.18 0.07 0.16 0.09
TOTmax 0.13 0.18 0.07 0.16 0.09
Table 9.5 Pearson’s Correlations between Carotid IMT scores after
adjustment for BSA and coronary angiography scores (*p<0.05, all other
correlations are not significant).
CAD
Severity
Vessel
Score
Clinical
Vessel
CAD
Diffuseness
CAD
Gensini
CCAmean 0.25* 0.26* 0.32** 0.19 0.21
BIFmean 0.10 0.23 0.12 0.18 0.10
TOTmean 0.12 0.27 0.25 0.21 0.16
CCAmax 0.23 0.24 0.31* 0.16 0.21
BIFmax 0.09 0.19 0.14 0.11 0.04
TOTmax 0.09 0.09 0.14 0.11 0.04
Table 9.6 Pearson’s Correlations between Carotid IMT scores after
adjustment for BMI and coronary angiography scores (*p<0.05, **p<0.01,
all other correlations are not significant).
CAD
Severity
Vessel
Score
Clinical
Vessel
CAD
Diffuseness
CAD
Gensini
CCAmean 0.16 0.21 0.22 0.10 0.11
BIFmean 0.03 0.17 0.02 0.12 0.02
TOTmean 0.13 0.21 0.22 0.20 0.16
CCAmax 0.15 0.18 0.20 0.09 0.13
BIFmax 0.03 0.16 0.06 0.08 -0.01
TO Tmax 0.03 0.16 0.06 0.08 -0.01
Table 9.7 Pearson’s Correlations between Carotid IMT scores after
adjustment for CCA diameter and coronary angiography scores (all
correlations are not significant).
Number mean SD
Age (years) 70 57.70 9.11
Total cholesterol 
(mmol/I)
62 5.64 1.07
LDL cholesterol 
(mmol/l)
54 3.60 0.81
HDL cholesterol 
(mmol/l)
56 0.91 0.22
HDL/LDL ratio 54 6.58 1.44
Log Trigs 62 0.20 0.22
Log Lp(a) 52 1.42 0.43
Fibrinogen (g/dl) 53 331.5 89.6
Cigarettes 
(lifetime pkts)
61 9253 7947
Table 9.8 Distribution of continuous cardiovascular risk factors.
2
2
i -
O
h - 0
.3
0
** 60
0
- -0
.1
0 tCD
CO
o
CO
Cvl
d■ -0
.2
6
-0
.1
8
-0
.0
7
0
.3
1
**
3
2
LL
m 0.
3
2
** 60
0
-
o
o'1
{
ID
CO
o' -0
.2
8
-0
.2
7 CO
o’1 -0
.0
7
0
.3
0
**
3
2
<o
o 0.
4
3
* 9
0
0
COo
o 0.
2
3
-0
.2
1
6
0
0
- -0
.1
5
o1 0.
2
1
TO
Tm
ea
n
1
CD
CO
O -0
.0
2 COo
o’ 0 -0
.3
1 CO
d■ -0
.1
9
o1 0.
2
7
z
1352
LL
CD
to
CO
o' -0
.0
3
6
0
0
“ 0
.2
4
-0
.1
7 T “
d■ -0
.1
8
-0
.1
5
0
.2
1
z
S52
<o
o 0.
4
3
* o
o’
6
0
0
0
.2
5
-0
.2
0
zoo- -0
.1
2
0
.0
2
0
.2
0
Ag
e
To
ta
l
Ch
ol
es
te
ro
l
LD
L
Ch
ol
es
te
ro
l
H
D
L
Ch
ol
es
te
ro
l
H
D
L/
LD
L
Lo
gT
rig
s
Lo
gL
p(
a)
Fi
br
in
og
en
Ci
ga
re
tte
(p
kt
s)
Ta
bl
e 
9.9
 
Pe
ar
so
n’
s 
Co
rre
la
tio
ns
 
be
tw
ee
n 
co
nt
in
uo
us
 
ca
rd
io
va
sc
ul
ar
 
ris
k 
fa
ct
or
s 
an
d 
ca
ro
tid
 
IMT
 
sc
or
es
(*
p<
0.
00
1,
 
**p
<0
.0
5 
all
 o
th
er
 c
or
re
la
tio
ns
 
no
t 
si
gn
ifi
ca
nt
).
CAD
Severity
Vessel
score
Clinical
Vessel
CAD
Diffuseness
CAD
Gensini
Age 0.42* 0.47* 0.45* 0.50* 0.41*
Total
Cholesterol
0.22 0.23 0.12 0.18 0.25**
LDL
Cholesterol
0.17 0.23 0.09 0.07 0.13
HDL
Cholesterol
0.10 0.11 0.10 0.12 0.13
HDL/LDL -0.07 0.08 -0.10 -0.03 -0.04
LogTrigs 0.08 0.04 0.01 0.17 0.20
LogLp(a) -0.03 0.17 0.09 -0.08 -0.04
Fibrinogen 0.10 0.23 0.19 0.12 0.12
Cigarette
(pkts)
0.07 0.10 0.13 0.10 0.08
Table 9.10 Pearson’s Correlations between continuous cardiovascular 
risk factors and coronary angiography scores(*p<0.001, p=0.06, all other 
correlations not significant).
CCAmax BIFmax TOTmax CAD
Gensini
Age 0.43* 0.32** 0.30** 0.41*
Total
Cholesterol
0.06 -0.09 -0.09 0.25***
LDL
Cholesterol
0.06 -0.10 -0.10 0.13
HDL
Cholesterol
0.23 0.35 0.36 0.13
HDL/LDL -0.21 -0.28 -0.28 -0.04
LogTrigs -0.09 -0.27 -0.26 0.20
LogLp(a) -0.15 -0.18 -0.18 -0.04
Fibrinogen -0.1 -0.07 -0.07 0.12
Cigarette
(pkts)
0.21 0.30** 0.31** 0.08
Table 9.11 Pearson’s Correlations between continuous cardiovascular 
risk factors carotid IMT and coronary angiography scores(*p<0.001, 
p<0.05, p=0.06, all other correlations not significant).
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Figure 9.4 Carotid B-mode scan of 59 year old subject showing right far-wall 
Common Carotid intimal-medial thickening and bifurcation plaque. Patient had 
no angiographic evidence of coronary atherosclerosis, (note the annotation 
error, IMTs should be a factor of 10 less).
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Figure 9.5 Carotid B-mode scan of 63 year old subject with no Carotid artery 
intimal-medial thickening, right far-wall common and bifurcation illustrated here. 
Patient had angiographic evidence of severe coronary atherosclerosis 
(Severity Score 91 compared to mean of 39.7). (note the annotation error, IMTs 
should be a factor of 10 less).
9.5 DISCUSSION
The correlations between CCAmean and CCAm ax IMT scores and the severity 
and diffuseness of coronary atherosclerosis are disappointingly low (for 
example, r=0.29 and 0.27 for severity, r=0.20 and r=0.18 for diffuseness and 
r=0.26 and 0.24 for the Gensini score and see Table 9.3 and Figures 9.1-9.5). 
These results are very similar to that previously reported in one large 
recent study (186) using similar coronary angiography scoring (r=0.26 for 
severity, r=0.23 for diffuseness and r=0.29 for Gensini) and one other smaller 
studies (219). Rather surprisingly, the addition of further carotid artery 
segments to the score (ie TOTmean and TO Tm ax scores) led to a reduction in 
the correlations (see Table 9.3). Similarly the BIF scores by themselves 
(BIFm ax and BIFmean ) correlated less well than the CCA scores.
There are a number of possible explanations as to why the correlations are not 
of greater magnitude and do not approach the strength of the correlations 
between carotid and coronary atherosclerosis found at autopsy, r=0.4-0.6 (193- 
195).
Firstly carotid IMT and coronary angiography scores may be measuring 
differing pathological processes or different stages or combinations of stages of 
the same process. Certainly plaque formation is rare in the CCA and the intimal 
cell layer extremely thin (0.02mm), presumably because it is a straight non­
branching artery (186).Thus increased CCA-IMT is mostly due to diffuse 
thickening of the media. Conversely when coronary arteries develop 
atherosclerosis sufficiently severe to impinge on the lumen there is usually
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significant eccentric intimal thickening. Thus we maybe comparing different 
processes or different stages of the same process. Plaque formation is more 
common at the BIF but using BIF IMT measurements is comparing the 
combination of medial thickening and intimal thickening (plaque) in the carotids 
with coronary intimal thickening (plaque) alone.
Secondly there are a number of potential problems and inaccuracies with the 
coronary angiography scores. There are significant inter-individual variation in 
coronary anatomy. The most common variation is between dominance by either 
RCA or Cx arteries. None of our scores or those of others (186,219) had any 
adjustment for this and potentially it could lead to significant inaccuracies. For 
example if a person had diffuse and severe disease of a tiny non-dominant 
RCA this would contribute a lot of points to overall scores although there really 
is very little atherosclerosis present and it is of limited clinical significance. 
Another problem is that of complete occlusions which again can lead to 
inaccuracies. Although it is usually stenoses <50% which rupture and occlude 
our scores and those of others rate an occlusion as the most severe lesion. 
Also there is the problem of how to deal with the ‘missing’ segments distal to 
the occlusion. Most systems give these segments the same score as normal 
segments.
Thirdly there is accumulating evidence of differential effects of risk factors on 
the two vascular beds. For example hypercholesterolaemia is more strongly 
associated with coronary disease than carotid atherosclerosis. Adams et al 
(186) showed that increasing age , male sex and presence of Diabetes were all
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associated with a significantly (p<0.01) higher CAD score than average for any 
level of carotid IMT. In our study cholesterol correlated with CAD Gensini 
(r=0.25, p=0.06) score but not carotid IMT( Table 9.11). Conversely life-time 
smoking consumption correlated with carotid IMT but not coronary disease (see 
Table 9.11). We made an effort to control for some of the differential effects by 
including only males and non-diabetics and this may explain the slightly higher 
correlations in our study than in others.
The fourth problem is the theoretical one that carotid IMT may vary with body 
size or artery size whist coronary angiography scores by their nature do not. 
We specifically investigated this by in turn adjusting carotid IMT for two 
measures of body size, BSA (Table 9.5), BMI (Table 9.6) and for CCA diameter 
(Table 9.7). However only adjusting IMT for BMI lead to an improvement in the 
correlations with any of the scores (e.g the correlation between ‘clinical vessel 
score’ and CCAmean was =0.28 before and r=0.32 after adjusting IMT score for 
BMI). This improvement might be because bigger people have bigger arteries 
and thus thicker IMT. Alternatively it could be because obesity is a more 
important risk factor for coronary atherosclerosis than carotid atherosclerosis 
although I know of no data to support this.
Fifthly there was selection bias as we studied a consecutive group of patients 
undergoing elective cardiac catheterisation and therefore our data may not be 
applicable to the general population. However in our cohort with no coronary 
stenosis >50% the CCAmean IMT was 0.66 ± 0.15 mm (n=11), the BIFmean IMT 
was 1.28 ± 0.58 mm (n=8) and the mean age was 50 ± 9 years. The CCAmean
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IMT value is similar but the BIFmean IMT is greater than that from the large ARIC 
database (180), (mean CCA-IMT and BIF IMT for healthy 50 year-old white 
men were 0.65 mm and 0.90mm respectively). It is likely therefore that certainly 
with reference to the CCA data, our patients without important CAD are similar 
to age-matched unselected subjects.
Thus there are five broad reasons why the correlations between carotid and 
coronary atherosclerosis in this study and others (186,219) are not partipularily 
strong. Does this data indicate that carotid IMT is of no use as a non-ihvasive 
assessment of coronary atherosclerosis? Certainly the large overlap between 
subjects with and without CAD (see Figures 9.2-9.5) precludes the use of 
carotid IMT measurement as an additional diagnostic modality for individuals or 
as a screening test for those being considered for coronary angiography.
Our data also casts doubt on the validity of the large number of epidemiological 
and interventional studies using IMT as a surrogate endpoint for CHD mortality 
and morbidity. The overwhelming need is for further prospective studies to 
answer this question. These prospective studies should examine the 
correlation between change in carotid IMT with change in coronary severity and 
extent score. Most importantly they should investigate whether carotid IMT is 
indeed a risk factor for cardiovascular events. There has only been one 
prospective study to date. Salonen & Salonen (191) reported findings in 1,257 
Finnish men who had 36 AMIs over 2 years. They showed that any 
atherosclerotic lesion in the common carotid artery increased the risk of Ml 
threefold (95% confidence intervals, 1.4-6.5).
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This is the first study to compare IMT scores including data from the BIF with 
detailed coronary angiography severity and extent scores. Surprisingly the 
correlations with these scores were less good than with the CCA scores. Any of 
the five reasons detailed above may contribute to explain this, perhaps most 
notably our group with no important CAD did not have typical BIF IMT 
measurements.
Thus in summary we have demonstrated significant correlations between 
carotid IMT and the angiographic severity and extent of coronary 
atherosclerosis. However the correlations were quite modest and there are five 
possible explanations for this. Simple CCA-IMT scores were better predictors of 
the severity and extent of disease than more complex IMT scores. There was 
no convincing evidence to suggest that IMT should be adjusted for body size or 
carotid arterial size.
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CHAPTER 10: ENDOGENOUS FIBRINOLYTIC FUNCTION AND 
CORONARY ATHEROSCLEROSIS : A REVIEW
10.1. INTRODUCTION
The endogenous fibrinolytic system is a cascade of reactions each 
catalysed by a Serine Protease. The crucial event in the fibrinolytic 
cascade is the conversion of plasminogen to plasmin catalysed by tissue 
plasminogen activator (t-PA) and less importantly urokinase (uKA). The 
major physiological regular of this reaction is plasminogen activator inhibitor 
1 (PAI-1).
t-PA is a 70Kda glyco-protein, with a plasma concentrations of about 5 ng/mL. 
PAI-1 was first reported in 1954, but was only defined clearly in the early 
1980's. PAI-1 is a 48kDa glycoprotein occurring at a low concentration in 
normal plasma (about 20 ng/ml) and at higher concentrations in platelets (224) 
and is widely distributed in tissues (225). The endothelium and liver are the 
likely sites of important plasma PAI-1 synthesis. It is clear that plasma PAI- 
1 does not arise simply by leakage from platelets. Platelet PAI-1 is 
present in much higher concentrations (up to 90% of the total blood pool), 
but with much lesser activity (3-6% of the possible activity). Overall, platelets 
account for about half the circulating PAI-1 activity (226).
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Overall fibrinolytic activity can be measured by techniques such as dilute blood 
clot lysis or euglobulin lysis and in the last 10 years it has become possible 
to measure individual components. It is the balance of t-PA and PAI-1 
that is most susceptible to fine regulation and therefore most likely to be 
affected in disease (226).
10.2 REGULATION OF ENDOGENOUS FIBRINOLYSIS
10.2.1 Insulin
Alessi et al (227) showed that insulin induces a dose-dependent increase 
of PAI-1 secretion by a hepatocyte cell line in culture. Insulin, pro-insulin 
and split pro-insulin also augment accumulation of functionally active PAI-1 in 
the media of porcine aortic endothelial cells (228).
Data from a subset (1500 patients) of the large European Concerted Action on 
Thrombosis (ECAT) study has shown that PAI-1 acidity levels is most closely 
related to insulin level and that relationships between PAI-1 and body mass, 
triglyceride level and blood pressure are secondary to this (229). Further, 
reduction of plasma insulin levels by physiological methods or 
pharmacological means is accompanied by a decrease in PAI-1 levels in 
humans (230,231). The evidence has led Juhan-Vague et al (232) to propose 
that insulin may be the major physiological regulator of PAI-1 activity in 
plasma and in turn the major regulator of endogenous fibrinolysis (232).
It has recently been proposed that elevated PAI-1 is a further component of 
syndrome X (233). Reaven in 1988 (234) proposed the term syndrome X for 
the cluster of a number of CHD risk factors: Insulin resistance, glucose
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intolerance, hyperinsulinaemia, increased VLDL triglyceride, decreased HDL 
cholesterol and increased central (upper body obesity). The syndrome is 
alternatively known just as the insulin resistance syndrome.
10.2.2 Very LDL (VLDL) and Triglycerides
Stiko-Rahn et al (235) showed that VLDL stimulates PAM secretion 
from endothelial cells in culture and that hypertriglycerideaemic VLDL is a more 
potent stimulus than normo-triglycerideaemic VLDL.
10.2.3 Oxidised LDL
The putative central role of oxidised LDL in the pathogenesis of 
atherosclerosis at a number of levels is discussed in Chapter 1. An 
additional possible pathogenic process is the influence of oxidised LDL on 
fibrinolysis. Latron et al (236) showed a dose-dependent increase in PAM  
secretion from cultured hepatocytes, whereas inactive LDL had no affect.
10.3 RELATIONSHIP BETWEEN ENDOGENOUS FIBIRNOLYSIS AND CHD 
RISK FACTORS
10.3.1 Smoking
The acute and chronic effects of cigarette smoking on the fibrinolytic system 
appear to be contradictory. The acute effect is an increase in plasma t-PA. 
Conversely, endothelial cells seem to produce less t-PA in chronic smokers 
(237). Further contradictory evidence is provided by the ECAT study, (see 
Table 10.1) which found higher levels of t-PA and PAM in smokers than non- 
smokers .
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Non-smokers Ex-smokers Smokers P Value
PAI-1 Activity 
(U/ml)
13.0 14.1 14.1 <0.004
PAI-1 Antigen 
(ng/ml)
16.2 18.2 18.5 <0.0001
t-PA Antigen 
(ng/ml)
9.3 10.3 10.3 <0.0001
Table 10.1 Comparison of fibrinolytic factors (adjusted for age, sex and centre) 
according to smoking habit in the ECAT study (variable means are shown, P 
values for differences between smoking categories by ANOVA, reproduced 
from 238)
10.3.2 Hypertension
Most studies have been inconclusive due to small numbers, the use of non­
specific assays of fibrinolytic components and the problems of the complex 
interactions pertaining to blood pressure, fibrinolysis and metabolic risk factors. 
In the ECAT study (238) there was a minor relationship between systolic blood 
pressure and PAI-1 and t-PA but this could largely be explained by BMI.
10.3.3 Obesity
Of various anthropometric variables, the waist to hip circumference ratio has 
been most strongly related with both t-PA antigen and PAI-1 antigen and 
activity levels (239,240). The ECAT study (46) reported convincing data for a 
strong association between fibrinolytic factors and data for BMI (see Table
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10.2) Multiple linear regression analysis of a subset of this data has suggested 
that this relationship might be secondary to that between PAI-1 and insulin 
(229).
Quintiles of BMI (kg/m )
<23.68 23.68- 25.25- 26.67- 28.40
PAI-1 Antigen 
(ng/ml)
13.9 16.4 17.5 19.0 21.3
PAI-1 Activity 
(U/ml)
9.9 13.0 13.7 14.9 18.1
t-PA Antigen 
(ng/ml)
8.9 9.5 10.1 10.7 10.9
Table 10.2 Mean fibrinolytic factor levels* according to quintiles of BMI 
(*adjusted for age, sex and centre. P value <0.0001 for all, from 238)
10.3.4 Hyperlipoproteinaemia
t-PA and PAI-1 levels do not correlate with cholesterol or Lipoprotein (a) 
but do quite strongly with triglycerides (241) and this has been confirmed 
in a number of studies (238). In addition, interventions to reduce 
triglyceride levels quickly leads to fall in fibrinolytic activity (242). In all 
studies subjects lost weight which in turn has been related to fibrinolytic 
function and, thus, it is not possible to deduce a direct causal 
association between triglycerides and fibrinolysis from this data alone.
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However taken together with the in vitro evidence detailed above, all the 
evidence strongly suggests a causal association does exist.
10.3.5 Diabetes
Patients with type II diabetes have higher values of PAI-1 activity than 
normal subjects (243) and there is a significant correlation between the 
levels of plasma insulin and PAI-1 activity in type II diabetes (244).
10.4 RELATIONSHIP BETWEEN ENDOGENOUS FIBRINOLYTIC ACTIVITY 
AND CHD
10.4.1 Introduction
There is reasonable evidence for a causal relationship between 
depressed circulating fibrinolytic activity and venous thromboembolism, but 
evidence for such a relationship with arterial disease is less clear (226). This 
might partly be because we are measuring fibrinolysis in venous blood and 
then relating this to events in the arterial circulation. As previously noted, 
PAI-1 is the major physiological regulator of t-PA and thus most work has 
concentrated on measuring PAI-1 antigen or activity. Earlier work measured 
global fibrinolysis and some recent work has also looked at t-PA antigen and 
activity and t-PA/PAI-1 complex.
10.4.2 Case control studies
Hamsten et al (245) first noted elevated levels of PAI-1 in young survivors of 
AMI in 1985. Other studies have confirmed the presence of elevated PAI-1 in 
myocardial infarction or other presentations of CHD (241).
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However, it is not possible for such studies to elucidate whether there is 
causal association or whether the elevated PAI-1 is simply a secondary 
phenomenon. The additional problem is that PAI-1 is considered by 
many to be an acute phase reactant and elevation at the time of myocardial 
infarction might just be as part of a general acute phase response.
10.4.3 Cross sectional studies: Correlations with extent of coronary 
atherosclerosis
There have been a number of studies showing correlations between plasma 
levels of fibrinolytic factors and severity and extent of coronary 
atherosclerosis. This relationship might be causal or alternatively more 
severe coronary atherosclerosis might lead to more frequent ischaemia, 
which in turn might lead to PAI-1 release from the endothelium.
The first study in 1985 (246) showed no relationship between PAI-1 
activity or t-PA antigen and angiographic severity of coronary 
atherosclerosis. However, no account was taken of the diurnal variation of 
the factor and they used an unvalidated angiographic scoring system which 
included lesion site in the calculation as well as severity.
The second study from Oberoff et al in 1989 (247) also did not show a 
correlation between the severity of coronary atherosclerosis and levels of 
fibrinolytic activity. However, again, their study could be criticised in a number 
of areas. Their patients were not fasting: the samples were not drawn at 
consistent times of day; some samples were taken before angiography
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and others after; and they used a very simplified and unvalidated 
angiographic scoring system.
The third study from Sakata et al (248) produced results contradictory to the 
above two studies. They showed that patients with multivessel coronary 
artery disease had significantly higher PAI-1 activity than those with single 
vessel disease. In addition, they demonstrated a significant positive 
correlation between PAI-1 activity in the basal state and the extent of 
ischaemia (r=0.47, p<0.01).
Fourthly, in the ECAT study (238), patients with any stenosis of more than 50% 
had lower fibrinolytic activity in comparison to subjects with normal coronaries. 
This was assessed by longer clot lysis times and higher PAI-1 antigen (18.0 
ng/ml versus 16.4 ng/ml, p=0.0004), PAI-1 Activity (14.3 U/ml compared to 12.8 
U/ml, p=0.0008) and t-PA antigen (10.2 versus 9.5 ng/ml, p=0.0005).Factors 
adjusted for age, sex and centre. No association was found between these 
factors and the severity of stenosis. It should be noted that they graded the 
severity very simply on a scale of 0-4, depending on the number of coronary 
arteries with > 1 stenosis > 50%.
Fifthly, Negri et al (150) in a population of 64 non-obese men with angina and 
angiographically documented coronary atherosclerosis, demonstrated a 
significant correlation between PAI-1 antigen and coronary atherosclerosis 
severity (r=0.55, p<0.00001) and diffuseness (r=0.27, p=0.032). This was the 
most recent and probably best conducted study. Most importantly their 
sampling protocol for PAI-1 was excellent and they used good and well
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validated coronary atherosclerosis scores which quantified the severity and 
extent of disease in great detail. Further, they controlled for the important 
confounding influence of BMI by excluding the obese. Therefore it is likely that 
the reasons for their contradictory results with the preceding studies are these 
methodological details. They did not look at PAI-1 Activity or t-PA antigen.
10.4.4 Prospective Studies
The Northwick Park Heart Study (249) was the first to show a 
strong and independent relationship between low global fibrinolytic activity 
and subsequent risk of CHD events (in a cohort of men aged 40-54).
Secondly, the Physician Health Study (250) showed that higher levels of t- 
PA was a risk factor for later myocardial infarction. This initially seemed to be 
a paradoxical result, but it is now considered (241) that the elevated t-PA 
level reflects primarily an increase in circulating complexes formed by t- 
PA and PAI-1. It therefore seems likely that the association between a 
high t-PA antigen concentration and coronary artery disease is explained by 
high plasma PAI-1 activity and reduced overall fibrinolytic activity.
Thirdly, the ECAT study (90) followed 3,000 men and women with stable 
angina for 2 years. They showed that a higher t-PA antigen (11.9ng/ml 
versus 10.0 ng/ml, p=0.02) was an independent predictor of myocardial 
infarction or cardiac death, independent of other CHD risk factors and 
base-line angiographic severity of coronary atherosclerosis and of left 
ventricular ejection fraction. However, neither PAI-1 antigen and activity, nor 
the ratio of PAI-1 antigen to t-PA antigen differed significantly between the
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group with coronary events and the event-free, (after adjusting for all 
confounding factors p > 0.2, for all comparisons).
10.5 PATHOGENIC MECHANISMS
The three epidemiological studies suggest that low fibrinolytic activity 
is an independent risk factor for CHD events (90,249,250). The most 
likely explanation for the increase in CHD risk is due to decreased clearance 
of thrombosis after atherosclerotic plaque rupture has occurred.
However, the correlations between the angiographic extent of coronary 
atherosclerosis and fibrinolytic activity suggests alternative pathogenic 
mechanisms. Certainly there is some evidence to suggest that altered 
fibrinolysis may play a role in the pathogenesis of atherosclerosis 
itself as opposed to thrombosis. Fibrin is consistently found in 
atherosclerotic lesions (251). In addition, considerable quantities of PAI- 
1 mRNA and PAI-1 antigen (252) have been noted in plaques but not normal 
artery.
A third alternative is that levels of PAI-1 antigen and activity reflect the 
underlying inflammatory state of atherosclerosis. There is increasing 
evidence that increased plaque inflammatory activity leads to increased 
chance of plaque rupture and therefore CHD events (see chapter 2).
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CHAPTER 11: FIBRINOLYTIC FACTORS IN THE 
ASSESSMENT OF CORONARY ATHEROSCLEROSIS
11.1 INTRODUCTION
As detailed in Chapter 10, there is considerable contradiction in the 
published results (150,238,246-249) relating the level of fibrinolytic factors to 
the severity and extent of coronary atherosclerosis. There were various 
methodological problems with these studies and in addition, they could be 
criticised in that they used tridosium citrate as an anticoagulant for PAI-1 
assays. Trisodium citrate does not prevent release of platelet PAI-1 antigen 
and unless the samples are centrifuged immediately a variable amount of 
platelet PAI-1 will have contaminated the plasma samples. Thus, we 
performed plasma determination of PAI-1 antigen in blood collected in a 
mixture of anticoagulant and inhibitors of platelet aggregation (253). Hence, 
potentially the correlations between PAI-1 antigen and extent and severity of 
coronary artery disease might be even greater than that observed by Negri 
et al (150).
11.2 OBJECTIVES
1.To assess the correlation between PAI-1 antigen and severity and extent 
of coronary atherosclerosis.
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2.To assess the correlation between PAI-1 activity, t-PA antigen and severity 
and extent of coronary atherosclerosis.
3.To examine the predictive accuracy of fibrinolytic factors in the diagnosis 
of the presence and severity of coronary atherosclerosis.
4.To investigate the relationships of fibrinolytic factors with 
other CHD risk factors.
5. To compare levels of fibrinolytic factors between patients with and 
without previous myocardial infarction. In addition, in those with previous 
Ml, to compare a cohort with prior crescendo angina with a group who had no 
prior angina.
11.3 MATERIALS AND METHODS
11.3.1 Subjects
We recruited 101 consecutive eligible male subjects (age mean 55.17, range 
32.07-76.07) admitted for elective coronary angiography for the 
investigation of chest pain into the ‘entire cohort’. Exclusion criteria were 
diabetes mellitus (previously diagnosed or a screening fasting glucose > 7.8 
mmol/L); evidence of active infection, inflammation or malignancy; other 
significant disease (including more than mild renal or hepatic dysfunction); 
previous coronary angioplasty or coronary artery bypass surgery; 
myocardial infarction or UA in the previous 3 months. There was an 8 
month recruitment period and Table 11.1 lists the population demographics. 
The study was approved by the Hospital Ethical Committee and all
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patients gave informed consent. Patients were examined, including height, 
weight, hip and waist measurements and excluded if any of the above 
criteria was revealed. Patients filled in a short health questionnaire 
including questions on previous myocardial infarctions, past and 
concomitant health problems, drug history, history of hypertension, family 
history of atherosclerosis and smoking record. Family and smoking 
histories were handled in the same way as in Chapters 6 and 9. There 
was a small overlap between this cohort and that in Chapters 6 (40 
subjects) and 9 (20 subjects).
In addition we created a ‘Negri cohort’ from the ‘entire cohort’ with identical 
inclusion and exclusion criteria to that in Negri et al’s paper (150) by 
excluding individuals who were obese, who had normal coronary arteries 
and who had elevated CRP. The ‘Negri cohort’ is described in Table 11.23.
11.3.2 Sample Preparation
The patients fasted and abstained from smoking from 2200 hours the 
previous evening; 40 ml_ of blood was removed between 0800 and 1100 
hours following a 10 minute supine rest and prior to coronary 
angiography. Venesection was performed by a single person using a 19 
gauge butterfly vacutainer system from a large antecubital fossa vein with 
minimal use of tourniquet to minimise venous status. Blood was added 
to two vacutainer tubes containing no additive, two containing trisodium 
citrate and two Diatubes (Diatube® H, Diagnostic Stago, Asnieres, France). 
These last tubes contain a mixture of sodium citrate and citric acid,
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supplemented with inhibitors of platelet aggregation - theophylline, adenosine, 
and dipyridamole.
11.3.3 Assays
(i) PAI-1 Antigen
The ELISA used was a slight modification of a previously published assay
(254). The technique has been shown to be accurate, reproducible and 
extremely sensitive, with a detection limit of 1.5 ng/ml (224). Purified 
endothelial cell PAI-1 was used as a standard in the ELISA. This was serially 
diluted in "assay buffer" (50 mM sodium phosphate, pH 7.4, 150mM NaCI, 
0.1% (w/v) BSA and 0.05% (v/v) Tween 20, supplemented with 5% (v/v) heat 
inactivated rabbit serum and 10 mM EDTA), to give a range of 
concentrations from 5 ng/ml -312pg/ml.
Polystyrene microplates were coated with 100 pi of 10 pg/ml rabbit anti­
human PAI-1 IgG in 50 mM bicarbonate/carbonate buffer, pH 9.6, and 
incubated overnight at 4°C. The plates were then washed with "wash buffer" 
(15 mM phosphate buffer, pH 7.4., 150 mM NaCI, 0.05% (v/v) Tween 20), 
then "blocked" by adding 200 pi of 1.0% (w/v) bovine serum albumin in 
50 mM bicarbonate/carbonate buffer to each of the wells and incubated at 
37° C for 30 minutes in a closed, humid chamber.
After a further wash the plates were then incubated for 3 hours at 37°C with 
100pl of standards (in triplicate) and samples (in duplicate). After a further 
wash the plates were incubated for 2 hours at 37°C with 100 pi of biotinylated 
anti-PAI-1 IgG (2 pg/ml in supplemented assay buffer). After further
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washing the plates were incubated for an hour with 100 pi of a solution 
composed of streptavidin-biotin-horseradish peroxidase complex diluted 
1:50000 in 50 mM phosphate buffer, pH 7.4, 150 mM NaCI, 0.05% (v/v) 
Tween 20, 0.1 % (w/v) BSA.
Finally after more washing colour was developed by adding 100pl of substrate 
solution (tetramethylbenzidine, 0.1 mg/ml in 100 mM acetate/citrate 
buffer, pH 6.0, containing 0.015% (w/v) hydrogen peroxide). After exactly 15 
minutes at room temperature the reaction was stopped by the addition of 25 
pi 2.5M H2S 04, which instantly changes the blue colouration to bright yellow. 
The absorbance was measured at 450 nm, using a reference wavelength of 
620 nm. The mean absorbence was calculated for each test sample and 
compared with the serial dilution’s of the standard and the unknown values for 
each test sample were interpolated from the standard curve.
(ii) PAI-1 Activity
This assay was developed from that described by Chmielewska and Wiman
(255). The central principal is the detection of the extent of neutralisation of 
known amounts of t-PA activity by test samples, as determined by the relative 
colour changes produced in a chromogenic plasmin substrate (S-2251). One 
unit of PAI-1 activity is the quantity that inhibits one unit of t-PA under the 
conditions of the assay.
Des-AA fibrin (fibrin monomer I) was prepared by treating fibrinogen 
with bathroxobin (a snake venom that selectively cleaves fibrinopeptide 
A from fibrinogen) followed by solubilising the fibrin gel using 3.5M urea.
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Human plasminogen was prepared from plasma on a lysine-Sepharose 
column.
Sample dilutions were prepared in phosphate buffer and an equal volume 
of two-chain t-PA, final concentration 10 U/ml, was added with incubation 
for exactly 45 minutes at room temperature. The reaction was stopped by 
adding an equal volume of acetate buffer 15 minutes at room temperature. 
Samples were then frozen overnight at-70°C.
Purified two-chain t-PA from a melanoma cell line was used as a standard 
and serially diluted (from 10 U/ml to 0.625 U/ml) by addition of Tris buffer, pH 
7.4, containing 0.1% (w/v) Tween 80. An equal volume of 20 mM 
phosphate buffer, pH 7.3, 0.1 M NaCI, 0.1% (w/v) Tween 80 was added and 
the mixture incubated at room temperature for exactly 45 minutes. After 
this, an equal volume of 1M acetate buffer, pH 3.9, was added and the tubes 
incubated for 15 minutes at room temperature and then the standards were 
frozen overnight at -70°C.
The following day samples and standards were thawed and diluted 50 times 
by addition of 50 mM Tris buffer, pH 8.8, containing 0.01% (w/v) Tween 80. 
Residual t-PA activity was then measured in a 96 well microplate by adding 
equal volumes of standard or sample, and a solution containing 0.05 mg/ml 
plasminogen 0.3 mM S-2251 and 0.1 mg/ml des-A fibrin monomer (all 
final concentrations in 50 mM Tris buffer containing 0.01% (w/v) Tween 
80) at 37°C in a humid chamber. Plasmin cleavage of S-2251 produces a
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yellow/green colour in the substrate. The absorbance of this colour was 
measured every hour at 405 nm using 620 nm as a reference wavelength.
A calibration curve was plotted and the residual t-PA activity in samples was 
obtained by extrapolation from this curve. Subtraction of the samples' 
residual t-PA activity from 10 U/ml ( the original quantity added) reveals the 
amount of t-PA inhibition in the samples, which is assumed to be due to PAI- 
1 activity.
(iii) t-PA Antigen
A sandwich ELISA technique was used, modified from that described by 
MacGregor et al (256). Briefly, 96 well microplates were coated with a 
monoclonal antibody against t-PA at 2.5pg/ml and incubated for three hours at 
37°C. Excess binding sites were then blocked by 1% BSA in PBS and 
incubated for one hour at room temperature. The plates were then washed four 
times with wash buffer (15 mM sodium phospate pH 7.4 containing 150 mM 
NaCI and 0.05% Tween 20), and standard and test samples were added. 
Standard t-PA were diluted serially down to 0.03ng/ml in buffer consisting of 
PBS-T and 5% heat inactivated horse serum, 0.1% BSA and 10mM 
ethylenediaminetetraacetic acid (EDTA) adjusted to pH 7.4. Test and serum 
samples were diluted 1/20 in buffer from which horse serum had been omitted. 
200jliI of test and standards were doubly aliqouted and incubated overnight at 
room temperature. The following day after four washes 200jliI of anti-t-PA 
monoclonal antibody conjugated horse radish peroxidase was added to each 
well and incubated for three hours at room temperature.
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After further washing 200pl tetramethylbenzadine substrate was added per well 
and the reaction was stopped by the addition of 50pl 2.5M H2S 04 and the 
plates were read at 450nm. A calibration curve was plotted and t-PA antigen 
concentration in samples was obtained by extrapolation from the curve.
(iv) Other Assays
Insulin levels in serum were assayed using an ELISA kit (Incstar 
Corporation, minnesota, USA). Liver function tests albumin, aspartate 
transaminase (AST), alkaline phosphatase (ALP), bilirubin (BIL), 
gammaGT (yGT) and protein were all assayed by standard techniques 
on an autoanalyser. In addition, subjects had total cholesterol and subtraction, 
triglycerides, CRP, lipoprotein (a), and fibrinogen all assayed as detailed in 
Chapter 6.
11.3.4 Coronary Angiography
These were performed and analysed as in Chapter 6. Five coronary 
angiography scores were developed, the vessel score, the clinical vessel 
score, diffuseness score, severity score (Chapter 6) and the Gensini score 
(Chapter 8).
11.3.5 Statistical Analysis
Seven of the variables measured - insulin, PAI-1 antigen and activity, t-PA 
antigen, lipoprotein (a), and triglycerides were approximately log normally 
distributed and thus were expressed logarithmically. Relationships between 
continuous variables were examined using Pearson's Correlation Analysis. 
Comparison between continuous and categorical variable was performed using
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Student’s T-Test (2 categories) and one-way analysis of variance (>2 
categories). Multiple linear regression was used to devise the best models for 
predicting the extent of coronary atherosclerosis and also to predict levels of 
fibrinolytic factors.
11.4 RESULTS
Table 11.2 describes the distributions of all the plasma and serum variables 
measured and Table 11.3 details the distribution of the coronary 
atherosclerosis severity, diffuseness and Gensini scores. Using the vessel 
score there was 12,5,24 and 60 subjects with 0,1,2 and 3 diseased coronary 
arteries respectively. The same figures for the clinical vessel score was 
18,21,24 and 38 respectively. Table 11.4 shows that there was no 
correlation between any of the fibrinolytic factors and any of the coronary 
atherosclerosis scores. In Tables 11.5 and 11.6 cohort is divided into two 
groups, those with and those without significant coronary atherosclerosis 
(an analysis identical to that performed in the ECAT study (238)). In our 
study subjects with significant coronary atherosclerosis were older, 
heavier and had higher fibrinogen levels than those without. There was 
no difference in the fibrinolytic factors between the two groups (Table 11.5). 
However, after adjustment for the confounding influences of age and weight, 
there was a trend for those subjects with atherosclerosis to have higher levels 
of fibrinolytic factors (Table 11.6).
Table 11.7 demonstrates the correlations between the fibrinolytic factors, age, 
Insulin and anthropometric measurements. The greatest correlation was
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between PAI-1 antigen and Insulin (r=0.44, p<0.001 see Figure 11.1). PAI-1 
antigen correlated next best with weight (r=0.34, p<0.001) and to a lesser 
extent with the other measurements. PAI-1 activity only correlated with Insulin 
(r=0.31, p<0.01). t-PA antigen correlated best with waist/hip ratio (r=0.36, 
p<0.001) and to a lesser extent with the other measurements and with Insulin 
(r=0.28, p<0.001).
The correlations between fibrinolytic factors and continuous CHD risk 
factors are shown in Table 11.8. PAI-1 antigen and PAI-1 activity most 
strongly correlated with triglycerides (r=0.47 (see Figure 11.2) and r=0.44 
respectively, p<0.001 for both) and to a lesser extent with t-PA antigen. PAI- 
1 antigen and activity also correlated with the LDL/HDL ratio. This, 
however, can be attributed to a common correlation with triglycerides 
(correlation between triglycerides and LDL/HDL ratio =0.47, partial 
correlation between triglycerides and PAI-1 antigen, after adjusting for 
LDL/HDL ratio =0.36, p=0.008; partial correlation coefficient between LDL/HDL 
ratio and PAI-1 antigen, after adjusting for triglycerides = 0.15, ns). Similarly, 
for PAI-1 activity there was no residual correlation with LDL/HDL ratio 
after adjusting for triglycerides.
The effect of history of hypertension is examined in Table 11.9. Those 
with hypertension had significantly greater body mass index, t-PA antigen, 
insulin and glucose. The most significant association (p<0.00001) with 
hypertension was BMI and adjusting the other variables for this led to a loss 
of their relationship with hypertension.
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Subjects with a family history of symptomatic CHD (defined as a first degree 
relative developing symptoms before the age of 60) were significantly younger 
(p=0.001) and had higher PAI-1 activity and antigen and t-PA antigen and 
lower fibrinogen (see Table 11.10). Fibrinolytic factors were corrected for 
potential confounders (Table 11.11) and only t-PA antigen remained 
statistically significant. Fibrinogen correlated with age (r=0.290, p= 0.003). 
However, even after adjusting fibrinogen for age, subjects with a family 
history still had significantly lower fibrinogen (305.4 g/dL compared to 342.3 
g/dL, p=0.009). In addition, there was no difference between the cohorts in 
proportions of smokers, non-smokers and ex-smokers (Chi Square = 0.311,
p=0.86).
Table 11.12 compares mean values of CHD risk factors between groups of 
non-smokers, ex-smokers and current smokers (p=ns for all). In 
addition, comparing life-long non-smokers with the combination of current 
smokers and ex-smokers and adjusting for the confounding influence of BMI, 
again there was no statistically significant differences between group means 
(Table 11.13).
PAI-1 antigen and activity correlated significantly with yGT (r=0.38, p<0.0001 
and 0.23, p<0.05 respectively Table 11.14) and t-PA antigen correlated with 
albumin and protein (r=0.24, p<0.05 Table 11.14). When 5 subjects with 
significant elevation of yGT (>100 lU/ml) were removed from the analysis the 
correlation between PAI-1 antigen and yGT was 0.46, (p<0.001). When 
patients with mild elevation of yGT were removed as well (10 patients with yGT
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above the upper limit of normal) the correlation was 0.31 (p<0.01). Similarily 
the correlations between yGT and PAI-1 antigen remained when the cohort was 
divided into subsets depending on triglyceride level (Table 11.15). There was 
no correlation between alcohol intake (units/week) and yGT or PAI-1 antigen or 
activity.
There was no difference in the mean levels of fibrinolytic factors between 
groups with/without prior history of myocardial infarction (Table 11.16). 
However, subjects with a previous Ml had significantly higher total cholesterol 
(p=0.025) and lipoprotein (a) (p=0.014). There was no difference in mean 
levels of fibrinolytic factors or indeed any risk factor between groups 
with/without a history of angina prior to their Ml (Table 11.17).
Patients on betablockers had higher levels of all fibrinolytic components than 
those not on betablockers and this reached statistical significance for PAI-1 
antigen (50.0 ng/ml compared to 35.08 ng/ml, p=0.035, Table 11.18). 
However, the significance was lost after correction for the potential 
confounding influence of triglyceride levels.
Table 11.19 is the best multivariate model for prediction of the extent and 
severity of coronary atherosclerosis (Gensini score). The addition of t-PA 
antigen adds little to the predictive ability of the model (multiple r improves 
from 0.55 to 0.56). The addition of PAI-1 antigen or PAI-1 activity adds 
nothing to the model (multiple r stays at 0.55). Tables 11.20-11.22 are 
multiple linear regression analysis to predict PAI-1 antigen, PAI-1 activity 
and t-PA antigen, respectively. Insulin and yGT are the most significant
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predictors of PAI-1 antigen level, insulin is the most significant predictor of 
PAI-1 activity and PAI-1 antigen is the most important predictor of t-PA antigen 
level.
Table 11.23 is the description of the "Negri cohort". The results from this 
cohort were very similar to that from the “entire cohort”. There were no 
significant correlations between fibrinolytic components and coronary 
atherosclerosis scores (Table 11.24), however insulin did correlate with the 
scores (r=0.30, p<0.05); the correlations between fibrinolytic components 
and anthropomotic measures were slightly stronger than in the entire cohort 
(data not shown).
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Number with 
data available
Mean SD
Age 101 57.17 10.42
BMI (Kg/m5) 101 27.08 3.48
Waist (cm) 100 96.45 8.80
Hips (cm) 100 100.20 5.85
Waist/Hips 100 0.96 0.05
Waist/Height 100 0.55 0.05
Number with 
data available
% with variable present
Family history of 
CAD
98 51.0
History of 
hypertension
100 32.7
Non-smokers 100 20.0
Ex-smokers 100 59.0
Current smokers 100 21.0
Previous Ml 95 42.1
Table 11.1 Demographics of cohort (n=101)
Variable Number Mean S.D
Total Cholesterol (mmol/l) 101 5.63 1.00
LDL Cholesterol (mmol/l) 92 3.66 0.80
HDL Cholesterol (mmol/l) 101 0.91 0.23
LDL/HDL ratio 94 6.60 1.85
Triglycerides (mmol/l)* 101 1.66 1.62
Lipoprotein (a)(mg/dl)* 97 22.39 2.57
Fibrinogen (g/dl) 97 323.76 77.81
Insulin (mU/L)* 101 10.71 1.95
Glucose (mmol/L) 99 5.80 0.61
CRP (mg/l) 97 10.20 0.29
PAI-1 Antigen (ng/ml)* 101 45.71 2.09
PAI-1 Activity (U/ml)* 101 15.85 3.98
TPA Antigen (ng/ml)* 101 6.92 1.62
Albumin (g/l) 100 42.77 2.58
ALT (U/l) 100 22.70 12.05
ALP (U/l) 100 175.49 53.17
yGT (U/l) 100 41.48 29.95
BIL(|4,mol/l) 100 10.49 5.11
Protein (g/l) 100 68.67 3.90
Table 11.2 Distribution of serum and plasma variables. (* for variables 
which were log transformed, geometric mean and approximate SD are 
shown in this table and subsequently.)
Number of 
patients
mean SD
CAD severity 101 45.61 33.52
CAD diffuseness 101 4.43 2.72
CAD Gensini 101 8.48 5.49
Table 11.3 Distribution of coronary atherosclerosis scores.
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0 Vessel Disease 1 -3 Vessel Disease P value
No. 18 83
Age (years) 47.86 56.75 0.0018
BMI (Kg/m*) 28.97 26.67 0.030
Weight (kg) 89.3 80.50 0.016
Waist/hip Ratio 0.96 0.96 ns
Waist/Ht ratio 0.56 0.55 ns
PAI-1 Activity (U/ml) 18.19 15.48 ns
PAI-1 Antigen (ng/ml) 46.65 45.71 ns
TPA Antigen (ng/ml) 6.31 7.24 ns
Insulin (mll/L) 12.59 10.47 ns
Glucose (m m o l/l) 5.83 5.80 ns
Total Cholesterol 
(mmol/l)
5.35 5.70 ns
Ratio LDL/HDL 6.24 6.68 ns
T  riglycerides(mmol/l) 1.79 1.64 ns
Lipoprotein(a)(mg/dl) 19.45 22.96 ns
Fibrinogen (g/dl) 296.20 329.60 0.047
Table 11.5 Comparison of variable means between cohort with no 
coronary stenosis > 50% with cohort having > 1 stenosis > 50%.
0 Vessel 
Disease
1 -3 Vessel 
Disease
p value for 
difference 
between means
PAI-1 Activity 
(U/ml)
37.32 47.42 0.31
PAI-1 Antigen 
(ng/ml)
14.86 16.05 0.81
TPA Antigen 
(ng/ml)
5.90 7.26 0.11
Table 11.6 Comparison of variable means between cohort with no 
coronary stenosis > 50% with cohort having > 1 stenosis > 50%. (n=101, 
Variables adjusted for age and weight).
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No Hypertension 
(n=66)
Hypertension
(n=33)
P for difference 
between means
Age (years) 54.9 55.81 ns
BMI (kg/m") 25.96 29.39 <0.00001
PAI-1 Activity 
(U/ml)
14.79 18.20 ns
PAI-1 Antigen 
(ng/ml)
42.07 53.33 0.10
TPA Antigen 
(ng/ml)
6.50 8.32 0.032*
Insulin (mll/L) 9.42 13.87 0.011
Glucose (mmol/l) 5.71 6.00 0.024
Total Cholesterol 
(mmol/l)
5.69 5.52 ns
Ratio LDL/HDL 6.79 6.23 ns
Triglycerides
(mmol/l)
1.64 1.73 ns
Lipoprotein 
(a) (mg/d I)
20.32 27.16 ns
Fibrinogen (g/dl) 321.50 328.50 ns
CRP (mg/l) 10.2 10.2 ns
CAD severity 45.8 45.30 ns
Cad diffuseness 4.61 4.08 ns
CAD Gensini 8.69 8.06 ns
Table 11.9 Comparison of mean values of cardiovascular risk factors 
between groups with and without history of hypertension. (* non­
significant after correcting for BMI)
No Family History 
(n= 50)
Family History 
(n=48 )
P for difference 
between means
Age (years) 58.76 51.03 0.0001
BMI (kg/m") 26.80 27.44 ns
PAI-1 Activity 
(U/ml)
11.17 22.33 0.013
PAI-1 Antigen 
(ng/ml)
43.55 47.64 ns
TPA Antigen 
(ng/ml)
7.73 6.28 0.038
Insulin (mU/L) 9.95 11.89 ns
Glucose (mmol/l) 5.80 5.84 ns
Total Cholesterol 
(mmol/l)
5.53 5.76 ns
Ratio LDL/HDL 5.57 6.68 ns
Triglycerides
(mmol/l)
1.57 1.79 ns
Lipoprotein 
(a) (mg/d I)
21.28 22.80 ns
Fibrinogen (g/dl) 353.10 300.30 0.0002
CAD severity 47.1 42.60 ns
Cad diffuseness 4.69 4.04 ns
CAD Gensini 8.85 7.86 ns
Table 11.10 Comparison of mean values of cardiovascular risk factors 
between groups with and without a family history of CAD.
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Never Smoked (n=20) Ex-smoker (n=59) Current smoker (n=21)
Age (years) 54.91 55.80 53.71
BMI* (kg/m") 28.80* 26.73* 26.30*
PAI-1 Activity 
(U/ml)
14.90 16.25 15.55
PAI-1 Antigen 
(ng/ml)
47.86 45.71 43.65
TPA Antigen (ng/ml) 6.76 7.41 6.90
Insulin (mU/L) 11.48 10.72 9.33
Glucose (mmol/l) 5.76 5.84 5.7
Total Cholesterol 
(mmol/l)
5.8 5.6 5.6
Ratio LDL/HDL 6.47 6.52 7.08
Triglycerides
(mmol/l)
1.65 1.55 1.74
Lipoprotein 
(a) (mg/d I)
25.12 22.38 18.62
Fibrinogen (g/dl) 307.32 322.02 340.50
CRP (mg/l) 9.50 10.51 9.86
Table 11.12 Comparison of mean values of cardiovascular risk factors 
between groups of non smokers, ex-smokers and current smokers 
(*p=0.030, otherwise p=ns for all).
Never 
(n=20 )
Smoked Ex or current smoker 
(n=80)
p Value
PAI-1
(ng/ml)
Antigen 46.88 50.82 0.50
PAI-1
(U/ml)
Activity 13.03 16.63 0.65
TPA
(ng/ml)
Antigen 6.03 7.19 0.10
Table 11.13 Comparison of mean levels of fibrinolytic factors between a 
group of lifelong non smokers with a group of combined current and 
previous smokers (factors adjusted for BMI).
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Number of 
subjects
PAI-1 antigen 
(U/ml)
PAI-1 activity 
(ng/ml)
All 101 0.38*** 0.24**
Hypertiglyceridaemic 13 0.40** 0.18
Normotriglyceridaemic 88 0.31** 0.18*
Normotriglyceridaemic 
Normal yGT
73 0.27** 0.17
Table 11.15 Correlations between PAI-1 activity and antigen and yGT in 
the “entire cohort” and three subsets (see ref 43b) (*p<0.05, **p<0.01, *** 
p<0.001 all other correlations are not significant).
No Ml (n= 55) Previous Ml (n=40) P for difference 
between means
Age (years) 54.50 55.47 ns
BMI (kg/m") 27.52 56.74 ns
PAI-1 Activity 
(U/ml)
18.20 14.45 ns
PAI-1 Antigen 
(ng/ml)
45.71 46.77 ns
TPA Antigen (ng/ml) 6.62 7.83 0.09
Insulin (mU/L) 10.59 10.62 ns
Glucose (mmol/l) 5.86 5.75 nss
Total Cholesterol 
(mmol/l)
5.41 5.86 0.025
Ratio LDL/HDL 6.38 6.86 ns
Triglycerides
(mmol/l)
1.64 1.67 ns
Lipoprotein 
(a) (mg/d I)
17.42 27.42 0.014
Fibrinogen (g/dl) 320.70 329.5 ns
CRP (mg/l) 9.81 10.10 ns
CAD severity 39.20 53.59 0.032
Cad diffuseness 4.03 5.09 0.065
CAD Gensini 7.42 9.91 0.030
Table 11.16 Comparison of mean values of cardiovascular risk factors 
between groups with and without previous Ml
No prior angina (n= 19) Prior angina (n= 14)
Age (years) 53.52 56.29
BMI (kg/m") 27.26 27.15
PAI-1 Activity 
(U/ml)
17.78 18.62
PAI-1 Antigen 
(ng/ml)
44.67 47.86
TPA Antigen (ng/ml) 8.13 7.59
Insulin (mU/L) 12.02 12.02
Glucose (mmol/l) 5.88 5.75
Total Cholesterol 
(mmol/l)
5.71 6.08
Ratio LDL/HDL 6.50 7.03
Triglycerides
(mmol/l)
1.61 1.74
Lipoprotein 
(a) (mg/d I)
28.84 21.88
Fibrinogen (g/dl) 331.20 322.7
CRP (mg/l) 10.50 11.10
CAD severity 55.20 57.60
Cad diffuseness 5.38 5.14
CAD Gensini 10.29 10.43
Table 11.17 Comparison of mean values of cardiovascular risk factors 
between groups with and withuot a history of angina prior to Ml (p=ns for 
all)
No B Blocker (n=27) B Blocker (n=74) P for difference 
between means
Age (years) 55.40 55.10 ns
BMI (kg/m") 27.26 27.01 ns
PAI-1 Activity 
(U/ml)
14.82 16.21 ns
PAI-1 Antigen 
(ng/ml)
35.08 50.00 0.035*
TPA Antigen (ng/ml) 6.22 7.31 ns
Insulin (mU/L) 13.15 9.93 ns
Glucose (mmol/l) 5.89 5.77 ns
Total Cholesterol 
(mmol/l)
5.65 5.63 ns
Ratio LDL/HDL 6.41 6.67 ns
Triglycerides
(mmol/l)
1.43 1.76 0.064
Lipoprotein 
(a) (mg/d I)
26.24 20.99 ns
Fibrinogen (g/dl) 326.00 323.00 ns
CRP (mg/l) 11.42 9.75 ns
CAD severity 42.00 46.90 ns
Cad diffuseness 3.94 4.61 ns
CAD Gensini 7.71 8.75 ns
Table 11.18 Comparison of mean values of cardiovascular risk factors 
between groups with and without B Blocker therapy (*significance lost after 
correcting for Triglycerides.) Similar analyses for groups with and without 
each of Aspirin, Calcium Antagonist and Nitrate therapy showed no 
significant results.
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Number with 
data available
Mean SD
Age (years) 68 57.30 10.13
BMI(kg/m2) 68 25.62 2.55
Weight (kg) 68 7.80 9.77
Waist/Hips 67 0.96 0.05
Waist/Height 67 0.54 0.04
CAD severity 67 54.67 28.89
CAD diffuseness 67 5.32 2.13
CAD Gensini 67 10.19 4.32
Table 11.23 Description of ‘Negri’ cohort (n=68)
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11.5 DISCUSSION
There was no correlation between PAI-1 antigen and either the 
severity or diffuseness of coronary atherosclerosis (r=0.04 for severity, r=0.01 
for diffuseness, Table 11.4). This is in agreement with other studies 
(227,238,256) but in marked contrast to the work of Negri et al (150), who 
found correlations between plasma PAI-1 antigen and severity of 
coronary atherosclerosis (r=0.55, p<0.00001) and PAI-1 antigen and
diffuseness score (r=0.27, p<0.032).
Our entire cohort (Table 11.1) was different from that of Negri et al (29) 
in that we included individuals who were obese, who had normal 
coronary arteries and who had elevated CRP. Thus we excluded these 
subjects to create our "Negri cohort" (Table 11.23). However, again there 
was no correlation between PAI-1 antigen and severity or diffuseness of 
coronary atherosclerosis (Table 11.24).
There are a number of possible explanations for the contradictory results. 
Firstly, our angiography scoring systems were slightly different from that of 
Negri. The only difference between the severity scores is that they gave a 
stenosis of 50-75% 10 points and 76-89% 15 points, whereas we treated 50- 
89% stenosis as one category, gaining a score of 12.5 points. Otherwise the 
severity scores were identical in all respects. There were more differences 
between the diffusseness scores in Negri's and our studies. They examined 
first to third order coronary artery branches whilst we just looked at the first 
two orders. They graded a stenosis in a given segment as being diffuse or
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discrete, whereas we simply looked for presence or absence of stenosis in 
a segment.
A second possibility is that in Negri's studies some platelet PAI-1 antigen 
leaked out and contributed to the measured and presumed plasma PAI-1 
antigen. We used anticoagulant tubes containing an anti-platelet mixture 
which prevents platelet secretion of PAI-1 antigen and thus can be confident 
that we measured only plasma PAI-1 antigen (253).
A third possibility is that populations were different in respect of potential 
confounding variable(s) and there seems to be at least one important 
difference between the populations. In Negri's paper there was some 
association between increasing triglyceride level and severity of coronary 
atherosclerosis in that those with multivessel coronary disease had 
significantly higher triglycerides than subjects with only single vessel disease. 
A similar analysis in our Negri cohort showed a trend in the opposite direction 
with a higher triglyceride level in those with single vessel disease 
compared to multivessel disease (1.79 mmol/L compared to 1.56 mmol/L). 
As discussed below, triglyceride levels are a very important influence on PAI- 
1 levels.
There were also no correlations between PAI-1 activity or t-PA antigen 
and the severity and extent of coronary atherosclerosis in the entire cohort 
(Table 11.4) or the "Negri cohort" (Table 11.24) and this is in agreement with 
previous work (238,246). Further, there was no statistical difference for 
mean PAI-1 antigen or activity or t-PA antigen between groups with/without
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coronary atherosclerosis (Table 11.5). However, age and weight- 
adjusted data showed a clear trend for those with atherosclerosis to 
have higher levels of all three measurements (Table 11.6). The proportional 
difference between the means of the groups for each measurement is similar 
to that in the large ECAT study (238) (PAI-1 antigen 18.0 ng/ml versus 16.4 
ng/ml, p=0.0004; PAI-1 Activity 14.3 U/ml compared to 12.8 U/ml, p=0.0008; t- 
PA antigen 10.2 versus 9.5 ng/ml, p=0.0005). The results in the ECAT study 
were highly significant but this is likely to be because of their larger sample 
size.
We, however, did show that insulin correlated with both severity and 
extent of coronary atherosclerosis in our "Negri cohort" (r=0.30, p<0.05, 
Figure 11.3). This agrees with the findings of Negri et al (150) who showed a 
correlation between insulin and severity of r=0.37 and between insulin and 
diffuseness of r=0.19. The correlations of PAI-1 antigen and activity with 
insulin were greater than with any of the anthropometric measurements 
(r=0.44, p<0.001 for PAI-1 antigen, Figure 11.1 and Table 11.7). This agrees 
with data from the ECAT study (229), suggesting that the relationship between 
PAI-1 and body mass index and waist/hip ratio is generally secondary to the 
relationship between PAI-1 and insulin. This is further investigated by multiple
linear regression in Tables 11.20-22 and discussed below.
t-PA correlated more strongly with waist/hip ratio than other
anthropmometric measurements (r=0.36, p<0.001) as previously
documented (239,240,245). However, contrary to this previous work,
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PAI-1 antigen correlated more strongly with weight (r=0.34, p<0.001) than 
with waist/hip ratio (r=0.22, p<0.05, Table 11.7). Again, contrary to previous 
data, PAI-1 activity did not correlate with any of the anthropometric 
measurements.
PAI-1 antigen and PAI-1 activity and t-PA antigen correlated most strongly 
with triglycerides (r=0.47, p<0.001(see Figure 11.1), r=0.44, p<0.001 and 
r=0.29, p<0.01, respectively) of the continuous CHD risk factors (Tables 
11.8), as previously noted (241). The apparent correlation between
fibrinolytic factors and LDL/HDL ratio is shown to be spurious and due to 
confounding effects of triglycerides.
Subjects with hypertension had greater BMI and higher PAI-1 antigen, t-PA 
antigen, insulin and glucose than those without (Table 11.9). However, 
the strongest association was with BMI and after correcting for this, the 
significance of the other relationships were lost and this is similar to previous 
data (238).
A comparison of mean values of CHD risk factors between groups with 
and without a family history of coronary atherosclerosis produced some 
surprising results (Table 11.10). Those with a family history were younger, 
had higher PAI-1 activity but lower t-PA antigen and most surprisingly, 
highly significant lower fibrinogen (300.3 g/l vs 353.1 g/l, p=0.0002). 
Adjustment for potentially confounding influences led to a loss of 
significance for PAI-1 antigen, however, there was no obvious confounding 
factors for t-PA. It is difficult to fit this finding with the epidemiological
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evidence regarding higher t-PA antigen levels as a CHD risk factor
(90,250). It is also difficult to explain the fibrinogen results as their association 
remained after adjusting for the potential influence of age. Further there was 
no difference between the groups regarding smoking the other 
potential confounding variable. There is known to be a large hereditary 
component (51%) to fibrinogen levels (257) and elevated fibrinogen is 
increasingly regarded as a risk factor for CHD mortality and morbidity 
(258).
Current smokers and ex-smokers had trends towards higher levels of PAI 
antigen and t-PA antigen than lifelong non-smokers (Table 11.13, after 
adjusting for the confounding influence of BMI). These trends were in the same 
direction as the significant results from the ECAT study (see Table 10.1).
There were moderate correlations between PAI-1 antigen and activity and 
yGT (see Table 11.14). Leiper et al (259) showed increases in the plasma 
concentration of PAI-1 and t-PA antigens in patients with a variety of hepatic 
diseases including alcoholic cirrhosis, primary biliary cirrhosis and hepatic 
malignancy. It should be noted that none of the patients in our study had a 
history or clinical evidence of past or present hepatic disease.
To my knowledge, Asplund-Carlsson and colleagues (260) have published the 
only other data relating levels of liver function with fibrinolytic factors. They 
showed that yGT levels correlated with PAI-1 activity in a population of 29 
hypertryglyceridaemic (triglycerides >3.05mmol/l) males who also had elevated 
yGT (r=0.50, p<0.001). There was no correlation in cohorts of
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normotriglyceridaemic males or hypertiglyceridaemic men with normal yGT and 
they did not look at PAI-1 or t-PA antigen levels. We divided our cohort using 
Asplund’s criteria (Table 11.15) and there remained significant correlations 
between yGT and PAI-antigen in all groups but not PAI-1 activity. To my 
knowledge this is the first description of correlations between yGT and PAI-1 
activity in these populations and with PAI-1 antigen in any population.
Why PAI-1 antigen should correlate with yGT is unclear. Elevated yGT is 
usually related to regular daily consumption of alcohol (260). Experimental 
studies have fairly consistently shown a decrease in blood fibrinolytic activity 
with alcohol both acutely and in the long term. Whereas in contrast the 
epidemiological studies have generally shown a positive association between 
alcohol consumption and fibrinolytic capacity (see review by Veenstra et al 
261). In our study there was no correlation between reported alcohol 
consumption (units/week) and yGT or PAI antigen or activity. This suggests that 
yGT varies independently of or inconsistently with alcohol consumption
The endothelium and liver are the likely sites of important plasma PAI-1 
antigen synthesis although there relative importance remains unclear (226). 
Our data suggests that the liver contributes significantly. Indeed yGT was the 
most important predictor of PAI-1 antigen levels in a multiple linear regression 
analysis (Table 9). Perhaps yGT is involved with transmembrane transport of 
PAI-1 and thus increased yGT expression leads to increased PAI-1 excretion 
into plasma. yGT becomes a less important and Insulin a more important
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influence on PAI-1 antigen if patients with elevated yGT are excluded from the 
analysis (correlation between Insulin and PAI-1 antigen =0.50.)
There was a tendency for subjects with a history of previous myocardial 
infarction to have higher levels of t-PA antigen compared to those with no 
history of myocardial infarction (7.83 ng/ml vs 6.62 ng/ml, p=0.09). However, 
there was no difference in PAI-1 antigen or activity between the two groups 
(Table 11.16). This is in keeping with the emerging prospective 
epidemiological data that it is a higher level of t-PA antigen which reflects a 
decreased fibrinolytic activity and a risk factor for myocardial infarction
(90,250). This initially seemed to be a paradoxical result, but it is now 
considered (241) that the elevated t-PA level reflects primarily an increase 
in circulating complexes formed by t-PA and PAI-1. It therefore seems 
likely that the association between a high t-PA antigen concentration and 
coronary artery disease is explained by high plasma PAI-1 activity and 
reduced overall fibrinolytic activity.
There was no difference in any continuous CHD risk factor including the 
fibrinolytic factors between groups with a history of proceeding angina prior 
to their Ml compared to a group with no prior angina (Table 11.17). I had 
hypothesised that the former group might have better fibrinolytic function and 
thus be able to resist occlusion and subsequent Ml for longer than the latter 
group, but there were no data to support this.
We examined the effects of four commonly used cardiac medications on 
fibrinolytic factors (Table 11.18) and the only significant results were for
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betablockers. Subjects on betablockers had higher levels of fibrinolytic factors 
than those not receiving this therapy and this reached statistical 
significance for PAI-1 antigen. However, patients on betablockers also 
had higher triglycerides. This is in agreement with one similar study (262) 
which studied 385 patients with hyperlipidaemia. The 39 patients who were 
receiving beta blockers had significantly elevated PAI-1 antigen and activity 
and t-PA antigen than the remainder of the cohort, After adjusting for age, sex, 
Quetelet index and triglycerides however the trend to higher levels remained 
but the statistical significance was lost. Our patients on betablockers also had 
higher triglyceride levels, which is a well documented effect of betablockers 
(263) and the significant association of PAI-1 antigen and betablockers was 
lost after adjusting for triglycerides. An adverse effect of beta blockers on 
fibrinolysis mediated via triglycerides cannot be excluded. However in contrast 
to the above data, two longitudinal studies (264,265) have demonstrated that 
patients had improved fibrinolytic activity after commencing betablockers. It 
seems unlikely that Beta blockers can have an important adverse effect on 
fibrinolysis as they are of proven mortality benefit post-myocardial infarction ( 
266).
Table 11.19 was the best multivariate model for prediction of the severity 
and extent of coronary atherosclerosis. As can be seen, the inclusion of 
any of the fibrinolytic components in the model adds nothing to the predictive 
accuracy of the model.
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Table 11.20 demonstrates that yGT and insulin are the most important
factors in determining PAI-1 antigen levels and the next important
factor is triglyceride. The latter two of these factors are well
documented but this is the first time that the influence of yGT on PAI-1
antigen levels has been demonstrated. yGT is a less important and Insulin a 
more important influence on PAI-1 antigen if patients with elevated yGT are 
excluded from the analysis (correlation between Insulin and PAI-1 activity 
=0.50.)
For PAI-1 activity, insulin and triglycerides are the most important influences 
(Table 11.21). For t-PA antigen, PAI-1 antigen and waist/hip ratio are the most 
important factors (Table 11.22).
In summary, there was no evidence of a correlation between plasma PAI-1 
antigen levels and the angiographic severity of coronary atherosclerosis and 
this contradicts recently published work (150). Three possible explanations for 
this are presented. Also there was little evidence of a relationship between PAI- 
1 activity or t-PA antigen and the extent of coronary atherosclerosis. The 
relationship between PAI-1 and the components of the Insulin Resistance 
Syndrome are confirmed. Novel data is presented suggesting that yGT is an 
important influence on PAI-1 antigen levels in a normotriglyceridaemic 
population.
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CHAPTER 12: GENERAL DISCUSSION
12.1 INTRODUCTION
CHD is the biggest single cause of death in the United Kingdom (11). In 
1990 there were nearly 170,000 coronary heart disease deaths which 
represents 27% of all deaths and 17% of these deaths in people under 65 
years of age. There is also an appreciable morbidity with 5% of men and 3% 
of women reporting having had angina (12). It is estimated that in 1989/90 
CHD attracted about 4% of total NHS expenditure in the U.K (11). Thus there 
are huge incentives to improve the prevention, diagnosis and treatment of all 
stages of CHD. This thesis examined one aspect of this, the non-invasive 
assessment of coronary atherosclerosis.
It seems unlikely that non-invasive measurement of atherosclerosis will 
replace angiography for assessing the significantly symptomatic who are 
being considered for surgical intervention and this is outwith the scope of 
this thesis. However, the development of valid and reliable techniques 
of non-invasive assessment would be invaluable in a number of ways as 
follows:
1.As an additional diagnostic tool in those with minor or atypical symptoms 
which are insufficient to justify the risks and costs of invasive investigation.
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2.To identify those with a large but still sub-clinical atherosclerotic 
load, both for intervention to halt the progression of disease and for 
intensive research.
3.Serial measurements of atherosclerosis from an early age in 
large epidemiological studies would allow evaluation of the natural history of 
the disease.
4. If it can be shown that non-invasive techniques of quantification was valid 
and that the measured atherosclerotic extent correlated with the likelihood 
of clinical events, then serial measurements could be used to follow 
anti-atherosclerotic interventions, either by lifestyle adjustments 
or pharmacological interventions.
This thesis examined three techniques for the non-invasive assessment of 
coronary atherosclerosis. The second objective was to investigate the role of 
the immune response to hsp65 and H.pylori and of the endogenous fibrinolytic 
system in the pathogenesis of atherosclerosis and athero-thrombosis.
12.2 THE IMMUNE RESPONSE TO HSP60/65 AND H.PYLORI AND 
ATHEROSCLEROSIS
Data is presented in chapter 6 showing that levels of anti-hsp65 correlate with 
both the severity (r=0.21, p=0.018) and diffuseness (r=0.21, p=0.016) of 
coronary atherosclerosis (Table 6.4). In addition, elevated anti-hsp65 
remained significantly associated with the presence of coronary 
atherosclerosis after adjustment for all confounding factors (27.86 AU/ml
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compared to 17.10 AU/ml, p=0.012). Anti-hsp65 has been suggested as the 
diagnostic marker of atherosclerosis that clinical medicine had been waiting for 
(131) and this was a major stimulus for this work. However, very 
disappointingly, levels of anti-hsp65 clearly had insufficient predictive 
accuracy to be a useful clinical test as at best anti-hsp65 titre had a sensitivity 
of 77.8% and specificity of 57.8% for the detection of atherosclerosis (see 
Table 6.4 and Figures 6.2 and 6.3)
Anti-hsp65 does not meet all the eight criteria for causal risk factor status 
detailed in Chapter 1, although few risk factors do. Nevertheless, our data 
along with the evidence of Xu et al (112,126-130) suggest that it is likely that
the antibodies to hsp60/65 and the immune response to hsp60/65 is
involved with the pathogenesis of atherosclerosis.
In Chapters 4-7, the influence of other factors on anti-hsp65 titre are 
examined. There was no significant familial influences on development of 
titres (chapter 4). Further, any minor familial influences were likely to be
environmental rather than genetic. This is in keeping with experimental
evidence in animals which have shown that it is the environmental 
exposure to micro-organisms which is most important in producing anti-hsp65 
titres (141).
There is no difference between the sexes in titres of anti-hsp65 (chapters 4 
and 7) and this is in keeping with data from other groups (120,130). This is 
perhaps surprising in view of the different incidence of coronary heart 
disease between the two sexes (see Figure 1.3) and therefore you might
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expect males to have higher anti-hsp65 levels. We only investigated males 
in our cohort with coronary atherosclerosis (Chapter 6), but Xu et al (130) 
showed that elevated anti-hsp65 was associated with carotid 
atherosclerosis in both sexes.
Thirdly, anti-hsp65 titre increases with advancing age (r=0.24, p<0.005, 
Chapter 6). This is in contradiction to the data from Chapter 4 when there was 
no evidence of an association with age, however, this was in a much 
younger population. On the whole these results are similar to others published 
showing no age effect in populations with mean ages <35 (118, 140) but a 
positive association with age in those with mean age >55 as in Chapter 6 and 
that of Xu et al (130). Titres of other auto-antibodies, for example RF (130) 
have been shown to increase with age.
Life-time smoking consumption and smoking habit generally may be a minor 
influence on anti-hsp65 titre (Chapter 6).
Probably the most important piece of data in this thesis is presented in 
Chapter 7. There has been suggestions of a link between infection and the 
pathogenesis of atherosclerosis for many years (reviewed in chapter 2). 
Mendall’s study (73) in 1994 followed in 1995 by a second paper from the 
same centre (74) both showing an independent association between 
seropositivity to Helicobacter pylori and increased CHD risk, 
provoked a lot of interest. They postulated (74) that H.pylori infection leads 
to an increase in CHD events by inducing a hypercoaguable 
state and they presented data indicating an independent positive association
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between fibrinogen and H.pylori seropositivity. However, a third paper later 
in 1995 from Belfast (75) showed an odds ratio for CHD events after 
adjustment for all potential confounders in those with H.pylori infection was 
1.51, but with a 95% confidence interval of 0.93-2.45 (p=0.1). They did not rule 
out the possibility of an independent association between H.pylori and 
coronary heart disease but stated that it was unlikely that fibrinogen was the 
mechanism as they showed a weak negative association with CHD.
The difficulty is in dissecting a possible relationship between two diseases 
when each is closely related to age and social class (compare Figures 1.2 and 
7.2) and it could be that H.pylori infection is part of the mechanism by which 
age and social class lead to increased CHD risk. Thus, it is important to look 
for a potential causal relationship in other ways and investigation of possible 
pathogenic processes is one such way (chapter 7).
Firstly, there was a relatively strong and highly significant independent 
correlation between anti-hsp65 titre and antibodies to H.pylori (r=0.38, 
p<0.00001). Secondly, anti-hsp65 titres were measured serially in a 
randomised double-blind study of H.pylori eradication therapy. In the 
subjects who received placebo and had continued active H.pylori infection, 
the anti-hsp65 titre remained essentially static over the year of the study. 
However, in the group who had active therapy and confirmed eradication of 
H.pylori the mean anti-hsp65 titre fell from 25.64 AU/ml to 13.75 AU/ml 
(p=0.033) (see Figure 7.4).
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Further, the data also suggests that about 40% of the anti-hsp65 titre in the 
population with H.pylori infection is due to H.pylori infection itself, although 
there was marked inter-individual variation. It is very likely that exposure to 
other micro-organisms with cross-reacting hsp60/65 contribute to the 
measured titres as well. Indeed another interpretation of our data is that the 
antibiotics given to eradicate H.pylori may have eradicated or decreased the 
load of other chronic bacterial infections and the reduction of these infections 
may be responsible to a greater or lesser extent for the fall in anti-hsp65 titre. 
In support of this is our data in from the group who received antibiotics but 
subsequent breath tests indicated persistent H. pylori infection. In this cohort 
(n=15) there was a trend for anti-hsp65 titre to fall (from 10.3 AU/ml to 9.31 
Au/ml). It can at least be concluded that giving antibiotics leads to a fall in anti- 
hsp65 titre thus indicating that bacterial infections are an important influence 
on anti-hsp65 titre. In this regard it would be very interesting to examine the 
influence of Chlamydia pneumoniae on anti-hsp65 titres as this organism 
has also be associated with CHD (reviewed in chapter 2 and see 74,77-80,82- 
84) and expresses cross-reacting hsp60/65 (76).
Thus, an alternative hypothesis to explain the association between 
H.pylori and ischaemic heart disease based on my data and the evidence of 
Xu et al is as follows; endogenous hsp60 expression is induced on normal 
arterial intima by stresses such as hypertension and smoking. Exposure to
H.pylori and other micro-organisms induces an immune response to 
bacterial hsp60/62/65 and the antibodies produced cross-react with hsp60.
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This could either initiate or contribute to the local inflammatory and 
autoimmune process in the arterial intima, leading to initiation or 
worsening of atherosclerotic lesion.
Our data links in very well with some interesting evidence emerging in the last 
three years since the conception of this thesis, which has implicated elevated 
levels of CRP as a risk factor for ischaemic heart disease (267) and for 
the progression of stable (90) and unstable (91) angina. CRP is the major 
acute phase reactant in humans and the level reflects the stimulation of 
hepatic production by circulating inflammatory mediators such as cytokines 
(268). In unchallenged subjects, concentrations are usually low, rising several 
hundred fold in acute illness (269). The causes of variations in CRP in 
otherwise normal people has received little attention (267). In the first of 
these papers in 1994 Liuzzo et al (91) reported a group of 32 patients 
with UA. Eighteen of 20 patients with CRP > 0.3 mg/dl had a further CHD 
event during their hospital stay. In contrast, only 2 out of 11 with CRP < 0.3 
mg/dl had CHD events (p<0.001).
The second paper was reported in 1995 by Thomson et al (90) on behalf of 
the ECAT study group. They followed 3,043 patients with stable angina for 
2 years who had undergone coronary angiography at baseline. The group 
who experienced further CHD events (n=106) had a mean baseline CRP of 
0.22 mg/dl in comparison to those without events (n=2700) with mean 
baseline CRP 0.16 mg/dl (p=0.05). The values were adjusted for age,
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sex and all other established CHD risk factors including baseline severity 
of coronary atherosclerosis and left ventricular ejection fraction.
Thirdly, Mendal et al in 1996 (267) showed in a population based cross- 
sectional study of 303 white men aged 50-69 years that the independent odds 
ratio per doubling of CRP for all prevalent coronary heart disease was
1.55 (95% Cl, 1.25-1.92). Further, they examined factors which might 
influence CRP levels and showed that age, smoking, history of chronic 
bronchitis and seropositivity to H.pylori or C.pneumoniae were all 
individually related to increased CRP levels. This supports the idea that the 
acute phase response is a continuum and not an all or nothing phenomenon. 
In addition, they showed that triglycerides, cholesterol and fibrinogen 
were all positively associated with increased levels of CRP.
It is unlikely that CRP reflects underlying quantity or severity of 
atherosclerosis as we (data from chapters 6 and 11 not shown) and others 
(90) observed no correlation between CRP and the coronary angiographic 
extent of disease (Chapters 6 & 11). Elevated CRP is also unlikely to reflect 
more frequent episodes of ischaemia as we could find no evidence of a 
correlation between CRP and frequency of anginal episodes (Chapters 6 & 
11). Similarly, Liuzzo et al (270) showed that there was no elevation of CRP in 
patients with variant angina (characterised by severe transmural 
myocardial ischaemia associated with transient ST segment elevation 
and accompanied by occlusive epicardial coronary artery spasm). Other 
more likely possibilities include that serum CRP could be related to the
192
pathogenesis of atherosclerosis via the effects of inflammation (induced by 
e.g. smoking, H.pylori, chronic bronchitis etc.) on conventional risk 
factors. Alternatively the raised CRP may result from inflammation in 
the arterial wall associated with the atherosclerosis itself. A final possibility is 
that the cytokine and cellular mediators of the acute phase response 
originating at a distance from the coronary arteries are directly involved in 
the pathogenesis of atherosclerosis. Potentially a combination of these 
might be the true explanation and certainly our data would fit very well with 
the latter two.
Thus, it has been suggested (268) that the biological (inflammatory) state 
of a coronary lesion might be a more important determinant of the clinical 
outcome than for example the degree of stenosis. Certainly mechanical 
testing of aortic fibrous caps indicates that increased foam cell infiltration 
weakens caps locally, reducing their tensile strength (96). This has been 
corroborated by immunohistochemical studies showing there are more 
macrophages at regions of plaque rupture than at unruptured segments (97). 
This might help to explain why most myocardial infarctions occur as a result 
of the formation of thrombi on lesions that are not highly stenotic (40) and 
why knowledge of the angiographic location of coronary stenosis does not 
allow one to predict the location of subsequent sites of acute occlusion (41). 
Conversely, elimination of the inflammatory response in the arterial wall may 
be associated with a decreased risk of subsequent acute events, even 
without substantial reduction in the degree of atherosclerosis. This may 
explain the recent findings from a number of large lipid-lowering studies for
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the regression of coronary artery disease. In these studies there was 
only a minor angiographic regression of atherosclerosis, but a dramatic 
reduction in the rate of a cardiac events (268). Further, in studies of non­
human primates, inflammatory cells in atherosclerotic lesions decreased in 
number after reversion from a high cholesterol to a normal cholesterol 
containing diet (277).
This emerging data which has changed since the original conception of this 
thesis indicates that the ideal prognostic assessment of coronary 
atherosclerosis would measure both the stenotic severity of the disease and, 
perhaps even more importantly, the biological (inflammatory) activity of the 
atherosclerosis (268).
In this regard, CRP is currently being assessed in further prospective studies 
(270). However, the search must continue for other reliable markers of the 
inflammatory activity of the disease which have prognostic significance (268).
Anti-hsp65 already has an advantage over CRP in that it correlates, albeit 
weakly, with the stenotic severity of disease. The second stage would be 
to show that elevated levels of anti-hsps65 have an adverse 
prognostic significance independently of the angiographic severity of 
disease, and certainly there is considerable theoretical evidence to 
suggest that this might be so. Although Chapter 5 indicates that there was 
no difference between anti-hsp65 titres between stable and unstable 
atherosclerosis (Figure 5.4), this was performed on small numbers, on a 
cross-sectional basis and without adjustment for severity of underlying
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atherosclerosis (This data was not available for the acute coronary 
syndrome cohorts). Anti-hsp65 should be assessed prospectively in cohorts 
of patients with stable and unstable angina. Further, anti-huhsp65 should be 
assessed similarly as well as in cross-sectional studies. In addition, further 
basic work to identify which epitopes react with hsp60/65 antibodies and T 
cells is required. It is also not as yet clear where the sensitisation of 
hsp60/65 reactive lymphocytes occur and whether we are dealing with a 
cross-reaction between hsp65 and hsp60 induced by an exogenous 
antigen (e.g. following an infection) or with a bona fide autoimmune 
reaction against hsp60.
Thus, in conclusion, we have been unable to substantiate the original 
hypothesis that anti-hsp65 titres could be a useful clinical diagnostic marker 
(131) of atherosclerosis. However clearly they may be may be an important 
prognostic marker, and much further work is required.
12.3 CAROTID IMT IN THE ASSESSMENT OF CORONARY 
ATHEROSCLEROSIS
Over 40,000 patients have been recruited in more than 20 trials using 
carotid IMT measurements as a surrogate marker for CHD morbidity and 
mortality (186). This wide acceptance is remarkable in view of the fact that 
there has been only one prospective study of carotid IMT with CHD endpoints 
(220). The other grounds for the use of carotid IMT as a surrogate marker 
are the close autopsy correlations between carotid and coronary disease 
(192-195), the associations between carotid IMT and CHD risk factors
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(reviewed in Chapter 9) (196-212) and the correlations between carotid IMT 
with the angiographic severity and extent of coronary atherosclerosis. There 
is reasonable evidence to support the former two, but insufficient data 
regarding the latter point. Therefore, in Chapter 8, the correlations 
between a detailed assessment by B-Mode ultrasound of the extent and 
severity of carotid atherosclerosis with a detailed angiographic assessment 
of severity and extent of coronary atherosclerosis were examined for the 
first time. The results were very disappointing for those who advocate 
the use of carotid IMT as a surrogate marker. At best the correlations 
between the severity of coronary atherosclerosis and carotid IMT score 
(C C A mean) was 0.29 (p=0.016). In the last three years, two other studies 
(186,219) have examined correlations between continuous assessments of 
carotid IMT and coronary atherosclerosis in similar but less detailed manner 
than my study, and their results (correlations ranging from 0.23 to 0.29) were 
also very similar.
This data casts significant doubt on the validity of carotid IMT as a surrogate 
for CHD morbidity and mortality. However, further prospective studies of 
carotid IMT are underway and these should clarify this definitively.
However, it is likely that carotid IMT by itself will have a limited future as a 
surrogate marker for CHD events, not least because it poorly correlates with 
the stenotic severity of atherosclerosis. Further, it is difficult to see how a 
physical measurement of plaque and wall thickening will be able to reflect 
the biological, inflammatory activity of plaques.
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Carotid IMT may continue to have a role to play as a surrogate in conjunction 
with a marker of biological activity. In addition, it is likely to continue to have 
a role in large scale epidemiological studies of pre-morbid atherosclerosis 
such as the ARIC study.
Also In Chapter 8, data is presented towards answering a number of 
other issues regarding the measurement of carotid IMT (72). Adjustment for 
body size or mass or carotid artery diameter does not importantly improve the 
correlations between the extent and severity of atherosclerosis in the two 
vascular beds. Also coronary atherosclerosis correlated better with C C A mean 
IMT than with B IF mean or more complex IMT scores, combining measurements 
from multiple coronary artery sites, suggesting that the former should be 
used. This is perhaps because the contribution of various CHD risk 
factors is different between the two carotid artery sites and that the risk 
factor profile of C C A imt is more similar to that of coronary atherosclerosis 
than that of BIFimt and we show some data to support this (Table 9.11). 
Certainly we and others (188) show that various risk factors differ in the 
relative importance between the two vascular beds and this further casts 
doubt on the validity of carotid IMT as a surrogate marker of CHD.
12.4 FIBRINOLYTIC FACTORS IN THE ASSESSMENT OF CORONARY 
ATHEROSCLEROSIS
One paper by Negri et al (150) in 1993 suggested that PAI-1 antigen might 
be a useful diagnostic marker of the severity of coronary atherosclerosis, 
demonstrating a correlation of 0.55. To my knowledge this is a higher
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correlation than with any other peripheral blood marker. It has great 
potential as a marker as in vitro and animal studies had suggested that 
PAI-1 antigen might be involved in the pathogenesis of each of chronic 
atherosclerosis, plaque rupture and thrombosis.
Improvements to Negri et al's (150) methodology were made, to investigate 
whether the correlations were even greater than they reported. However we 
could demonstrate no evidence of a correlation between PAI-1 antigen (or 
the other fibrinolytic parameters, PAI-1 activity or t-PA antigen) and measures 
of the severity and extent of coronary atherosclerosis. The marked 
discrepancy between our results and those of Negri et al are difficult to
explain, but may be due to the confounding influence of triglycerides.
Whilst none of the fibrinolytic parameters were useful in assessing the 
stenotic severity of coronary atherosclerosis, t-PA antigen has some promise 
as a prognostic marker in other studies (90,250 see Chapter 10). The data 
in Chapter 11 did produce some interesting insights into factors which 
regulate endogenous fibrinolysis. Previous findings that components of the 
insulin-resistance syndrome, hyperinsulinaemia, increased weight, increased 
central obesity, hypertension and triglyceridaemia are all related to fibrinolysis 
and that the most important relationship for PAI-1 antigen and activity is with 
insulin were confirmed. Levels of PAI-1 antigen was the most important
determinant of t-PA antigen in our study and this helps to explain the
apparently paradoxical finding that higher levels of t-PA antigen (90,250)
carry a worst prognosis. This data certainly agrees with the consensus (239)
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that the elevated t-PA antigen reflects increase in t-PA and PAI-1 
complexes and that high measured t-PA is secondary to high PAI-1 antigen 
and overall reflects reduced fibrinolytic activity.
For the first time we showed that levels of yGT seem to be an important 
influence on PAI-1 antigen levels in a normo- triglyceridaemic population. The 
source of the majority of plasma PAI-1 is unclear (226) but our data 
suggests that hepatic production is important. yGT reflects increasing hepatic 
liver enzyme induction generally, and potentially increased PAI-1 antigen 
production. Alternatively, there may be reduced hepatic clearance of PAI-1 
antigen.
12.5 CONCLUSIONS
The first objective of this thesis was to investigate techniques for non- 
invasively assessing atherosclerosis for four main potential uses. Unfortunately 
the main conclusion from this thesis is that the techniques we assessed are not 
very promising.
On the basis of data which has largely been published since the conception of 
this thesis, it has been suggested (268) that the biological (inflammatory) 
state of a coronary lesion might be a more important determinant of the 
clinical outcome than for example the degree of stenosis. It is likely 
therefore that the most accurate prognostic assessment of coronary 
atherosclerosis in the future will combine a physical measurement of
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stenotic severity with a biological measurement of atherosclerotic inflammatory 
activity.
In my opinion the peripheral inflammatory blood markers, including anti- 
hsp65, hold most promise for the assessment of the biological activity 
of coronary atherosclerosis and require urgent prospective validation. These 
may be combined in the future with a non-invasive assessment of the 
physical severity of coronary lesions by MRI or by measuring a surrogate like 
carotid IMT. The work of Lees et al (274) using radiolabelled peptides derived 
from an apolipoprotein holds great promise. The radioisotopes are mostly 
taken up into unstable plaques. Thus, potentially this technique could give 
information on both the physical severity and biological activity of lesions. The 
thesis was more successful in achieving the second objective in examining 
pathogeneic mechanisms of atherosclerosis and athero-thrombosis. Most 
importantly elevated anti-hsp65 is shown to be a risk factor for coronary 
atherosclerosis. Intriguing data is presented suggesting that H.pylori and 
(possibly other micro-organisms) may be important influences on anti-hsp65 
titre and thus be involved in the pathogenesis of atherosclerosis. This 
interesting observation requires urgent further investigation. Novel data is also 
presented suggesting that yGT maybe an important influence on endogenous 
fibrinolytic function.
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